**Clinical Experience with Intravenous Angiotensin II Administration:  
A Systematic Review of Safety**

Laurence W. Busse, MD; Xueyuan Shelly Wang, MD; Divya M. Chalikonda, BS;   
Kevin W. Finkel, MD; Ashish K. Khanna, MD; Harold M. Szerlip, MD;   
David Yoo, BS; Sharon L. Dana, PhD; and Lakhmir S. Chawla, MD

**SUPPLEMENTAL DIGITAL CONTENT 1**

**Bibliography of All Studies Meeting Search Inclusion Criteria**

1. Abdelhamid S, Lewicka S, Bige K, Haack D, Lorenz H, Nensel U, Rockel A, Fiegel P, Walb D, and Vecsei P. Role of 21-deoxyaldosterone in human hypertension. *J Steroid Biochem Mol Biol*. 1994;50(5-6):319-27.
2. Abdi-Ali A, Nicholl DD, Hemmelgarn BR, MacRae JM, Sola DY, and Ahmed SB. 25-Hydroxyvitamin D status arterial stiffness and the renin-angiotensin system in healthy humans. *Clin Exp Hypertens*. 2014;36(6):386-91.
3. Abdi-Ali A, Mann MC, Hemmelgarn BR, MacRae JM, Turin TC, Benediktsson H, Sola DY, and Ahmed SB. IgA nephropathy with early kidney disease is associated with increased arterial stiffness and renin-angiotensin system activity. *J Renin Angiotensin Aldosterone Syst*. 2015;16(3):521-8.
4. Abdul-Karim R, and Assalin S. Pressor response to angiotonin in pregnant and nonpregnant women. *Am J Obstet Gynecol*. 1961;82:246-51.
5. Adair CD, Sanchez-Ramos L, Briones DL, and Ogburn P Jr. The effect of high dietary n-3 fatty acid supplementation on angiotensin II pressor response in human pregnancy. *Am J Obstet Gynecol*. 1996;175(3 Pt 1):688-91.
6. Adler GK, Moore TJ, Hollenberg NK, and Williams GH. Changes in adrenal responsiveness and potassium balance with shifts in sodium intake. *Endocr Res*. 1987;13(4):419-45.
7. Admiraal PJ, Danser AH, Jong MS, Pieterman H, Derkx FH, and Schalekamp MA. Regional angiotensin II production in essential hypertension and renal artery stenosis. *Hypertension*. 1993;21(2):173-84.
8. Ahmed SS, Levinson GE, Weisse AB, and Regan TJ. The effect of angiotensin on myocardial contractility. *J Clin Pharmacol*. 1975;15(4 Pt 1):276-85.
9. Ahmed SB, Kang AK, Burns KD, Kennedy CR, Lai V, Cattran DC, Scholey JW, and Miller JA. Effects of oral contraceptive use on the renal and systemic vascular response to angiotensin II infusion. *J Am Soc Nephrol*. 2004;15(3):780-6.
10. Ajzen H, Andrade U, Cipullo JP, Sustovich DR, and Ramos OL. Effect of angiotensin II on urinary sodium excretion in normal subjects and in cirrhotic patients. *Am J Med Sci*. 1968;256(6):373-9.
11. Ames RP, Borkowski AJ, Sicinski AM, and Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure electrolyte balance and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. *J Clin Invest*. 1965;44:1171-86.
12. Anderson GH Jr, Howland T, Domescek R, and Streeten DH. Effect of sodium balance and calcium channel blocking drugs on blood pressure responses. *Hypertension*. 1987;10(3):239-48.
13. Anderson JV, Struthers AD, Payne NN, Slater JD, and Bloom SR. Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man. *Clin Sci (Lond)*. 1986;70(5):507-12.
14. Aoki K, Sato K, and Kawaguchi Y. Increased cardiovascular responses to norepinephrine and calcium antagonists in essential hypertension compared with normotension in humans. *J Cardiovasc Pharmacol*. 1985;7 Suppl 6:S182-6.
15. Apperloo AJ, de Zeeuw D, and de Jong PE. Discordant effects of enalapril and lisinopril on systemic and renal hemodynamics. *Clin Pharmacol Ther*. 1994;56(6 Pt 1):647-58.
16. Arafah BM, Gordon NH, Salazar R, and Douglas JG. Modulation of tissue responsiveness to angiotensin-II in hyperprolactinemic subjects. *J Clin Endocrinol Metab*. 1990;71(1):60-6.
17. Arens JF, and Adriani J. The use of angiotensin as an adjunctive agent to correct hypotensive states during anesthesia. *Anesth Analg*. 1963;42:536-41.
18. Ashida T, Nishioeda Y, Kimura G, Kojima S, Kawamura M, Imanishi M, Abe H, Kawano Y, Yoshimi H, Yoshida K, Kuramochi M, and Omae T. Effects of salt prostaglandin and captopril on vascular responsiveness in essential hypertension. *Am J Hypertens*. 1989;2(8):640-2.
19. Ashida T, Tanaka T, Yutani C, Kawamura M, Mandai T, Imanishi M, Kimura G, Kojima S, Ito K, Kuramochi M, and Omae T. Vascular responsiveness to angiotensin II and phenylephrine the tubular function and the prostaglandin renin- angiotensin system in a patient with Bartter's syndrome. *Intern Med*. 1992;31(1):134-9.
20. Aurell M, and Rudin A. Effect of captopril on blood pressure renal function the electrolyte balance and the renin- angiotensin system in Bartter's syndrome. *Nephron*. 1983;33(4):274-8.
21. Baker PN, Broughton Pipkin F, and Symonds EM. Comparative study of platelet angiotensin II binding and the angiotensin II sensitivity test as predictors of pregnancy-induced hypertension. *Clin Sci (Lond)*. 1992a;83(1):89-95.
22. Baker PN, Kilby MD, and Broughton Pipkin F. The effect of angiotensin II on platelet intracellular free calcium concentration in human pregnancy. *J Hypertens*. 1992b;10(1):55-60.
23. Baldoncini R, Bellini C, Desideri G, De Angelis C, Ferri C, and Santucci A. Elevated albumin excretion in nonmodulating essential hypertensive patients. *Nephron*. 1997;76(3):264-9.
24. Barany FR. Reactivity of the skin vessels to noradrenalin and angiotensin in arterial hypertension. *Scand J Clin Lab Invest*. 1963;15:317-22.
25. Bardelli M, Jensen G, Volkmann R, Caidahl K, and Aurell M. Experimental variations in renovascular resistance in normal man as detected by means of ultrasound. *Eur J Clin Invest*. 1992;22(9):619-24.
26. Barrett BJ, Foley R, Morgan J, Hefferton D, and Parfrey P. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. *Kidney Int*. 1994;46(4):1118-23.
27. Bartter FC, Pronove P, Gill JR Jr, and MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. 1962. *J Am Soc Nephrol*. 1998;9(3):516-28.
28. Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vohringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, and Williams GH. Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. *Circulation*. 2015;132(19):1825-33.
29. Bayerle-Eder M, Langenberger H, Pleiner J, Polska E, Mensik C, Eichler HG, Wolzt M, and Schmetterer L. Endothelin ETA receptor-subtype specific antagonism does not mitigate the acute systemic or renal effects of exogenous angiotensin II in humans. *Eur J Clin Invest*. 2002;32(4):230-5.
30. Beermann C, Schloos J, and Belz GG. Constriction of human dorsal hand veins in vivo with several vasoconstrictors and the influence of oral administration of carvedilol. *J Cardiovasc Pharmacol*. 1992;19 Suppl 1:S12-7.
31. Beland B, Tuchelt H, Bahr V, and Oelkers W. The role of atrial natriuretic factor [alpha-human ANF-(99-126)] in the hormonal and renal adaptation to sodium deficiency. *J Clin Endocrinol Metab*. 1994;79(1):183-8.
32. Belle MS, and Jaffee RJ. The use of large doses of angiotensin in acute myocardial infarction with shock. *J Lancet*. 1965;85:193-4.
33. Belz GG, Breithaupt-Grogler K, Butzer R, Fuchs W, Hausdorf C, and Mang C. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man. *J Renin Angiotensin Aldosterone Syst*. 2000;1(4):336-41.
34. Benck U, Haeckel S, Clorius JH, and van der Woude FJ. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system. *Clin J Am Soc Nephrol*. 2007;2(1):58-67.
35. Benjamin N, Collier JG, and Webb D J. Angiotensin II augments sympathetically induced venoconstriction in man. *Clin Sci (Lond)*. 1988;75(4):337-40.
36. Bentsen N, Larsen B, and Lassen NA. Chronically impaired autoregulation of cerebral blood flow in long-term diabetics. *Stroke*. 1975;6(5):497-502.
37. Beretta-Piccoli C, and Weidmann P. Exaggerated pressor responsiveness to norepinephrine in nonazotemic diabetes mellitus. *Am J Med*. 1981a;71(5):829-35.
38. Beretta-Piccoli C, Weidmann P, and Keusch G. Responsiveness of plasma renin and aldosterone in diabetes mellitus. *Kidney Int*. 1981b;20(2):259-66.
39. Beretta-Piccoli C, Bianchetti MG, Weidmann P, Boehringer K, Link L, and Morton JJ. Effects of acute mild hypercalcemia or of the calcium antagonist nifedipine on cardiovascular responsiveness to norepinephrine or angiotensin II in normal humans. *J Cardiovasc Pharmacol*. 1982a;4 Suppl 3:S306-12.
40. Beretta-Piccoli C, Weidmann P, Schiffl H, Cottier C, and Reubi FC. Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal disease. *Kidney Int*. 1982b;22(3):297-303.
41. Beretta-Piccoli C, Weidmann P, and Fraser R. Responsiveness of plasma 18-hydroxycorticosterone and aldosterone to angiotensin II or corticotropin in nonazotemic diabetes mellitus. *Diabetes*. 1983;32(1):1-5.
42. Beretta-Piccoli C, Weidmann P, Boehringer K, Link L, Bianchetti MG, and Morton JJ. Relationship between plasma aldosterone and angiotensin II before and after noradrenergic inhibition in normal subjects and patients with mild essential hypertension. *J Clin Endocrinol Metab*. 1984;59(2):316-20.
43. Beretta-Piccoli C, Ferrier C, and Weidmann P. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension. *J Hypertens Suppl*. 1985;3(3):S231-4.
44. Beretta-Piccoli C, Ferrier C, and Weidmann P. Alpha 1-adrenergic blockade and cardiovascular pressor responses in essential hypertension. *Hypertension*. 1986;8(5):407-14.
45. Beretta-Piccoli C. Ketanserin in the treatment of diabetes-associated hypertension. *Drugs*. 1988a;36 Suppl 1:35-43.
46. Beretta-Piccoli C, Pusterla C, Stadler P, and Weidmann P. Blunted aldosterone responsiveness to angiotensin II in normotensive subjects with familial predisposition to essential hypertension. *J Hypertens*. 1988b;6(1):57-61.
47. Beretta-Piccoli C, Ziegler WH, Antonini P, Bernasconi-Zapf M, Kressebuch H, and Pianezzi F. Cardiovascular regulation during angiotensin converting enzyme inhibition with captopril in diabetes-associated hypertension. *J Hypertens*. 1990;8(7):671-8.
48. Berlowitz MS, Latif F, Hankins SR, Ennezat PV, Moskowitz R, Tandon S, Colombo PC, and Le Jemtel TH. Dose-dependent blockade of the angiotensin II type 1 receptor with losartan in normal volunteers. *J Cardiovasc Pharmacol*. 2001;37(6):692-6.
49. Berman LB, Roza O, Mitra S, and Vertes V. Mechanism of action of angiotensin cofactor. *Am J Physiol*. 1971;220(5):1332-6.
50. Bernasconi M, Marone C, Beretta-Piccoli C, Lepori G, Shaw S, and Weidmann P. Cardiovascular pressor reactivity after chronic converting enzyme inhibition. *Am J Hypertens*. 1991;4(4 Pt 1):348-55.
51. Bianchetti L, Ferrier C, Beretta-Piccoli C, Fraser R, Morton JJ, and Ziegler WH. Adrenergic activity and aldosterone regulation: no evidence for an alpha-1 adrenoceptor-mediated influence in normal subjects. *Clin Endocrinol (Oxf)*. 1986;25(1):87-95.
52. Bianchetti MG, Beretta-Piccoli C, Weidmann P, Boehringer K, Link L, and Morton JJ. Studies on aldosterone responsiveness to angiotensin II during clinical variations in calcium metabolism in normal man. *Clin Sci (Lond)*. 1982;63(3):325-8.
53. Bianchetti MG, Beretta-Piccoli C, Weidmann P, Link L, Boehringer K, Ferrier C, and Morton JJ. Calcium and blood pressure regulation in normal and hypertensive subjects. *Hypertension*. 1983;5(4 Pt 2):II57-65.
54. Bianchetti MG, Beretta-Piccoli C, Weidmann P, and Ferrier C. Blood pressure control in normotensive members of hypertensive families. *Kidney Int*. 1986;29(4):882-8.
55. Bianchetti MG, Weidmann P, Beretta-Piccoli C, and Ferrier C. Potassium and norepinephrine- or angiotensin-mediated pressor control in pre-hypertension. *Kidney Int*. 1987;31(4):956-63.
56. Bianco JA, Makey DG, Laskey WK, and Shafer RB. Radionuclide left ventricular dV/dt for the assessment of cardiac function in patients with coronary disease. *J Nucl Med*. 1979;20(1):1-6.
57. Bianco JA, Laskey WK, Makey DG, and Shafer RB. Angiotensin infusion effects on left ventricular function. Assessment in normal subjects and in patients with coronary disease. *Chest*. 1980;77(2):172-5.
58. Biggi A, Musiari L, Iori M, De Iaco G, Magnani G, Pelloni I, Pinelli S, Pela GM, Novarini A, Cabassi A, and Montanari A. Contribution of bradykinin B2 receptors to the inhibition by valsartan of systemic and renal effects of exogenous angiotensin II in salt-repleted humans. *J Pharmacol Exp Ther*. 2010;334(3):911-6.
59. Birkhauser M, Gaillard R, Riondel AM, Scholer D, Vallotton MB, and Muller AF. Effect of volume expansion by hyperosmolar and hyperoncotic solutions under constant infusion of angiotensin II on plasma aldosterone in man and its counterbalance by potassium administration. *Eur J Clin Invest*. 1973;3(4):307-16.
60. Birkhauser M, Riondel A, and Vallotton MB. Bromocriptine-induced modulation of plasma aldosterone response to acute stimulations. *Acta Endocrinol (Copenh)*. 1979;91(2):294-302.
61. Birkhauser M, Riondel AM, Gaillard R, Mantero F, and Vallotton MB. Plasma aldosterone response to acute stimulation in panhypopituitarism. *Acta Endocrinol (Copenh)*. 1981;97(4):514-21.
62. Biron P, Koiw E, Nowaczynski W, Brouillet J, and Genest J. The effects of intravenous infusions of valine-5 angiotensin II and other pressor agents on urinary electrolytes and corticosteroids including aldosterone. *J Clin Invest*. 1961;40(2):338-47.
63. Biron P, Chretien M, Koiw E, and Genest J. Effects of angiotensin infusions on aldosterone and electrolyte excretion in normal subjects and patients with hypertension and adrenocortical disorders. *Br Med J*. 1962;1(5292):1569-75.
64. Biron P. Angiotensin infusions in an adrenalectomized patient. *Rev Can Biol*. 1964;23:473-5.
65. Bisht DB. Studies on response to intrasplenic angiotensin with special reference to congestive splenomegaly of cirrhosis of the liver. *J Assoc Physicians India*. 1964;12:283-91.
66. Bisht DB, Shyamalan NC, and Singh SS. Studies on the responses to intravenous angiotensin II in normal subjects and in cirrhosis of the liver. *Indian Heart J*. 1965;17:46-52.
67. Bisht DB, Uthamalingam K, and Pranesh MB. Angiotensin response in various liver diseases with special reference to liver function tests. *J Assoc Physicians India*. 1966;14(3):159-60.
68. Bisht DB, and Dasgupta D. Intrasplenic angiotensin--a simple test for the diagnosis of porto-systemic venous anastomosis. *Indian Heart J*. 1970;22(1):57-60.
69. Bjorck S, Aurell M, Bresater LE, Herlitz H, Welin L, and Wikstrand J. Renal sensitivity to angiotensin II in type 1 diabetes. *Scand J Urol Nephrol*. 1990;24(4):267-73.
70. Blackshear JL, Garnic D, Williams GH, Harrington DP, and Hollenberg NK. Exaggerated renal vasodilator response to calcium entry blockade in first-degree relatives of essential hypertensive subjects. *Hypertension*. 1987;9(4):384-9.
71. Blau A, Battler A, Eldar M, Rath S, Neufeld HN, Kapuler S, Iaina A, Cohen D, and Eliahou HE. Hemodynamic effects of nifedipine in hypertension in the presence of elevated angiotensin-II and beta-adrenergic blockade. *J Clin Hypertens*. 1986;2(1):13-20.
72. Bloomfield DK, Schneider DH, and Vertes V. Renin and angiotensin II studies in malignant hypertension after x-irradiation for seminoma. *Ann Intern Med*. 1968;68(1):146-51.
73. Boddi M, Poggesi L, Coppo M, Zarone N, Sacchi S, Tania C, and Serneri GG. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. *Hypertension*. 1998;31(3):836-42.
74. Boehringer K, Beretta-Piccoli C, Weidmann P, Meier A, and Ziegler W. *Pressor* factors and cardiovascular pressor responsiveness in lean and overweight normal or hypertensive subjects. Hypertension. 1982;4(5):697-702.
75. Bolen JL, Lopes MG, Harrison DC, and Alderman EL. Analysis of left ventricular function in response to afterload changes in patients with mitral stenosis. *Circulation*. 1975;52(5):894-900.
76. Bolen JL, Holloway EL, Zener JC, Harrison DC, and Alderman EL. Evaluation of left ventricular function in patients with aortic regurgitation using afterload stress. *Circulation*. 1976;53(1):132-8.
77. Botticelli JT, Lange RL, and Kelly OA. Postural hypotension with decreased central blood volume and impaired aldosterone response. *Am J Med*. 1964;37:147-55.
78. Bourgoignie JJ, Catanzaro FJ, and Perry HM Jr. Renin-angiotensin-aldosterone system during chronic thiazide therapy of benign hypertension. *Circulation*. 1968a;37(1):27-35.
79. Bourgoignie JJ, Gallagher NI, Perry HM Jr, Kurz L, Warnecke MA, and Donati RM. Renin and erythropoietin in normotensive and in hypertensive patients. *J Lab Clin Med*. 1968b;71(3):523-36.
80. Boyd GW, Adamson AR, James VH, and Peart WS. The role of the renin-angiotensin system in the control of aldosterone in man. *Proc R Soc Med*. 1969;62(12):1253-4.
81. Boyd GW, Adamson AR, Arnold M, James VH, and Peart WS. The role of angiotensin II in the control of aldosterone in man. *Clin Sci*. 1972;42(1):91-104.
82. Bradley S, and Parker B. The hemodynamic effects of angiotonin in normal man. *J Clin Invest*. 1941;20(6):715-9.
83. Branzi A, Lolli C, Piovaccari G, Rapezzi C, Binetti G, Specchia S, Zannoli R, and Magnani B. Echocardiographic evaluation of the response to afterload stress test in young asymptomatic patients with chronic severe aortic regurgitation: sensitivity of the left ventricular end-systolic pressure-volume relationship. *Circulation*. 1984;70(4):561-9.
84. Breckenridge A. Angiotensin-infusion test. *Lancet*. 1965;2(7405):209-11.
85. Breithaupt-Grogler K, Malerczyk C, Belz GG, Butzer R, Herrmann V, Stass H, and Wensing G. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist – characterization by use of Schild regression technique in man. *Int J Clin Pharmacol Ther*. 1997;35(10):434-41.
86. Brickman AS, Trujillo AL, Gutin MS, and Tuck ML. Diminished aldosterone responses to angiotensin II and adrenocorticotropin in hypocalcemic subjects: restoration of responsiveness with normocalcemia. *J Clin Endocrinol Metab*. 1987;64(2):297-303.
87. Brillante DG, O'Sullivan AJ, Johnstone MT, and Howes LG. Arterial stiffness and haemodynamic response to vasoactive medication in subjects with insulin-resistance syndrome. *Clin Sci (Lond)*. 2008;114(2):139-47.
88. Brod J, Hejl Z, Hornych A, Jirka J, Slechta V, and Burianova B. Comparison of haemodynamic effects of equipressor doses of intravenous angiotensin and noradrenaline in man. *Clin Sci*. 1969;36(2):161-72.
89. Broughton Pipkin F, Turner SR, and O'Brien PM. Angina-like pain: an unexpected side-effect following the simultaneous administration of angiotensin II and prostaglandin E2 in normal adults. *Prostaglandins Med*. 1981;6(1):9-11.
90. Broughton Pipkin F, Hunter JC, Turner SR, and O'Brien PM. Prostaglandin E2 attenuates the pressor response to angiotensin II in pregnant subjects but not in nonpregnant subjects. *Am J Obstet Gynecol*. 1982a;142(2):168-76.
91. Broughton Pipkin F, O'Brien PM, and Sant-Cassia LJ. The effect of prostaglandin E1 on the pressor response to angiotensin II in second trimester human pregnancy and in the non-pregnant subject. *Clin Exp Hypertens B*. 1982b;1(4):493-504.
92. Broughton Pipkin F, Hunter JC, O'Brien PM, Sant-Cassia LJ, and Turner SR. Effects on the renin-angiotensin system of the administration of prostaglandin E1 and E2 in second trimester human pregnancy. *Clin Exp Hypertens B.* 1983;2(2):233-45.
93. Broughton Pipkin F, Hunter JC, Turner SR, and O'Brien PM. The effect of prostaglandin E2 upon the biochemical response to infused angiotensin II in human pregnancy. *Clin Sci (Lond)*. 1984;66(4):399-406.
94. Broughton Pipkin F, Morrison R, and O'Brien PM. The effect of prostaglandin E1 upon the pressor and hormonal response to exogenous angiotensin II in human pregnancy. *Clin Sci (Lond)*. 1987;72(3):351-7.
95. Broughton Pipkin F, Morrison R, and O'Brien PM. Prostacyclin attenuates both the pressor and adrenocortical response to angiotensin II in human pregnancy. *Clin Sci (Lond)*. 1989;76(5):529-34.
96. Broughton Pipkin F, and Baker PN. Angiotensin II has depressor effects in pregnant and nonpregnant women. *Hypertension*. 1997;30(5):1247-52.
97. Brown CE, Gant NF, Cox K, Spitz B, Rosenfeld CR, and Magness RRLow-dose aspirin. II. Relationship of angiotensin II pressor responses circulating eicosanoids and pregnancy outcome. *Am J Obstet Gynecol*. 1990;163(6 Pt 1):1853-61.
98. Brown JJ, and Peart WS. The effect of angiotension on urine flow and electrolyte excretion in hypertensive patients. *Clin Sci*. 1962;22:1-17.
99. Brown JJ, Matthew GK, and Robertson JI. The effect of angiotensin on the function of the separate kidneys in patients with unilateral renal artery stenosis. *Clin Sci*. 1964;26:381-95.
100. Brown JJ, Fraser R, Lever AF, Robertson JI, James VH, McCusker J, and Wynn V. Renin, angiotensin, corticosteroids, and electrolyte balance in Addison's disease. *Q J Med*. 1968;37(145):97-118.
101. Brown JJ, Chinn RH, Fraser R, Lever AF, Morton JJ, Robertson JI, Tree M, Waite MA, and Park DM. Recurrent hyperkalaemia due to selective aldosterone deficiency: correction by angiotensin infusion. *Br Med J*. 1973;1(5854):650-4.
102. Brown JM, Underwood PC, Ferri C, Hopkins PN, Williams GH, Adler GK, and Vaidya A. Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. *Hypertension*. 2014a;63(6):1205-11.
103. Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK, and Vaidya A. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. *Hypertension*. 2014b;63(2):273-80.
104. Brown MA, Broughton Pipkin F, and Symonds EM. The effects of intravenous angiotensin II upon blood pressure and sodium and urate excretion in human pregnancy. *J Hypertens*. 1988;6(6):457-64.
105. Brown RD, Strott CA, and Liddle GW. Site of stimulation of aldosterone biosynthesis by angiotensin and potassium. *J Clin Invest*. 1972;51(6):1413-8.
106. Brunner HR, Delacretaz E, Nussberger J, Burnier M, and Waeber B. Angiotensin II antagonists DuP 753 and TCV 116. *J Hypertens Suppl*. 1994;12(9):S29-34.
107. Buchanan TA, Thawani H, Kades W, Modrall JG, Weaver FA, Laurel C, Poppiti R, Xiang A, and Hsueh W. Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. *J Clin Invest*. 1993;92(2):720-6.
108. Burke D, Davies MM, Zweit J, Flower MA, Ott RJ, Dworkin MJ, Glover C, McCready VR, Carnochan P, and Allen-Mersh TG. Continuous angiotensin II infusion increases tumour: normal blood flow ratio in colo-rectal liver metastases. *Br J Cancer*. 2001;85(11):1640-5.
109. Cachovan M, Brod J, Bahlmann J, Sippel R, Celsen B, and Hundeshagen H. The effect of intravenous angiotensin II on the peripheral circulation with particular reference to its bearing on general haemodynamics. *Clin Sci Mol Med Suppl*. 1976;3:219s-21s.
110. Cade R, Wagemaker H, Vogel S, Mars D, Hood-Lewis D, Privette M, Peterson J, Schlein E, Hawkins R, Raulerson D, and Campbell K. Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. *Am J Med*. 1987;82(3):427-38.
111. Calogero AE, Fornito MC, Aliffi A, Vicari E, Moncada ML, Mantero F, Polosa P, and D'Agata R. Role of peripherally infused angiotensin II on the human hypothalamic-pituitary-adrenal axis. *Clin Endocrinol (Oxf)*. 1991;34(3):183-6.
112. Carey RM, Thorner MO, and Ortt EM. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone. *J Clin Invest*. 1979;63(4):727-35.
113. Carey RM. Acute dopaminergic inhibition of aldosterone secretion is independent of angiotensin II and adrenocorticotropin. *J Clin Endocrinol Metab*. 1982;54(2):463-9.
114. Carey RM, and Drake CR Jr. Dopamine selectively inhibits aldosterone responses to angiotensin II in man. *J Hypertens Suppl*. 1984;2(3):S267-9.
115. Carey RM, and Drake CR Jr. Dopamine selectively inhibits aldosterone responses to angiotensin II in humans. *Hypertension*. 1986;8(5):399-406.
116. Cargill RI, Coutie WJ, and Lipworth BJ. The effects of angiotensin II on circulating levels of natriuretic peptides. *Br J Clin Pharmacol*. 1994a;38(2):139-42.
117. Cargill RI, and Lipworth BJ. Acute effects of hypoxaemia and angiotensin II in the human pulmonary vascular bed. *Pulm Pharmacol*. 1994b;7(5):305-10.
118. Cargill RI, Struthers AD, and Lipworth BJ. Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II. *Cardiovasc Res*. 1995a;29(1):108-11.
119. Cargill RI, Struthers AD, and Lipworth BJ. Comparative effects of atrial natriuretic peptide and brain natriuretic peptide on the aldosterone and pressor responses to angiotensin II in man. *Clin Sci (Lond)*. 1995b;88(1):81-6.
120. Cargill RI, and Lipworth BJ. Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. *Thorax*. 1995c;50(2):183-5.
121. Caruso A, Ferrazzani S, De Carolis S, Lanzone A, and Mancuso S. Low-dose aspirin and vascular response in pregnant patients sensitive to angiotensin II. *Int J Gynaecol Obstet*. 1991;35(2):123-8.
122. Catanzaro F, Bourgoignie J, Serirat P, and Perry HM Jr. Angiotensin-infusion test. Correlation with renin activity in peripheral venous blood. *Arch Intern Med*. 1968;122(1):10-7.
123. Cevese A, Gulli G, Polati E, Gottin L, and Grasso R. Baroreflex and oscillation of heart period at 0.1 Hz studied by alpha-blockade and cross-spectral analysis in healthy humans. *J Physiol*. 2001;531(Pt 1):235-44.
124. Chalmers GW, Millar EA, Little SA, Shepherd MC, and Thomson NC. Effect of infused angiotensin II on the bronchoconstrictor activity of inhaled endothelin-1 in asthma. *Chest*. 1999;115(2):352-6.
125. Chalon S, Bedarida GV, Moreno H Jr, Tejura B, Urae A, Hoffman BB, and Blaschke TF. Inhibition of angiotensin-converting enzyme in human hand veins. *Clin Pharmacol Ther*. 1999;65(1):58-65.
126. Chamarthi B, Williams JS, and Williams GH. A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II. *J Hypertens*. 2010;28(5):1020-6.
127. Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther JM, Jeunemaitre X, and Thomas A. Inflammation and hypertension: the interplay of interleukin-6 dietary sodium and the renin-angiotensin system in humans. *Am J Hypertens*. 2011;24(10):1143-8.
128. Chambers S, Nicholls MG, Espiner EA, Ikram H, and Livesey JH. Hormone and haemodynamic effects of angiotensin II infusion during captopril treatment for heart failure. *Horm Metab Res*. 1985;17(3):159-62.
129. Chawla LS, Busse LW, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, and Seneff MG. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. *Crit Care*. 2014;18(5):534.
130. Cherney DZ, Scholey JW, Nasrallah R, Dekker MG, Slorach C, Bradley TJ, Hebert RL, Sochett EB, and Miller JA. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. *Am J Physiol Renal Physiol*. 2008;294(6):F1336-41.
131. Cherney DZ, Reich HN, Miller JA, Lai V, Zinman B, Dekker MG, Bradley TJ, Scholey JW, and Sochett EB. Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. *Am J Physiol Regul Integr Comp Physiol.* 2010;299(1):R206-14.
132. Cherney DZ, Reich HN, Scholey JW, Lai V, Slorach C, Zinman B, and Bradley TJ. Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: a pilot study. *Can J Physiol Pharmacol*. 2012;90(1):113-21.
133. Chesley LC. Renal responses of pregnant and nonpregnant women to isopressor doses of angiotensin II. *Am J Obstet Gynecol*. 1963a;87:410-2.
134. Chesley LC, Wynn RM, and Silverman NI. Renal effects of angiotensin II infusions in normotensive pregnant and nonpregnanat women. *Circ Res*. 1963b;13:232-8.
135. Chesley LC, Talledo E, Bohler CS, and Zuspan FP. Vascular reactivity to angiotensin II and norepinephrine in pregnant women. *Am J Obstet Gynecol*. 1965;91:837-42.
136. Chesley LC, and Tepper IH. Effects of progesterone and estrogen on the sensitivity to angiotensin II. *J Clin Endocrinol Metab*. 1967;27(4):576-81.
137. Chiandussi L, Vaccarino A, Greco F, Muratori F, Cesano L, and Indovina D. Effect of drug infusion on the splanchnic circulation. I. Angiotensin infusion in normal and cirrhotic subjects. *Proc Soc Exp Biol Med*. 1963;112:324-6.
138. Chinn RH, and Dusterdieck GThe response of blood pressure to infusion of angiotensin II: relation to plasma concentrations of renin and angiotensin II. *Clin Sci*. 1972;42(4):489-504.
139. Chiodera P, and Coiro V. Different effects of the GABAergic agent sodium valproate on the oxytocin responses to angiotensin II and insulin-induced hypoglycemia in normal men. *Horm Res*. 1991;36(1-2):27-31.
140. Chiodera P, Volpi R, Capretti L, Caiazza A, Marchesi M, Caffari G, Rossi G, and Coiro V. Oxytocin response to challenging stimuli in elderly men. *Regul Pept*. 1994;51(2):169-76.
141. Chiodera P, Volpi R, Capretti L, Giuliani N, Caffarri G, and Coiro V. Melatonin inhibits oxytocin response to insulin-induced hypoglycemia but not to angiotensin II in normal men. *J Neural Transm (Vienna)*. 1998a;105(2-3):173-80.
142. Chiodera P, Volpi R, Caiazza A, Giuliani N, Magotti MG, and Coiro V. Arginine vasopressin and oxytocin responses to angiotensin II are mediated by AT1 receptor subtype in normal men. *Metabolism*. 1998b;47(8):893-6.
143. Chiodera P, Volpi R, Capretti L, Giuliani N, Maffei ML, and Coiro V. Effect of melatonin on arginine vasopressin secretion stimulated by physical exercise or angiotensin II in normal men. *Neuropeptides*. 1998c;32(2):125-9.
144. Chiodera P, Volpi R, Pilla S, Cataldo S, Capretti L, and Coiro V. Effect of aging on the arginine-vasopressin response to physostigmine and angiotensin II in normal men. *J Investig Med*. 2000;48(3):203-6.
145. Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PB, and Brunner HR. Dose-response relationships following oral administration of DuP 753 to normal humans. *Am J Hypertens*. 1991a;4(4 Pt 2):350S-3S.
146. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PB, and Brunner HR. Oral administration of DuP753 a specific angiotensin II receptor antagonist to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. *Circulation*. 1991b;83(4):1333-42.
147. Christlieb AR, Janka HU, Kraus B, Gleason RE, Icasas-Cabral EA, Aiello LM, Cabral BV, and Solano A. Vascular reactivity to angiotensin II and to norepinephrine in diabetic subjects. *Diabetes*. 1976;25(4):268-74.
148. Clark ML, and Hodge RL. The effects of angiotensin on the concentration of plasma free fatty acids in man. *J Physiol*. 1967;190(2):24P-5P.
149. Clarkson PB, Wheeldon NM, MacLeod C, Tennent M, and MacDonald TM. Effects of angiotensin II and aldosterone on diastolic function in vivo in normal man. *Clin Sci (Lond*). 1994;87(4):397-401.
150. Cohen N, Phillips P, Gilbert R, and Jerums G. Dissociation of blood pressure and albuminuria in normal subjects infused with angiotensin II and noradrenaline. *Clin Exp Pharmacol Physiol*. 1993;20(5):317-9.
151. Cohn JN, and Luria MH. Studies in clinical shock and hypotension, the value of bedside hemodynamic observations. *JAMA*. 1964;190:891-6.
152. Cohn JN, and Luria MH. Studies in clinical shock and hypotension. II. Hemodynamic effects of norepinephrine and angiotensin. *J Clin Invest*. 1965a;44:1494-504.
153. Cohn JN, and Luria MH. Studies in clinical shock and hypotension. 3. Comparative effects of vasopressor drugs and dextran. *Arch Intern Med*. 1965b;116(4):562-6.
154. Cohn JN. Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. *Clin Sci*. 1966;30(2):267-78.
155. Coiro V, and Chiodera P. Inhibition by sodium valproate of the arginine vasopressin and adrenocorticotropin responses to angiotensin II in normal men. *Brain Res*. 1989;491(1):169-72.
156. Coiro V, and Chiodera P. Naloxone increases the angiotensin II stimulated rise of arginine vasopressin and oxytocin secretion in man. *Neuroendocrinology*. 1991;53(3):209-13.
157. Coiro V, Cigarini C, Volpi R, Capretti L, Bacchi-Modena A, and Chiodera P. Naloxone enhances angiotensin II-induced increase in serum luteinizing hormone concentrations in normal women. *Regul Pept*. 1994;51(2):161-7.
158. Coiro V, Volpi R, Capretti L, Caffarri G, Colla R, Giuliani N, and Chiodera P. Stimulation of ACTH and GH release by angiotensin II in normal men is mediated by the AT1 receptor subtype. *Regul Pept*. 1998;74(1):27-30.
159. Cokkinos DV, and Voridis EM. Constancy of pressure-rate product in pacing-induced angina pectoris. *Br Heart J*. 1976;38(1):39-42.
160. Cokkinos DV, Haralambakis AG, Thalassinos NC, Heimonas ET, Demopoulos JN, Voridis EM, and Gardikas CD. Effect of digitalis on diminished baroreceptor sensitivity in diabetics. *Angiology*. 1979;30(8):549-57.
161. Coleman TG, Bower JD, Langford HG, and Guyton AC. Regulation of arterial pressure in the anephric state. *Circulation*. 1970;42(3):509-14.
162. Colice GL, and Ramirez G. Aldosterone response to angiotensin II during hypoxemia. *J Appl Physiol.* (1985). 1986;61(1):150-4.
163. Collier JG, and Robinson BF. Comparison of effects of locally infused angiotensin I and II on hand veins and forearm arteries in man: evidence for converting enzyme activity in limb vessels. *Clin Sci Mol Med*. 1974;47(2):189-92.
164. Coltamai L, Maillard M, Simon A, Vogt B, and Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. *J Hypertens*. 2010;28(3):520-6.
165. Conlin PR, Seely EW, Hollenberg NK, and Williams GH. Dissociation of vascular and adrenal responsiveness to angiotensin II following calcium channel blockade. *Endocr Res*. 1998;24(2):127-39.
166. Conlin PR, Moore TJ, Williams GH, and Hollenberg NK. Rapid modulation of renal and adrenal responsiveness to angiotensin II. *Hypertension*. 1993;22(6):832-8.
167. Connell JM, Tonolo G, Davies DL, Finlayson J, Ball SG, Inglis G, and Fraser R. Dopamine affects angiotensin II-induced steroidogenesis by altering clearance of the peptide in man. *J Endocrinol*. 1987;113(1):139-46.
168. Conti C, Tranquilli AL, Garzetti GG, and Romanini C. Modulation of vascular reactivity after acute calcium antagonist administration in pregnant women moderately sensitive to angiotensin infusion. *Boll Soc Ital Biol Sper*. 1994;70(10-11):243-8.
169. Convertino VA, Ludwig DA, Gray BD, and Vernikos J. Effects of exposure to simulated microgravity on neuronal catecholamine release and blood pressure responses to norepinephrine and angiotensin. *Clin Auton Res*. 1998;8(2):101-10.
170. Cook CM, and Trudinger BJ. Maternal angiotensin sensitivity and fetal Doppler umbilical artery flow waveforms. *Br J Obstet Gynaecol*. 1991;98(7):698-702.
171. Cook MD, Phillips MI, Cook VI, Kimura B, and Wilcox CS. Angiotensin II receptor subtypes on adrenal adenoma in primary hyperaldosteronism. *J Am Soc Nephrol*. 1993;4(1):111-6.
172. Corrie JE, Edwards CR, Jones DB, Padfield PL, and Budd PS. Factors affecting the secretion of 18-hydroxycortisol a novel steroid of relevance to Conn's syndrome*. Clin Endocrinol (Oxf)*. 1985;23(5):579-86.
173. Cosgriff TM, Olin DB, and Nash DA Jr. Hyporeninemic hypoaldosteronism – case report and observation of dissociated renin and erythropoietin activity*. J Chronic Dis*. 1978;31(3):195-200.
174. Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Colindres RE, and Powell JR. Clinical pharmacology of carvedilol in normal volunteers. *Clin Pharmacol Ther*. 1987a;41(1):31-44.
175. Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Colindres RE, and Powell JR. Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. *J Cardiovasc Pharmacol*. 1987b;10 Suppl 11:S81-4.
176. Cumming GR. Acute hemodynamic effects of angiotensin II. Preliminary report. *Can Med Assoc J*. 1963;88:827-32.
177. Cumming GR. Confirmation of closure of ventricular septal defects: value of vasopressor agents. *Am J Cardiol*. 1965;15:259-62.
178. Cuneo RC, Espiner EA, Nicholls MG, Yandle TG, and Livesey JH. Effect of physiological levels of atrial natriuretic peptide on hormone secretion: inhibition of angiotensin-induced aldosterone secretion and renin release in normal man. *J Clin Endocrinol Metab*. 1987;65(4):765-72.
179. Cunningham FG, Cox K, and Gant NF. Further observations on the nature of pressor responsivity to angiotensin II in human pregnancy. *Obstet Gynecol*. 1975;46(5):581-3.
180. Dagher FJ, Lyons JH, Lister J, and Moore FD. Hemorrhage in normal man. The effects of angiotensin. *J Surg Res*. 1966;6(2):66-73.
181. Dahn I, Ekman CA, Lassen NA, Nilsen R, and Westling H. On the conservative treatment of severe ischemia of the leg. *Scand J Clin Lab Invest Suppl*. 1967;99:160-5.
182. Dahn I, Hallbook T, Larsen OA, Lassen NA, Nilsen R, and Westling H. Treatment of acute ischemic pain in the leg by induced hypertension. *Acta Chir Scand*. 1969;135(5):391-4.
183. Davidson NC, and Struthers AD. Nitric oxide regulates renin release during salt depletion but does not alter angiotensin responses in normal humans. *J Cardiovasc Pharmacol Ther*. 1999;4(1):9-14.
184. Davies IB, Bannister R, Hensby C, and Sever PS. The pressor actions of noradrenaline and angiotensin II in chronic autonomic failure treated with indomethacin. *Br J Clin Pharmacol*. 1980;10(3):223-9.
185. Davies-Jones GA, and Cox JR. The effect of intravenous angiotensin on urinary aldosterone excretion body fluid compartments and intra- and extracellular sodium content. *Clin Sci*. 1965;28:591-7.
186. Dawson-Hughes BF, Moore TJ, Dluhy RG, Hollenberg NK, and Williams GH. Plasma angiotensin II concentration regulates vascular but not adrenal responsiveness to restriction of sodium intake in normal man. *Clin Sci (Lond)*. 1981a;61(5):527-34.
187. Dawson-Hughes BF, Moore TJ, Dluhy RG, Podolsky S, and Williams GH. Alterations in aldosterone biosynthesis in essential hypertensives. *Circ Res*. 1981b;49(3):627-32.
188. de Haas SL, Wilkinson IB, Boyd JL, and Webb DJ. Local nitric oxide release does not affect tachyphylaxis to angiotensin II in dorsal hand veins in man in the presence of prostaglandin synthesis inhibition. *Br J Clin Pharmacol*. 2002;53(2):193-5.
189. Debono E, Leegde J, Mottram FR, Pickering GW, Brown JJ, Keen H, Peart WS, and Sanderson PH. The action of angiotensin in man. *Clin Sci*. 1963;25:123-57.
190. degli Uberti EC, Trasforini G, Margutti A, Ambrosio MR, Rossi R, and Pansini R. Stimulatory effect of angiotensin II upon luteinizing hormone release normal women. *Neuroendocrinology*. 1991;53(2):204-8.
191. degli Uberti EC, Trasforini G, Margutti A, Rossi R, Ambrosio MR, and Pansini R. Stimulation of growth hormone and corticotropin release by angiotensin II in man. *Metabolism*. 1990;39(10):1063-7.
192. Deheneffe J, and Bernard A. A correlation between plasma renin activity and the pressor response to angiotensin II. *Acta Clin Belg*. 1974a;29(5):304-12.
193. Deheneffe J, and Bernard A. The pressor response to intravenously infused angiotensin II: correlation with plasma renin activity. *Clin Sci Mol Med*. 1974b;46(2):149-61.
194. Deheneffe J, Cuesta V, Briggs JD, Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson IS, and Tree M. Response of aldosterone and blood pressure to angiotensin II infusion in anephric man. Effect of sodium deprivation. *Circ Res*. 1976;39(2):183-90.
195. Dekker GA, Makovitz JW, and Wallenburg HCPrediction of pregnancy-induced hypertensive disorders by angiotensin II sensitivity and supine pressor test. *Br J Obstet Gynaecol*. 1990;97(9):817-21.
196. Del Greco F, and Johnson DC. Clinical experience with angiotensin II in the treatment of shock. *JAMA*. 1961a;178:994-9.
197. Del Greco F. Effects of valine-5 angiotensin II on excretion of water and salt in primary and secondary hypertension. *Proc Soc Exp Biol Med*. 1961b;107:943-6.
198. Del Greco F. Comparative effects of valine-5 angiotensin II amide and pitressin on renal excretory function in diabetes insipidus*. Proc Soc Exp Biol Med*. 1962;109:105-10.
199. Del Greco F, Roguska J, and Simon NM. Angiotensin II infusion in renal disease with hypertension. *Am J Med Sci*. 1966;251(3):323-7.
200. Delacretaz E, Nussberger J, Biollaz J, Waeber B, and Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. *Hypertension*. 1995;25(1):14-21.
201. Delemarre FM, Didden MA, and de Jong PA. Diurnal variation in angiotensin sensitivity in pregnancy. *Am J Obstet Gynecol*. 1996;174(1 Pt 1):259-61.
202. Delles C, Erdmann J, Jacobi J, Fleck E, Regitz-Zagrosek V, and Schmieder RE. Lack of association between polymorphisms of angiotensin II receptor genes and response to short-term angiotensin II infusion. *J Hypertens*. 2000;18(11):1573-8.
203. Delles C, Schmidt BM, Muller HJ, Oehmer S, Klingbeil AU, and Schmieder RE. Functional relevance of aldosterone for the determination of left ventricular mass. *Am J Cardiol*. 2003;91(3):297-301.
204. Denolle T, Rohmer V, Saint-Adnre J P, Guyene TT, Galland F, Bigorgne JC, Schambelan M, and Corvol P. Effect of the circulating renin-angiotensin system on prolactin release in humans. *J Clin Endocrinol Metab*. 1990;70(1):288-92.
205. De'Oliveira JM, Price DA, Fisher ND, Allan DR, McKnight JA, Williams GH, and Hollenberg NK. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. *Kidney Int*. 1997;52(3):771-7.
206. Depasquale NP, and Burch GE. Angiotensin II digital blood flow and the precapillary and postcapillary blood vessels of man. *Ann Intern Med*. 1963a;58:278-92.
207. Depasquale NP, and Burch GE. Effect of angiotensin II on the intact forearm veins of man. *Circ Res*. 1963b;13:239-45.
208. Derad I, Willeke K, Pietrowsky R, Born J, and Fehm HL. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. *Am J Hypertens*. 1998;11(8 Pt 1):971-7.
209. Derrick JR, Anderson JR, and Roland BJ. Adjunctive use of a biologic pressor agent angiotensin in management of shock. Circulation. 1962a;25:263-7.
210. Derrick JR. Blood pressure control during surgical procedures. New possibilities with administration of angiotensin. *Arch Surg*. 1962b;85:725-9.
211. Dhindsa P, Davis KR, and Donnelly R. Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind crossover study. *Br J Clin Pharmacol*. 2003;55(6):616-9.
212. Didden MA, Hoekstra MP, Vollebergh JH, Schellekens A, and de Jong PA. Effects of angiotensin II on atrial natriuretic peptide in pregnancy. *Am J Obstet Gynecol*. 1991;165(3):692-5.
213. Dietz U, and Belz GG. Low frequency arterial wall movements for indirect blood pressure measurement in man. Validation of a method for non-invasive assessment of blood pressure under the influence of isoprenaline and angiotensin. *Arzneimittelforschung*. 1991;41(5):557-62.
214. Disht DB, and Rajaram R. Mechanism of renal hypertension. Utilization of phentolamine (Regitine) test in essential renal and angiotensin induced hypertension. *J Assoc Physicians India* 1968;16(7):403-5.
215. Distler A, Barth C, Liebau H, Vecsei P, and Wolff HP. The effect of tyramine noradrenaline and angiotensin on the blood pressure in hypertensive patients with aldosteronism and low plasma renin. *Eur J Clin Invest*. 1970;1(3):196-203.
216. Dluhy RG, Bavli SZ, Leung FK, Solomon HS, Moore TJ, Hollenberg NK, and Williams GH. Abnormal adrenal responsiveness and angiotensin II dependency in high renin essential hypertension. *J Clin Invest*. 1979;64(5):1270-6.
217. Donati L, Buhler FR, Beretta-Piccoli C, Kusch F, and Heinen G. Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. *Clin Pharmacol Ther*. 1992;52(1):50-9.
218. Donato L, Coli A, Pasqualini R, and Duce T. Metabolic clearance rate of radioiodinated angiotensin II in normal men. *Am J Physiol.* 1972;223(5):1250-6.
219. Donker PJ, Ivanovici F, and Noach EL. Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. *Brit J Uro*l. 1972;44(2):180-93.
220. Donnelly R, Elliott HL, Meredith PA, and Reid JL. Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. *Br J Clin Pharmacol*. 1987;24(5):599-606.
221. Donnelly R, Elliott HL, Howie CA, Sumner DJ, and Reid JL. Vascular pressor responses in treated and untreated essential hypertension. *J Cardiovasc Pharmacol*. 1990a;16(2):191-6.
222. Donnelly R, Elliott HL, Meredith PA, and Reid JL. Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects. *J Cardiovasc Pharmacol*. 1990b;16(5):790-5.
223. Donnelly R, Elliott HL, Meredith PA, Howie CA, and Reid JL. Combination of nifedipine and doxazosin in essential hypertension. *J Cardiovasc Pharmacol*. 1992;19(4):479-86.
224. Donnelly SM, and Miller JA. Losartan may modulate erythropoietin production. *J Renin Angiotensin Aldosterone Syst*. 2001;2(4):255-60.
225. Drake CR Jr, and Carey RM. Dopamine modulates sodium-dependent aldosterone responses to angiotensin II in humans. *Hypertension*. 1984a;6(2 Pt 2):I119-23.
226. Drake CR Jr, Ragsdale NV, Kaiser DL, and Carey RM. Dopaminergic suppression of angiotensin II-induced aldosterone secretion in man: differential responses during sodium loading and depletion. *Metabolism*. 1984b;33(8):696-702.
227. Drury PL, Smith GM, and Ferriss JB. Increased vasopressor responsiveness to angiotensin II in type 1 (insulin-dependent) diabetic patients without complications. *Diabetologia*. 1984;27(2):174-9.
228. Duggan J, Nussberger J, Kilfeather S, and O'Malley K. Aging and human hormonal and pressor responsiveness to angiotensin II infusion with simultaneous measurement of exogenous and endogenous angiotensin II. *Am J Hypertens*. 1993;6(8):641-7.
229. Duke PC, Mittler G, and Wade JG. The effect of pancuronium on reflex regulation of heart rate in man. *Can Anaesth Soc J*. 1974;21(2):139-46.
230. Dusing R, Bartter FC, Gill JR Jr, Gullner HG, and Lake CR Jr. Effects of moderate short-term potassium depletion in normal humans. The role of prostaglandins. *Prostaglandins*. 1980;20(6):971-9.
231. Dusing R, Moritz J, Glanzer K, and Kramer HJ. Effect of angiotensin II and captopril on renal tubular function in man. *Br J Clin Pharmacol*. 1985;19(1):29-35.
232. Eadington DW, Swainson CP, and Lee MR. Oral carbidopa has no effect on the renal response to angiotensin II in normal man. *Clin Sci (Lond)*. 1991a;80(2):149-54.
233. Eadington DW, Swainson CP, Frier BM, and Semple PF. Renal responses to angiotensin II infusion in early type 1 (insulin-dependent) diabetes. *Diabet Med*. 1991b;8(6):524-31.
234. Eadington DW, Freestone S, Waugh CJ, Swainson CP, and Lee MR. Lithium pretreatment affects renal and systemic responses to angiotensin II infusion in normal man. *Clin Sci (Lond)*. 1992;82(5):543-9.
235. Eadington DW, Swainson CP, Frier BM, Johnston N, Samson RR, and Lee MR. Urinary dopamine response to angiotensin II is not abnormal in type 1 (insulin-dependent) diabetes mellitus. *Nephrol Dial Transplant*. 1993;8(1):36-40.
236. Eadington DW, Frier BM, and Swainson CP. Renal tubular responses to low-dose infusion of angiotensin II in type 1 diabetes mellitus, relation to chronic glycaemic control. *Nephrol Dial Transplant*. 1994;9(9):1264-70.
237. Efstratopoulos AD, and Peart WSEffect of single and combined infusions of angiotensin II and aldosterone on colonic potential difference blood pressure and renal function in patients with adrenal deficiency. *Clin Sci Mol Med*. 1975;48(3):219-26.
238. Egan BM, Petrin J, and Hoffmann RG. NaCl induces differential changes of regional vascular reactivity in salt-sensitive versus salt-resistant men. *Am J Hypertens*. 1991;4(12 Pt 1):924-31.
239. Egan B, Panis R, Hinderliter A, Schork N, and Julius S. Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. *J Clin Invest*. 1987;80(3):812-7.
240. Egan B, Schork N, Panis R, and Hinderliter A. Vascular structure enhances regional resistance responses in mild essential hypertension. *J Hypertens*. 1988;6(1):41-8.
241. Eisalo A, Jaervinen PA, and Viranko M. Effect of intravenous infusion of valine-5-angiotensin on the excretion of urinary electrolytes early in pregnancy. *Ann Chir Gynaecol Fenn*. 1964;53:389-93.
242. Eisalo A, and Raesaenen V. Effect of equi-pressor doses of synthetic alpha- and beta-angiotensin ii on urinary volume and urinary electrolytes in normotensive subjects. *Acta Med Scand*. 1965;177:121-6.
243. Eiskjaer H, Nielsen B, Sorensen SS, and Pedersen EB. Renal and hormonal actions of atrial natriuretic peptide during angiotensin II or noradrenaline infusion in man. *Eur J Clin Invest*. 1996;26(7):584-95.
244. Ekholm M, Kahan T, Jorneskog G, Broijersen A, and Wallen NH. Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. *Thromb Res*. 2009;124(1):110-5.
245. Ekholm M, Kahan T, Jorneskog G, Brinck J, and Wallen NH. Haemostatic and inflammatory alterations in familial hypercholesterolaemia and the impact of angiotensin II infusion. *J Renin Angiotensin Aldosterone Syst*. 2015;16(2):328-38.
246. Ekholm M, Kahan T, Jorneskog G, Broijersen A, and Wallen NH. Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia. *Blood Coagul Fibrinolysis*. 2016;27(1):113-6.
247. Elias AN, Anderson GH Jr, and Streeten DH. Role of angiotensin II in the aldosterone secretory response to adrenocorticotropin in sodium-restricted normal human subjects. *J Clin Endocrinol Metab*. 1978;47(2):401-4.
248. Elliott HL, Pasanisi F, and Reid JL. Effects of nicardipine on aldosterone release and pressor mechanisms. *Br J Clin Pharmacol*. 1985a;20 Suppl 1:99S-102S.
249. Elliott HL, Pasanisi F, Sumner DJ, and Reid JL. The effect of calcium channel blockers on alpha 1- and alpha 2-adrenoceptor-mediated vascular responsiveness in man. *J Hypertens Suppl*. 1985b;3(3):S235-7.
250. Elliott HL, Donnelly R, and Reid JL. Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension. *J Cardiovasc Pharmacol*. 1988;11 Suppl 1:S62-6.
251. Enevoldsen EM, and Jensen FT. Autoregulation and CO2 responses of cerebral blood flow in patients with acute severe head injury. *J Neurosurg*. 1978;48(5):689-703.
252. Erb KA, Essig J, Breithaupt K, and Belz GG. Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. *Drugs*. 1991;41 Suppl 1:11-7.
253. Erkkola RU, and Pirhonen JP. Flow velocity waveforms in uterine and umbilical arteries during the angiotensin II sensitivity test. *Am J Obstet Gynecol*. 1990;162(5):1193-7.
254. Erkkola RU, and Pirhonen JP. Uterine and umbilical flow velocity waveforms in normotensive and hypertensive subjects during the angiotensin II sensitivity test. *Am J Obstet Gynecol*. 1992;166(3):910-6.
255. Erley CM, Grau C, Furian TC, Wolf S, Braun N, and Risler T. Subpressor doses of angiotensin II do not increase albumin excretion in humans. *Clin Nephrol*. 1996;46(5):312-8.
256. Etzioni A, Chaimovitz C, Levi Y, Benderli A, and Better OS. Effect of indomethacin in a patient with Bartter's syndrome: evidence against a primary role of prostaglandin in this disorder. *Pediatr Res*. 1980;14(12):1395-7.
257. Everett RB, Worley RJ, MacDonald PC, and Gant NF. Effect of prostaglandin synthetase inhibitors on pressor response to angiotensin II in human pregnancy. *J Clin Endocrinol Metab*. 1978a;46(6):1007-10.
258. Everett RB, Worley RJ, MacDonald PC, and Gant NF. Modification of vascular responsiveness to angiotensin II in pregnant women by intravenously infused 5alpha-dihydroprogesterone. *Am J Obstet Gynecol*. 1978b;131(4):352-7.
259. Everett RB, Worley RJ, MacDonald PC, and Gant NF. Oral administration of theophylline to modify pressor responsiveness to angiotensin II in women with pregnancy-induced hypertension. *Am J Obstet Gynecol*. 1978c;132(4):359-62.
260. Fagard R, Lijnen P, and Amery A. The pressor effect of exogenous angiotensin II is diminished during dynamic exercise. *J Hypertens Suppl*. 1983;1(2):49-51.
261. Fagard R, Lijnen P, and Amery A. Effects of angiotensin II on arterial pressure renin and aldosterone during exercise. *Eur J Appl Physiol Occup Physiol*. 1985;54(3):254-61.
262. Fallo F, Sonino N, Armanini D, Luzzi T, Pedini F, Pasini C, and Mantero F. A new family with dexamethasone-suppressible hyperaldosteronism: aldosterone unresponsiveness to angiotensin II. *Clin Endocrinol (Oxf)*. 1985;22(6):777-85.
263. Fallo F, Rocco S, Pagotto U, Zangari M, Luisetto G, and Mantero F. Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism. *J Hypertens Suppl*. 1989;7(6):S192-3.
264. Ferri C, Bellini C, Coassin S, Baldoncini R, Luparini RL, Perrone A, and Santucci A. Abnormal atrial natriuretic peptide and renal responses to saline infusion in nonmodulating essential hypertensive patients. *Circulation*. 1994;90(6):2859-69.
265. Ferri C, Desideri G, Baldoncini R, Bellini C, Valenti M, Santucci A, and De Mattia G. Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels. *Clin Sci (Lond)*. 1999;96(3):261-70.
266. Ferris TF, and Gorden P. Effect of angiotensin and norepinephrine upon urate clearance in man. *Am J Med*. 1968;44(3):359-65.
267. Ferro A, Hall JA, Dickerson JE, and Brown MJ. A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects. *Br J Clin Pharmacol*. 1997;43(3):301-8.
268. Fichman MP, Crane MG, and Bethune JE. Hypokalemia with normal blood pressure aldosterone and renin levels secondary to a renal or adrenal tumor. *Am J Med*. 1970;48(4):509-14.
269. Fichman MP, Telfer N, Zia P, Speckart P, Golub M, and Rude R. Role of prostaglandins in the pathogenesis of Bartter's syndrome. *Am J Med*. 1976;60(6):785-97.
270. Finn WL, Tunny TJ, Klemm SA, Ryan SJ, and Gordon RD. Ageing and blood pressure regulation: dose-response relationships for angiotensin blood pressure atrial natriuretic peptide and aldosterone in normal subjects of varying ages. *Clin Exp Pharmacol Physiol*. 1993;20(5):392-4.
271. Finnerty FA Jr, Massaro GD, Chupkovich V, and Tuckman J. Evaluation of the pressor cardiac and renal hemodynamic properties of angiotensin II in man. *Circ Res*. 1961;9:256-63.
272. Fioretto P, Sambataro M, Cipollina MG, Duner E, Giorato C, Morocutti A, Mollo F, Ben GP, Carraro A, Sacerdoti D, Brocco E, Opocher G, and Nosadini R. Impaired response to angiotensin II in type 1 (insulin-dependent) diabetes mellitus. Role of prostaglandins and sodium-lithium countertransport activity. *Diabetologia*. 1991;34(8):595-603.
273. Fisher DA, and Morris MD. Idiopathic edema and hyperaldosteronuria: postural venous plasma pooling. *Pediatrics*. 1965;35:413-24.
274. Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, and Hollenberg NK. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. *Hypertension*. 1994a;23(1):44-51.
275. Fisher ND, Gleason RE, Moore TJ, Williams GH, and Hollenberg NK. Regulation of aldosterone secretion in hypertensive blacks. *Hypertension*. 1994b;23(2):179-84.
276. Fisher ND, Ferri C, Bellini C, Santucci A, Gleason R, Williams GH, Hollenberg NK, and Seely EW. Age, gender, and non-modulation. A sexual dimorphism in essential hypertension. *Hypertension*. 1997;29(4):980-5.
277. Fisher ND, Hurwitz S, Ferri C, Jeunemaitre X, Hollenberg NK, and Williams GH. Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. *Hypertension*. 1999a;34(3):388-94.
278. Fisher ND, Price DA, Litchfield WR, Williams GH, and Hollenberg NK. Renal response to captopril reflects state of local renin system in healthy humans. *Kidney Int*. 1999b;56(2):635-41.
279. Fisher ND, Hurwitz S, Jeunemaitre X, Price DA, Williams GH, and Hollenberg NK. Adrenal response to angiotensin II in black hypertension: lack of sexual dimorphism. *Hypertension*. 2001;38(3):373-8.
280. Fleischmann EH, John S, Delles C, Schneider MP, Schmidt BM, and Schmieder RE. The effect of statins on angiotensin II-induced hemodynamic changes in young mildly hypercholesterolemic men. *Am J Hypertens*. 2004;17(12 Pt 1):1120-6.
281. Fliser D, Arnold U, Kohl B, Hartung R, and Ritz E. Angiotensin II enhances insulin sensitivity in healthy volunteers under euglycemic conditions. *J Hypertens*. 1993;11(9):983-8.
282. Fliser D, Keller C, Bahrmann P, Franek E, Schreckling H, Bergis K, Ritz E. Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset. *J Hypertens*. 1997a;15(3):293-9.
283. Fliser D, Schaefer F, Schmid D, Veldhuis J D, Ritz E. Angiotensin II affects basal pulsatile and glucose-stimulated insulin secretion in humans. *Hypertension*. 1997b;30(5):1156-61.
284. Fliser D, Dikow R, Demukaj S, and Ritz E. Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditions. *J Am Soc Nephrol*. 2000;11(11):2001-6.
285. Fraser R, James VH, Brown JJ, Isaac P, Lever AF, and Robertson JI. Effect of angiotensin and of frusemide on plasma aldosterone corticosterone cortisol and renin in man. *Lancet*. 1965;2(7420):989-91.
286. Fraser R, Mason PA, and Young J. The acute effect of angiotensin II on adrenal and anterior pituitary function in normal subjects and subjects with primary hyperaldosteronism. *Prog Biochem Pharmacol*. 1980;17:14-9.
287. Fraser R, Beretta-Piccoli C, Brown JJ, Cumming AM, Lever AF, Mason PA, Morton JJ, and Robertson JI. Response of aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension Conn's syndrome and nontumorous hyperaldosteronism. *Hypertension*. 1981;3(3 Pt 2):I87-92.
288. Freudenthaler SM, Schreeb K, Korner T, and Gleiter CH. Angiotensin II increases erythropoietin production in healthy human volunteers*. Eur J Clin Invest*. 1999;29(10):816-23.
289. Freudenthaler SM, Lucht I, Schenk T, Brink M, and Gleiter CH. Dose-dependent effect of angiotensin II on human erythropoietin production. *Pflugers Arch*. 2000;439(6):838-44.
290. Fridman KU, Elmfeldt D, Wysocki M, Friberg PR, and Andersson OK. Influence of AT1 receptor blockade on blood pressure renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. *Blood Press*. 2002;11(4):244-52.
291. Frolich JC, Wilson TW, Sweetman BJ, Smigel M, Nies AS, Carr K, Watson JT, and Oates JA. Urinary prostaglandins. Identification and origin. *J Clin Invest*. 1975;55(4):763-70.
292. Frolich JC, Hollifield JW, Dormois JC, Frolich BL, Seyberth H, Michelakis AM, and Oates JA. Suppression of plasma renin activity by indomethacin in man. *Circ Res*. 1976;39(3):447-52.
293. Fruncillo RJ, Rotmensch HH, Vlasses PH, Koplin JR, Swanson BN, and Ferguson RK. Effect of captopril and hydrochlorothiazide on the response to pressor agents in hypertensives. *Eur J Clin Pharmacol*. 1985;28(1):5-9.
294. Fuchs B, Breithaupt-Grogler K, Belz GG, Roll S, Malerczyk C, Herrmann V, Spahn-Langguth H, and Mutschler E. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. *J Pharm Pharmacol*. 2000;52(9):1075-83.
295. Fuji Y, Suzuki H, Katsumata H, Nakajima S, and Saruta T. Hormonal and renal responses to oral once-daily calcium entry blocker in normotensive and hypertensive persons. *J Cardiovasc Pharmacol*. 1988;11(4):438-43.
296. Fujii Y, Hongo T, Masui H, Chiba T, Furukawa N, Nakajima H, Nasuda K, Yajima S, Horikoshi Y, and Igarashi Y. Angiotensin-induced hypertension chemotherapy in children with advanced solid tumors. *Acta Paed Jpn (Overseas ed.)* 1991;33(3):381-3.
297. Fujise Y, Hanawa K, Takada T, Kikuchi K, and Moriguchi O. Studies on etiology of essential hypertension. Hemodynamics water-sodium balance and response to pressor substances during long-term sodium restriction and after spontaneous blood pressure fall. *Jpn Circ J*. 1975;39(5):597-600.
298. Fujita M, Tamai H, Mizuno O, Nakagawa T. Secretory function of the renin-aldosterone system in patients with anorexia nervosa. *Nihon Naibunpi Gakkai Zasshi*. 1991;67(1):50-5.
299. Fujita T, Sakaguchi H, Shibagaki M, Fukui T, and Nomura M. The pathogenesis of Bartter's syndrome. Functional and histologic studies. *Am J Med*. 1977;63(3):467-74.
300. Fujita T, Ando K, Sato Y, Yamashita K, Nomura M, and Fukui T. Independent roles of prostaglandins and the renin-angiotensin system in abnormal vascular reactivity in Bartter's syndrome. *Am J Med*. 1982;73(1):71-6.
301. Fukuchi S, and Nakajima K. Diagnostic value of plasma renin activity and plasma angiotensin II in renovascular hypertension. *Jpn Circ J*. 1975;39(7):823-7.
302. Fukui M, Mizutani T, Sawabe Y, Nakamura N, and Kondo M. Severe hyponatremia resulting from insufficient conversion of angiotensin I to angiotensin II. *Am J Me*d. 2000;108(2):179-80.
303. Fyhrquist F, Holmberg C, Perheentupa J, and Wallenius M. Inappropriate secretion of antiduretic hormone hypertension and hypoplastic corpus callosum. *J Clin Endocrinol Metab*. 1977;45(4):691-4.
304. Fyhrquist FY, Klockars M, Gordin A, Tornroth T, and Kock B. Hyperreninemia lysozymuria and erythrocytosis in Fanconi syndrome with medullary cystic kidney. *Acta Med Scand*. 1980;207(5):359-65.
305. Gaasch WH, Quinones MA, Waisser E, Thiel HG, and Alexander JK. Diastolic compliance of the left ventricle in man. *Am J Cardiol*. 1975;36(2):193-201.
306. Gaboury CL, Simonson DC, Seely EW, Hollenberg NK, and Williams GH. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. *J Clin Invest*. 1994;94(6):2295-300.
307. Gachalyi B, and Kaldor A. Effect of clonidine (Haemiton) on plasma renin level and angiotensin sensitivity in man. Int *J Clin Pharmacol Biopharm*. 1978;16(9):433-6.
308. Gaillard RC, Merkelbach U, Riondel AM, Vallotton MB, and Muller AF. Effect on plasma aldosterone renin activity and cortisol of acute volume depletion induced by ethacrynic acid under constant infusion of angiotensin II and dexamethasone in man. *Eur J Clin Invest*. 1976;6(1):51-7.
309. Gaillard RC, Riondel A, Merkelbach U, and Vallotton MB. Changes in plasma aldosterone following the administration of various combinations of stimuli. *Acta Endocrinol (Copenh)*. 1979;92(2):309-18.
310. Gaillard RC, Riondel AM, Chabert P, and Vallotton MB. Effect of spironolactone on aldosterone regulation in man. *Clin Sci (Lond)*. 1980;58(3):227-33.
311. Gaillard RC, Riondel AM, Ling N, and Muller AF. Corticotropin releasing factor activity of CRF 41 in normal man is potentiated by angiotensin II and vasopressin but not by desmopressin. *Life Sci*. 1988;43(23):1935-44.
312. Gandhi SK, Gainer J, King D, and Brown NJ. Gender affects renal vasoconstrictor response to Ang I and Ang II. *Hypertension*. 1998;31(1):90-6.
313. Ganguly A, Meikle AW, Tyler FH, and West CD. Assessment of 11beta-hydroxylase activity with plasma corticosterone deoxycorticosterone cortisol and deoxycortisol: role of ACTH and angiotensin. *J Clin Endocrinol Metab*. 1977;44(3):560-8.
314. Gans RO, Bilo HJ, von Maarschalkerweerd WW, Heine R J, Nauta JJ, and Donker AJ. Exogenous insulin augments in healthy volunteers the cardiovascular reactivity to noradrenaline but not to angiotensin II. *J Clin Invest*. 1991;88(2):512-8.
315. Gant NF, Daley GL, Chand S, Whalley PJ, and MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. *J Clin Invest*. 1973;52(11):2682-9.
316. Gant NF, Chand S, Whalley PJ, and MacDonald PC. The nature of pressor responsiveness to angiotensin II in human pregnancy. *Obstet Gynecol*. 1974;43(6):854.
317. Gant NF, Madden JD, Siiteri PK, and MacDonald PC. The metabolic clearance rate of dehydroisoandrosterone sulfate. IV. Acute effects of induced hypertension hypotension and naturesis in normal and hypertensive pregnancies. *Am J Obstet Gynecol*. 1976;124(2):143-8.
318. Gant NF, Jimenez JM, Whalley PJ, Chand S, and MacDonald PC. A prospective study of angiotensin II pressor responsiveness in pregnancies complicated by chronic essential hypertension. *Am J Obstet Gynecol*. 1977;127(4):369-75.
319. Gantt CL, and Carter WJ. Acute effects of angiotensin on calcium phosphorus magnesium and potassium excretion. *Can Med Assoc J*. 1964;90:287-91.
320. Garg R, Hurwitz S, Williams GH, Hopkins P N, and Adler GK. Aldosterone production and insulin resistance in healthy adults. *J Clin Endocrinol Metab*. 2010;95(4):1986-90.
321. Gaskell P. Digital vascular response to angiotensin II in normotensive and hypertensive subjects. Evidence for a qualitatively abnormal response to angiotensin in essential hypertension. *Circ Res*. 1967;20(2):174-84.
322. Gaskell P, and Munson C. The influence of angiotensin II and of adrenaline on the critical opening pressure of vessels in forearm skin. Evidence for a qualitatively different response to angiotensin II in vessels of forearm skin from that in some digital vessels. *Bibl Anat*. 1973;12:422-8.
323. Geary VM, Thaker UN, Chalmers PC, and Sheikh F. The use of angiotensin II to treat profound hypotension in a patient taking amiodarone. *J Cardiothorac Anesth*. 1990;4(3):364-7.
324. Genest J, Biron P, Koiw E, Nowaczynski W, Boucher R, and Chretien M. Studies of the pathogenesis of human hypertension. The adrenal cortex and renal pressor mechanism. *Ann Intern Med*. 1961a;55:12-28.
325. Genest J, Biron P, Koiw E, Nowaczynski W, Chretien M, and Boucher R. Adrenocortical hormones in human hypertension and their relation to angiotensin. *Circ Res*. 1961b;9:775-91.
326. Gerber A, Weidmann P, Marone C, Uehlinger D, and Riesen W. Cardiovascular and metabolic profile during intervention with urapidil in humans. *Hypertension*. 1985;7(6 Pt 1):963-71.
327. Gerber A, Weidmann P, and Laederach K. Cardiovascular regulation during administration of co-dergocrine to normal subjects. *Eur J Clin Pharmacol*. 1986;29(5):565-72.
328. Geyskes GG, Van Schaik BA, Gaillard CA, and Koomans HA. The diuretic effect of calcium entry blockade in normals and hypertensive patients. *Tohoku J Exp Med*. 1992;166(1):135-46.
329. Giacche M, Vuagnat A, Hunt SC, Hopkins PN, Fisher ND, Azizi M, Corvol P, Williams GH, and Jeunemaitre X. Aldosterone stimulation by angiotensin II: influence of gender plasma renin and familial resemblance. *Hypertension*. 2000;35(3):710-6.
330. Gibbs CJ, and Millar JG. Renin-angiotensin-aldosterone and kallikrein investigations in a patient with resistant hypomagnesaemia due to Gitelman's syndrome. *Ann Clin Biochem*. 1995;32 ( Pt 4):426-30.
331. Gill JR Jr, Barbour BH, Slater JD, and Bartter FC. Effect of angiotensin II on urinary dilution in normal man. *Am J Physiol*. 1964;206:750-4.
332. Ginsburg J, O'Reilly B, and Swinhoe J. Effect of oral clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine. *Br J Obstet Gynaecol*. 1985;92(11):1169-75.
333. Goldberg JA, Fenner J, Bessent RG, Bradnam MS, McKillop J H, McKee RF, McArdle CS, and Kerr DJ. Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver disease. *Nucl Med Commun*. 1989;10(8):557-66.
334. Goldberg MR, de Mey C, Wroblewski JM, Li Q, Schroeter V, and Belz GG. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. *Clin Pharmacol Ther*. 1996;59(1):72-82.
335. Goldsmith SR, Dodge-Brown D, and Pentel P. Effects of infused norepinephrine and angiotensin-II on vasopressin levels in humans. *Am J Med Sci*. 1988;295(6):513-6.
336. Goldsmith SR, and Hasking GJ. Subpressor angiotensin II infusions do not stimulate sympathetic activity in humans. *Am J Physiol*. 1990;258(1 Pt 2):H179-82.
337. Goldsmith SR, and Hasking GJ. Effect of a pressor infusion of angiotensin II on sympathetic activity and heart rate in normal humans. *Circ Res*. 1991;68(1):263-8.
338. Goldsmith SR, Hasking GJ, and Miller E. Angiotensin II and sympathetic activity in patients with congestive heart failure. *J Am Coll Cardiol*. 1993;21(5):1107-13.
339. Goldsmith SR. Angiotensin II potentiates the arterial pressure response to volume loading in humans. *Am J Hypertens*. 1994;7(8):767-71.
340. Goldsmith SR, and Hasking GJ. Angiotensin II inhibits the forearm vascular response to increased arterial pressure in humans. *J Am Coll Cardiol*. 1995;25(1):246-50.
341. Golub MS, Speckart PF, Zia PK, and Horton R. The effect of prostaglandin A1 on renin and aldosterone in man. *Circ Res*. 1976;39(4):574-9.
342. Golub MS, Tuck ML, and Fittingoff DB. Effect of propranolol therapy on aldosterone responses to angiotensin II and adrenocorticotropic hormone in essential hypertension. *Clin Sci (Lond)*. 1981;61(1):107-10.
343. Good JM, Nihoyannopoulos P, Ghatei MA, Crossman D, Bloom SR, Clark P, Oakley CM, and Cleland JG. Elevated plasma endothelin concentrations in heart failure, an effect of angiotensin II? *Eur Heart J*. 1994;15(12):1634-40.
344. Goodwin TJ, James VH, and Peart WS. The control of aldosterone secretion in nephrectomized man. *Clin Sci Mol Med*. 1974;47(3):235-48.
345. Goorno WE, and Kaplan NM. Renal pressor material in various hypertensive diseases. *Ann Intern Med*. 1965;63(5):745-51.
346. Gordon MB, Moore TJ, Dluhy RG, and Williams GH. Dopaminergic modulation of aldosterone responsiveness to angiotensin II with changes in sodium intake. *J Clin Endocrinol Metab*. 1983;56(2):340-5.
347. Gordon MS, Steunkel CA, Conlin PR, Hollenberg NK, and Williams GH. The role of dopamine in nonmodulating hypertension. *J Clin Endocrinol Metab.* 1989;69(2):426-32.
348. Gordon MS, Williams GH, and Hollenberg NK. Renal and adrenal responsiveness to angiotensin II: influence of beta adrenergic blockade. *Endocr Res*. 1992;18(2):115-31.
349. Gordon MS, Gordon MB, Hollenberg NK, and Williams GH. Nonmodulating trait may precede the development of hypertension. *Am J Hypertens*. 1994;7(9 Pt 1):789-93.
350. Gordon MS, Majzoub JA, Williams GH, and Gordon MB. Sodium balance modulates thirst in normal man. *Endocr Res*. 1997;23(4):377-92.
351. Gordon MS, Price DA, and Hollenberg NK. Blunted suppression of plasma renin activity in diabetes. *J Renin Angiotensin Aldosterone Syst*. 2000;1(3):252-6.
352. Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, and Klemm SA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. *J Hypertens Suppl*. 1987a;5(5):S103-6.
353. Gordon RD, Hamlet SM, Tunny TJ, and Klemm SA. Aldosterone-producing adenomas responsive to angiotensin pose problems in diagnosis. *Clin Exp Pharmacol Physiol*. 1987b;14(3):175-9.
354. Gordon RD, Ravenscroft P J, Klemm SA, Tunny TJ, and Hamlet SM. A new Australian kindred with the syndrome of hypertension and hyperkalaemia has dysregulation of atrial natriuretic factor. *J Hypertens Suppl*. 1988;6(4):S323-6.
355. Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Haak T, Geiger H, and Scheuermann EH. Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers. *Clin Pharmacol Ther*. 2000;68(5):501-9.
356. Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Geiger H, and Scheuermann EH. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. *Kidney Int*. 2001;60(1):83-6.
357. Grant FD, Mandel SJ, Brown EM, Williams GH, and Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. *J Clin Endocrinol Metab*. 1992;75(4):988-92.
358. Greenfield JC Jr, and Tindall GT. Effect of norepinephrine epinephrine and angiotensin on blood flow in the internal carotid artery of man. *J Clin Invest*. 1968;47(7):1672-84.
359. Griffiths HB, and Whitwam JG. Ketanserin and the cardiovascular system. 1. Modification of the effects of pressor amines in patients undergoing myocardial revascularisation. *Anaesthesia*. 1986;41(7):708-11.
360. Grimm M, Weidmann P, Meier A, Keusch G, Ziegler W, Gluck Z, and Beretta-Piccoli C. Correction of altered noradrenaline reactivity in essential hypertension by indapamide. *Br Heart J*. 1981;46(4):404-9.
361. Grimm M, Weidmann P, Meier A, Keusch G, Ziegler W, Gluck Z, and Beretta-Piccoli C. Correction of altered noradrenaline reactivity in essential hypertension by indapamide. *Curr Med Res Opin*. 1983;8 Suppl 3:38-46.
362. Grossman E, Peleg E, Shiff E, and Rosenthal T. Hemodynamic and neurohumoral effects of fish oil in hypertensive patients. *Am J Hypertens*. 1993;6(12):1040-5.
363. Gullner HG, Bartter FC, Gill JR Jr, Dickman PS, Wilson CB, and Tiwari JL. A sibship with hypokalemic alkalosis and renal proximal tubulopathy. *Arch Intern Med*. 1983;143(8):1534-40.
364. Gupta BM, Chugh KS, Chaudhury RR, and Chhuttani PN. Variable sensitivity of different hypertensives to constant infusion of angiotensin. *J Assoc Physicians India*. 1974;22(4):293-9.
365. Guthrie GP Jr. Effects of digoxin on responsiveness to the pressor actions of angiotensin and norepinephrine in man. *J Clin Endocrinol Metab*. 1984;58(1):76-80.
366. Gutman RA, Forrey AW, Fleet WP, and Cutler RE. Vasopressor-induced natriuresis and altered intrarenal haemodynamics in cirrhotic man. *Clin Sci*. 1973;45(1):19-34.
367. Haefeli WE, Srivastava N, Kongpatanakul S, Blaschke TF, and Hoffman BB. Lack of role of endothelium-derived relaxing factor in effects of alpha-adrenergic agonists in cutaneous veins in humans. *Am J Physiol*. 1993;264(2 Pt 2):H364-9.
368. Hagmann M, Nussberger J, Naudin RB, Burns TS, Karim A, Waeber B, and Brunner HR. SC-52458 an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. *J Cardiovasc Pharmacol*. 1997;29(4):444-50.
369. Haller H, Bahr V, Exner P, and Oelkers W. Effect of angiotensin II on plasma ACTH in patients with Addison's disease. *Acta Endocrinol (Copenh)*. 1985;110(4):451-5.
370. Haller H, Hensen J, Bahr V, and Oelkers W. Effects of angiotensin II infusion on the early morning surge of ACTH and o-CRH-provoked ACTH secretion in normal man. *Acta Endocrinol (Copenh)*. 1986;112(2):150-6.
371. Haller H, Lenz T, Oelkers W, Luft FC, and Distler A. Angiotensin II infusions elevated blood pressure independently of platelet cytosolic calcium concentrations in humans. *J Hum Hypertens*. 1994;8(8):551-4.
372. Halushka PV, Wohltmann H, Privitera PJ, Hurwitz G, and Margolius HS. Bartter's syndrome: urinary prostaglandin E-like material and kallikrein, indomethacin effects. *Ann Intern Med*. 1977;87(3):281-6.
373. Hamer J, and Jackson E. The effect of ganglionic blockade on the pressor response to angiotensin in systemic hypertension. *Cardiovasc Res*. 1969;3(4):411-4.
374. Hammer M, Olgaard K, and Madsen S. The inability of angiotensin II infusions to raise plasma vasopressin levels in haemodialysis patients. *Acta Endocrinol (Copenh)*. 1980;95(3):422-6.
375. Hannedouche T, Ikeni A, Marques L P, Natov S, Dechaux M, Schmitt F, Lacour B, and Grunfeld JP. Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. *J Cardiovasc Pharmacol*. 1992;19 Suppl 6:S25-7.
376. Hannedouche T, Schmitt F, Ikeni A, Marques LP, Natov S, Dechaux M, Lacour B, and Grunfeld JP. Renal response to angiotensin after short-term angiotensin converting enzyme inhibition. *Hypertension*. 1993;21(3):261-6.
377. Hanson E, Eriksson BO, and Sivertsson R. Baroreceptor reflexes after coarctectomy. *Clin Physiol*. 1981;1(5):503-9.
378. Hansson L, Zweifler AJ, Julius S, and Hunyor SN. Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension. *Acta Med Scand*. 1974;196(1-2):27-34.
379. Hansteen V, and Lorentsen E. Induced hypertension in the treatment of severe ischemia of the foot. *Circulation*. 1972;46(5):976-82.
380. Hansteen V, and Lorentsen E. Induced hypertension in the treatment of severe foot ischemia. *Scand J Clin Lab Invest Suppl*. 1973;128:221-2.
381. Harada K, Sugimoto K. Kawaguchi A. Ohmori M. and Fujimura A. Effect of angiotensin II on venodilator response to nitroglycerin. *Clin Pharmacol Ther*. 2001;69(3):130-6.
382. Harada K, Ohmori M, Kitoh Y, Sugimoto K, and Fujimura A. Angiotensin II in human veins: development of rapid desensitization and effect of indomethacin. *Clin Exp Pharmacol Physiol*. 1999;26(12):959-63.
383. Harada K, Kawaguchi A, Ohmori M, and Fujimura A. Influence of losartan on alpha-adrenoceptor-mediated vasoconstrictor response in humans. *J Cardiovasc Pharmacol*. 2000;36(1):45-9.
384. Harada K, Ohmori M, and Fujimura A. Vasoconstricting effect of angiotensin II in human hand veins: influence of aging diabetes mellitus and hypertension. *Hypertens Res*. 2002;25(5):683-8.
385. Haragus ST, Uza G, and Duncea C. Guancydine a new hypotensive agent with complex action. *Cor Vasa*. 1977;19(3):214-9.
386. Harris WS, Schoenfeld CD, and Weissler AM. Effects of adrenergic receptor activation and blockade on the systolic preejection period heart rate and arterial pressure in man. *J Clin Invest*. 1967;46(11):1704-14.
387. Hata T, Ogihara T, Mikami H, Nakamaru M, Mandai T, and Kumahara Y. Effects of two angiotensin II analogues on blood pressure plasma aldosterone concentration plasma renin activity and creatinine clearance in normal subjects on different sodium intakes. *Eur J Clin Pharmacol*. 1980;18(4):295-9.
388. Hata T, Ogihara T, Nakamaru M, Gotoh S, Masuo K, Saeki S, Kumagai A, and Kumahara Y. Effect of three angiotensin II antagonists [Sar1 Thr8]- [Sar1 Ile8]- and [Sar1 Ala8]angiotensin II on blood pressure and endocrine factors in normal subjects. *Eur J Clin Pharmacol*. 1982;23(1):7-10.
389. Hatch FE, Crowe LR, Miles DE, Young JP, and Portner ME. Altered vascular reactivity in sickle hemoglobinopathy. A possible protective factor from hypertension. *Am J Hypertens*. 1989;2(1):2-8.
390. Hausdorf G, Gluth J, and Nienaber CA. Non-invasive assessment of end-systolic pressure-length and stress-shortening relationships in normal individuals: significance of different loading conditions induced by methoxamine and angiotensin II. *Eur Heart J*. 1987;8(10):1099-108.
391. Hausdorf G, Morf G, Beron G, Erttmann R, Winkler K, Landbeck G, and Keck EW. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. *Br Heart J*. 1988a;60(4):309-15.
392. Hausdorf G, Siglow V, and Nienaber CA. Effects of increasing afterload on early diastolic dysfunction in hypertrophic non-obstructive cardiomyopathy. *Br Heart J*. 1988b;60(3):240-6.
393. Healy JK. Effect of intravenous angiotensin infusion on adrenal medullary function in man. *Proc Soc Exp Biol Med*. 1967;125(3):679-83.
394. Healy JK, Elliott AJ, and Harrison LC. Effects of angiotensin on plasma electrolyte concentrations in rabbits and in man. *Clin Sci Mol Med*. 1974;46(1):19-36.
395. Heeg JE, de Jong PE, van der Hem GK, and de Zeeuw D. Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. *Kidney Int*. 1991;40(4):734-41.
396. Heistad DD, and Wheeler RC. Effect of acute hypoxia on vascular responsiveness in man. I. Responsiveness to lower body negative pressure and ice on the forehead. II. Responses to norepinephrine and angiotensin. 3. Effect of hypoxia and hypocapnia. *J Clin Invest*. 1970;49(6):1252-65.
397. Heistad DD, Wheeler RC, Mark AL, Abboud FM, and Schmid PG. Effects of adrenergic stimulation on ventilation in man. *J Lab Clin Med*. 1971;78(5):800.
398. Heistad DD, Wheeler RC, Mark AL, Schmid PG, and Abboud FM. Effects of adrenergic stimulation on ventilation in man. *J Clin Invest*. 1972;51(6):1469-75.
399. Hene RJ, Koomans HA, Dorhout Mees EJ, vd Stolpe A, Verhoef GE, and Boer P. Correction of hypokalemia in Bartter's syndrome by enalapril. *Am J Kidney Dis*. 1987;9(3):200-5.
400. Henning M, and Johnsson G. Interference of phenoxybenzamine and guanethidine with the vasoconstrictor responses of noradrenaline and angiotensin II in the hand. *Acta Pharmacol Toxicol (Copenh)*. 1967;25(4):373-84.
401. Henriksen JH, Kastrup J, and Christensen NJ. Reduced plasma noradrenaline during angiotensin II-induced acute hypertension in man. *Clin Sci (Lond)*. 1985a;68(6):621-4.
402. Henriksen JH, Kastrup J, and Schaffalitzky De Muckadell OB. Arterial blood-pressure change and endogenous circulating substance P in man. *Clin Physiol*. 1985b;5(4):377-81.
403. Henriksen O, and Wisborg K. The effect of induced arterial hypertension upon regional blood flow in subcutaneous tissue in patients with arterial insufficiency of the legs. *Scand J Clin Lab Invest*. 1975;35(2):115-20.
404. Herlitz H, Widgren B, Urbanavicius V, Attvall S, and Persson B. Stimulatory effect of insulin on tubular sodium reabsorption in normotensive subjects with a positive family history of hypertension. *Nephrol Dial Transplant*. 1996;11(1):47-54.
405. Herlitz H, Palmgren E, Widgren B, and Aurell M. Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension. *Clin Sci (Lond)*. 2005;109(3):311-7.
406. Hernandez-Lattuf PR, Quinones MA, and Gaasch WH. Usefulness and limitations of circumferential fibre shortening velocity in evaluating segmental disorders of left ventricular contraction. *Br Heart J*. 1974;36(12):1167-74.
407. Hilgers KF, Langenfeld M R, Schlaich M, Veelken R, and Schmieder RE. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. *Circulation*. 1999;100(13):1394-9.
408. Hilgers KF, Delles C, Veelken R, and Schmieder RE. Angiotensinogen gene core promoter variants and non-modulating hypertension. *Hypertension*. 2001;38(6):1250-4.
409. Hirsch AT, Dzau VJ, Cutler SS, Levenson DJ, and Creager MA. Effect of isradipine on cardiopulmonary baroreflex function regional blood flow and vascular responsiveness in hypertensive patients. *J Cardiovasc Pharmacol*. 1992;19(2):272-81.
410. Hladunewich MA, Kingdom J, Odutayo A, Burns K, Lai V, O'Brien T, Gandhi S, Zimpelmann J, Kiss A, Miller J, and Cherney D. Postpartum assessment of the renin angiotensin system in women with previous severe early-onset preeclampsia. *J Clin Endocrinol Metab*. 2011;96(11):3517-24.
411. Hocken AG, and Kark RM. Angiotensin infusion test. *Lancet*. 1965;2(7420):988-9.
412. Hocken AG, Kark RM, and Passovoy M. The angiotensin-infusion test. *Lancet*. 1966;1(7427):5-9.
413. Hogewind BL, Van Brummelen P, and Veltkamp JJ. Bartter's syndrome: an autosomal recessive disorder? Study of four patients in one generation of the same pedigree and their relatives. *Acta Med Scand*. 1981;209(6):463-7.
414. Hollenberg NK, Chenitz WR, Adams DF, and Williams GH. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. *J Clin Invest*. 1974;54(1):34-42.
415. Hollenberg NK, Adams DF, Solomon H, Chenitz WR, Burger BM, Abrams HL, and Merrill JP. Renal vascular tone in essential and secondary hypertension: hemodynamic and angiographic responses to vasodilators. *Medicine (Baltimore)*. 1975a;54(1):29-44.
416. Hollenberg NK, Williams G, Burger B, and Hooshmand I. The influence of potassium on the renal vasculature and the adrenal gland and their responsiveness to angiotensin II in normal man. *Clin Sci Mol Med*. 1975b;49(6):527-34.
417. Hollenberg NK, Williams GH, Burger B, Ishikawa I, and Adams DF. Blockade and stimulation of renal adrenal and vascular angiotensin II receptors with 1-Sar 8-Ala angiotensin II in normal man. *J Clin Invest*. 1976;57(1):39-46.
418. Hollenberg NK, Moore T, Shoback D, Redgrave J, Rabinowe S, and Williams GH. Abnormal renal sodium handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to angiotensin II. *Am J Med*. 1986;81(3):412-8.
419. Honda M, Den K, Kanbegawa A, Ueda Y, Tsuchiya M, Izumi Y, Oguri K, Shiratsuchi T, and Hatano M. Plasma levels of 18-hydroxy-11-deoxycorticosterone in essential hypertension. *Endocrinol Jpn*. 1978a;25(3):237-43.
420. Honda M, Ueda Y, Tsuchiya M, Izumi Y, Watanabe H, Shiratsuchi T, and Hatano M. Pathogenesis of essential hypertension with low renin: responses of plasma renin activity to various stimulation tests in essential hypertension. *Jpn Circ J*. 1978b;42(5):613-9.
421. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin MC, Skuppin J, Williams CS, Dluhy RG, Lalouel JM, Williams RR, and Williams GH. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. *J Hypertens*. 1996;14(2):199-207.
422. Hopkins PN, Hunt S C, Jeunemaitre X, Smith B, Solorio D, Fisher ND, Hollenberg NK, and Williams GH. Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension. *Circulation*. 2002;105(16):1921-7.
423. Horton R. Stimulation and suppression of aldosterone in plasma of normal man and in primary aldosteronism. *J Clin Invest*. 1969;48(7):1230-6.
424. Hosojima H, Morimoto S, Uchida K, Yamamoto I, Kigoshi T, Azukizawa S, and Negami T. Pseudohypoparathyroidism (PHP) type II and selective hypoaldosteronism in a patient with retinitis pigmentosa. *Jpn J Med*. 1984;23(2):144-8.
425. Hougaard K, Hansen A, and Brodersen P. The effect of ketamine on regional cerebral blood flow in man. *Anesthesiology*. 1974;41(6):562-7.
426. Howes LG, and Reid JL. Decreased vascular responsiveness to noradrenaline following regular ethanol consumption. *Br J Clin Pharmacol*. 1985a;20(6):669-74.
427. Howes LG, and Reid JL. Changes in blood pressure and vascular reactivity in normotensives following regular alcohol consumption. *J Hypertens Suppl*. 1985b;3(3):S443-5.
428. Huq MS, Jespersen D, Pfaff M, Zucker IR, and Kirschner MA. Concurrence of aldosterone androgen and cortisol secretion in adrenal venous effluents. *J Clin Endocrinol Metab*. 1976;42(2):230-8.
429. Hurwitz S, Potter B, Weiss R J, Jeunemaitre X, Hopkins PN, Hunt S C, Litchfield WR, and Williams GH. Influence of sodium intake on the reliability of active renin as a measure of the renin-angiotensin system in essential hypertension. *Am J Clin Pathol*. 2001;115(2):304-12.
430. Iba K, Morii H, Wada M, Yasumoto R, Kishimoto T, Mitsuhashi T, Hojo K, and Okahara T. A case report of pseudohypoparathyroidism (Drezner's type I) associated with probable Bartter's syndrome. *Endocrinol Jpn*. 1981;28(5):595-604.
431. Ichikawa S, Sakamaki T, Tonooka S, and Sugai Y. The diurnal rhythm of plasma aldosterone plasma renin activity plasma cortisol and serum growth hormone and subnormal responsiveness of aldosterone to angiotensin-II in the patients with normotensive acromegaly. *Endocrinol Jpn*. 1976;23(1):75-82.
432. Iimura O, and Miyahara M. Ischemic heart disease and catecholamines. *Jpn Circ J*. 1971;35(8):973-8.
433. Ikeda F, Kono T, Oseko F, Imura H, and Endo J. Effects of diltiazem hydrochloride on pressor and steroidogenic actions of angiotensins and norepinephrine in man. *Endocrinol Jpn*. 1980;27(6):779-84.
434. Imai Y, Abe K, Seino M, Haruyama T, Tajima J, Sato M, Goto T, Hiwatari M, Kasai Y, Yoshinaga K, and Sekino H. Attenuation of pressor responses to norepinephrine and pitressin and potentiation of pressor response to angiotensin II by captopril in human subjects. *Hypertension*. 1982a;4(3):444-51.
435. Imai Y, Abe K, Seino M, Haruyama T, Tajima J, Yoshinaga K, and Sekino H. Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II. *Am J Cardiol*. 1982b;49(6):1537-9.
436. Imhof PR, Muller P, and Keller R. Pharmacological profiling of cardiovascular agents in healthy volunteers by means of non-invasive methods. *Methods Find Exp Clin Pharmacol*. 1987;9(12):829-32.
437. Isenring P, Lebel M, and Grose JH. Endocrine sodium and volume regulation in familial hyperkalemia with hypertension. *Hypertension*. 1992;19(4):371-7.
438. Ishii M, Ono K, Ikeda T, Iizuka M, and Nakamura Y. Pressor responsiveness hemodynamics and plasma renin activity in essential hypertension. *Jpn Circ J*. 1974;38(12):1078-84.
439. Ishii M, and Ohno K. Comparisons of body fluid volumes plasma renin activity hemodynamics and pressor responsiveness between juvenile and aged patients with essential hypertension. *Jpn Circ J*. 1977;41(3):237-46.
440. Isles CG, MacDougall IC, Lever AF, and Fraser R. Hypermineralocorticoidism due to adrenal carcinoma: plasma corticosteroids and their response to ACTH and angiotensin II. *Clin Endocrinol (Oxf)*. 1987;26(2):239-51.
441. Ito M, Nakamura T, Yoshimura T, Koyama H, and Okamura H. The blood pressure response to infusions of angiotensin II during normal pregnancy: relation to plasma angiotensin II concentration serum progesterone level and mean platelet volume. *Am J Obstet Gynecol*. 1992;166(4):1249-53.
442. Ito T, Hidaka H, Kato T, and Yoshitoski Y. Response of plasma aldosterone to postural change diuretica angiotensin II sodium restriction or loading and prostaglandin. *Jpn Heart J*. 1973;14(6):518-30.
443. Itskovitz HD, Murphy JJ, and Schoenberg HW. Differential renal function studies of the effects of angiotensin in normotensive and hypertensive patients. *Am J Med Sci*. 1967;253(2):163-73.
444. Iwasaki R, Kigoshi T, Uchida K, and Morimoto S. Plasma 18-hydroxycorticosterone and aldosterone responses to angiotensin II and corticotropin in diabetic patients with hyporeninemic and normoreninemic hypoaldosteronism. *Acta Endocrinol (Copenh)*. 1989;121(1):83-9.
445. Jackson T, Corke C, and Agar J. Enalapril overdose treated with angiotensin infusion. *Lancet*. 1993;341(8846):703.
446. Jacobi J, Schlaich M P, Delles C, Schobel H P, and Schmieder RE. Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. *Am J Hypertens*. 1999;12(4 Pt 1):418-22.
447. Jandeleit K, Heintz B, Gross-Heitfeld E, Kindler J, Sieberth H G, Kirsten R, and Nelson K. Increased activity of the autonomic nervous system and increased sensitivity to angiotensin II infusion after therapy with recombinant human erythropoietin. *Nephron*. 1990;56(2):220-1.
448. Janukowicz-Lorenz H, Lorenz J, and Skora K. Intravenous infusion of angiotensin after surgical treatment of arterial hypertension. *Pol Med J*. 1970;9(4):794-7.
449. Jaspers WJ, De Jong PA, and Mulder AW. Angiotensin-II sensitivity and prostaglandin-synthetase inhibition in pregnancy. *Eur J Obstet Gynecol Reprod Biol*. 1981;11(6):379-84.
450. Jaspers WJ, de Jong PA, and Mulder AW. Decrease of angiotensin sensitivity after bed rest and strongly sodium-restricted diet in pregnancy. *Am J Obstet Gynecol*. 1983;145(7):792-6.
451. Jensen G, Bardelli M, Volkmann R, Caidahl K, Rose G, and Aurell M. Renovascular resistance in primary hypertension: experimental variations detected by means of Doppler ultrasound. *J Hypertens*. 1994;12(8):959-64.
452. Jespersen B, and Pedersen EB. Increased plasma levels of atrial natriuretic peptide in patients with chronic renal failure: effect of noradrenaline infusion. *Nephrol Dial Transplant*. 1988a;3(6):762-7.
453. Jespersen B, Pedersen EB, Christensen NJ, Danielsen H, and Sorensen SS. Reduced angiotensin II induced vascular reactivity in chronic renal failure. *Scand J Clin Lab Invest*. 1988b;48(7):705-13.
454. Jespersen B, Pedersen EB, Charles P, Danielsen H, and Juhl H. Elevated angiotensin II and vasopressin in primary hyperparathyroidism. Angiotensin II infusion studies before and after removal of the parathyroid adenoma. *Acta Endocrinol (Copenh)*. 1989;120(3):362-8.
455. Jespersen B, Brock A, and Pedersen EB. Lack of effect of calcium carbonate supplementation on 24h blood pressure angiotensin II reactivity and PTH(1-84) in essential hypertension. *J Hum Hypertens*. 1993;7(1):103-4.
456. Jespersen B, Fogh-Andersen N, and Brock A. Parathyroid hormone in blood pressure and volume homeostasis in healthy subjects hyperparathyroidism liver cirrhosis and glomerulonephritis. A possible interaction with angiotensin II and atrial natriuretic peptide. *Scand J Clin Lab Invest*. 1994;54(7):531-41.
457. Jezek V, and Schrijen F. Haemodynamic reaction to exercise and increased afterload in the detection of right heart failure in pulmonary diseases. *Cor Vasa* 1980;22(4):272-80.
458. Jilma B, Krejcy K, Dirnberger E, Eichler HG, Kapiotis S, Dorner GT, and Wagner OF. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. *Life Sci*. 1997;60(21):1859-66.
459. Jirka J, and David I. Baroreceptor activity and responsiveness to angiotensin in patients with chronic renal failure. *Proc Eur Dial Transplant Assoc*. 1973;10(0):540-4.
460. John S, Delles C, Klingbeil AU, Jacobi J, Schlaich MP, and Schmieder RE. Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. *J Hypertens*. 1999;17(12 Pt 2):1933-9.
461. Johnson WP, and Bruce RA. Hemodynamic and metabolic effects of angiotensin II during rest and exercise in normal healthy subjects. *American Heart Journal*. 1962;63(2):212-8.
462. Johnsson G, Henning M, and Ablad B. Studies on the mechanism of the vasoconstrictor effect of angiotensin II in man. *Life Sci*. 1965;4(16):1549-54.
463. Johnston CI, and Jose AD. Reduced vascular response to angiotensin II in secondary hyperaldosteronism. *J Clin Invest*. 1963;42:1411-20.
464. Johnston CI, Mendelsohn FA, and Doyle AE. Metabolism of angiotensin II in sodium depletion and hypertension in humans. *Circ Res*. 1972;31(9):Suppl 2:203-13.
465. Jones DC, and Sanchez-Ramos L. Effect of angiotensin II infusion during normal pregnancy on flow velocity waveforms in the uteroplacental and umbilical circulations. *Obstet Gynecol*. 1990;76(6):1093-6.
466. Jones NF, Barraclough MA, Perreiello VA, and Marsden CD. Effect of angiotensin on urea reabsorption in man. *Clin Sci*. 1967;32(2):257-69.
467. Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serne EH, Smulders YM, and Stehouwer CD. Angiotensin II enhances insulin-stimulated whole-body glucose disposal but impairs insulin-induced capillary recruitment in healthy volunteers. *J Clin Endocrinol Metab*. 2010;95(8):3901-8.
468. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, and Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. *Circulation*. 2002;106(9):1055-7.
469. Jorneskog G, Kahan T, Ekholm M, Broijersen A, and Wallen NH. Altered vascular responses to circulating angiotensin II in familial combined hyperlipidemia. *J Cardiovasc Med (Hagerstown)*. 2008;9(10):1037-44.
470. Jose AD, Bernstein L, and Taylor RR. The influence of arterial pressure on mitral incompetence in man. *J Clin Invest*. 1964;43:2094-103.
471. Jose AD. and Taylor RR. Autonomic blockade by propranolol and atropine to study intrinsic myocardial function in man. *J Clin Invest*. 1969;48(11):2019-31.
472. Kaldor A, Gachalyi B. Kallay K, Fekete S. and Foldvari A. Effect of alphamethyldopa and of phenobarbitone on angiotensin responsiveness and renin activity in man. *Int J Clin Pharmacol Biopharm*. 1975;11(1):10-4.
473. Kallay K, Kaldor A, Gachalyi B, and Sebestyen K. Effect of guanethidine and of reserpine on angiotensin responsiveness in man. *Int J Clin Pharmacol Biopharm*. 1975;11(1):35-9.
474. Kanaya H, and Arakawa K. Ultrasonodiagnosis of subclinical heart failure by increasing afterload with angiotensin II. *Jpn Heart J*. 1979;20(4):407-17.
475. Kane SP, and Gillespie JA. Induced hypertension in the treatment of the ischaemic foot. *Ann RColl Surg Engl*. 1970;47(5):287-93.
476. Kaneko Y, Takeda T, Nakajima K, and Ueda H. Effect of angiotensin on the pressor response to tyramine in normotensive subjects and hypertensive patients. *Circ Res*. 1966;19(4):673-80.
477. Kaplan NM, and Silah JG. The angiotensin-infusion test. A new approach to the differential diagnosis of renovascular hypertension. *N Engl J Med*. 1964a;271:536-41.
478. Kaplan NM, and Silah JG. The effect of angiotensin II on the blood pressure in humans with hypertensive disease. *J Clin Invest*. 1964b;43:659-69.
479. Kardia SL, Sing CF, and Turner ST. The response of renal plasma flow to angiotensin II infusion in a population-based sample and its association with the parental history of essential hypertension. *J Hypertens*. 1997;15(5):483-93.
480. Karnezis TA, Murphy MB, Weber RR, Nelson KS, Tripathi BJ, and Tripathi RC. Effects of selective dopamine-1 receptor activation on intraocular pressure in man. *Exp Eye Res*. 1988;47(5):689-97.
481. Katayama K, Kumada T, Matsuzaki M, Fujii T, Kohno M, Ogawa H, Ozaki M, Matsuda Y, and Kusukawa R. Effect of afterload on the left ventricular pressure fall during isovolumic relaxation period in man. *Jpn Circ J*. 1988a;52(6):518-24.
482. Katayama K, Matsuzaki M, Moritani K, Kohno M, Fujii T, Ogawa H, Matsuda Y, and Kusukawa R. Dynamic determinants of left ventricular early diastolic filling in old myocardial infarction. *Jpn Circ J*. 1992b;56(7):750-8.
483. Kato T, Murakami Y, Saito Y, Tomura N, Shindo M, Watarai J, and Tamakawa Y. New modality of radiation therapy under increased tumor oxygen tension with angiotensin II: a pilot study. *Radiat Med*. 1993;11(3):86-90.
484. Kaulhausen H, Oney T, Feldmann R, and Leyendecker G. Decrease of vascular angiotensin sensitivity by L-dopa during human pregnancy. *Am J Obstet Gynecol*. 1981;140(6):671-5.
485. Kaulhausen H, Oney T, and Leyendecker G. Inhibition of the renin--aldosterone axis and of prolactin secretion during pregnancy by L-dopa. *Br J Obstet Gynaecol*. 1982;89(6):483-8.
486. Kawasaki N, Matsui K, Ito M, Nakamura T, Yoshimura T, Ushijima H, and Maeyama M. Effect of calcium supplementation on the vascular sensitivity to angiotensin II in pregnant women. *Am J Obstet Gynecol*. 1985;153(5):576-82.
487. Kelly DT. Myocardial function (studied using angiotensin) after aortic homograft valve replacement. *N Z Med J*. 1965;64(400):Suppl:68-70.
488. Kelly RP, Millasseau SC, Ritter JM, and Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. *Hypertension*. 2001;37(6):1429-33.
489. Kennon B, Ingram MC, Friel EC, Anderson NH, MacKenzie SM, Davies E, Shakerdi L, Wallace AM, Fraser R, and Connell JM. Aldosterone synthase gene variation and adrenocortical response to sodium status angiotensin II and ACTH in normal male subjects. *Clin Endocrinol (Oxf)*. 2004;61(2):174-81.
490. Kerstens MN, van der Kleij FG, Boonstra AH, Sluiter WJ, van der Molen JC, Navis G, and Dullaart RP. Angiotensin administration stimulates renal 11 beta-hydroxysteroid dehydrogenase activity in healthy men. *Kidney Int*. 2004;65(6):2065-70.
491. Keynan A, Levy M, Czaczkes JW, and Ullmann TD. Pressor response to angiotensin and plasma renin activity in anephric patients. *Isr J Med Sci*. 1971;7(10):1136-9.
492. Kigoshi T, Morimoto S, Uchida K, Hosojima H, Yamamoto I, Imaizumi N, and Azukizawa S. Unresponsiveness of plasma mineralocorticoids to angiotensin II in diabetic patients with asymptomatic normoreninemic hypoaldosteronism. *J Lab Clin Med*. 1985;105(2):195-200.
493. Kigoshi T, Iwasaki R, Kaneko M, Nakano S, Azukizawa S, Uchida K, and Morimoto S. Lack of enhanced responsiveness of plasma 18-hydroxycorticosterone and aldosterone to adrenocorticotropin as well as to angiotensin-II during moderate sodium depletion in type II diabetic subjects with normoreninemia. *J Clin Endocrinol Metab*. 1991;72(6):1200-5.
494. Kisch ES, Dluhy RG, and Williams GH. Enhanced aldosterone response to angiotensin II in human hypertension. *Circ Res*. 1976;38(6):502-5.
495. Kistler PM, Davidson NC, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK, Sparks PB, and Kalman JM. Absence of acute effects of angiotensin II on atrial electrophysiology in humans. *J Am Coll Cardiol*. 2005;45(1):154-6.
496. Klein H, Abassi Z, and Keiser HR. Effects of angiotensin II and phenylephrine on urinary endothelin in normal female volunteers. *Metabolism*. 1995;44(1):115-8.
497. Klemm SA, Tunny TJ, and Gordon RD. Atrial natriuretic peptide levels during angiotensin infusion and indomethacin administration are consistent with angiotensin-mediated regulation in man. *J Hypertens Suppl*. 1987;5(5):S75-8.
498. Klemm SA, Gordon RD, Runny TJ, and Hamlet SM. Altering angiotensin levels by administration of captopril or indomethacin or by angiotensin infusion contributes to an understanding of atrial natriuretic peptide regulation in man. *Clin Exp Pharmacol Physiol*. 1988;15(4):349-55.
499. Klemm SA, Gordon RD, Tunny TJ, and Finn WL. Biochemical correction in the syndrome of hypertension and hyperkalaemia by severe dietary salt restriction suggests renin-aldosterone suppression critical in pathophysiology. *Clin Exp Pharmacol Physiol*. 1990;17(3):191-5.
500. Klemm SA, Gordon RD, Tunny TJ, Finn WL, and Hornych A. Prostaglandins and systolic blood pressure but not angiotensin II independently affect atrial natriuretic peptide levels in man. *Clin Exp Pharmacol Physiol*. 1992;19(5):323-6.
501. Klemm S, Pinet F, Rioual-Caroff N, Tunny T, Corvol P, and Gordon R. Detection of renin mRNA in aldosterone-producing adenomas by polymerase chain reaction. *Clin Exp Pharmacol Physiol*. 1993;20(5):303-5.
502. Klingbeil AU, Schobel H, Langenfeld MR, Hilgers K, Schaufele T, and Schmieder RE. Hyper-responsiveness to angiotensin II is related to cardiac structural adaptation in hypertensive subjects. *J Hypertens*. 1999;17(6):825-33.
503. Klingbeil AU, Jacobi J, Langenfeld MR, John S, Hilgers KF, and Schmieder RE. Enhanced antinatriuresis in response to angiotensin II in essential hypertension. *Am J Hypertens*. 2000;13(9):986-93.
504. Koch B, and Collins WE. The influence of angiotensin infusion on the urine composition in individual kidney function tests. *Can Med Assoc J*. 1971;104(10):905-7.
505. Koh T, Taniguchi H, and Yamagishi H. Oxygen-15 positron-emission tomography for predicting selective delivery of a chemotherapeutic agent to hepatic cancers during angiotensin II-induced hypertension. *Cancer Chemother Pharmacol*. 2003;51(4):349-58.
506. Kojima I, and Ogata E. Reversal by a dopamine antagonist of saline-induced attenuation of aldosterone response to angiotensin II infusion in man. *Endocrinol Jpn*. 1982;29(1):21-5.
507. Koletsky RJ, Gordon MB, LeBoff MS, Moore TJ, Dluhy RG, Hollenberg NK, and Williams GH. Captopril enhances vascular and adrenal responsiveness to angiotensin II in essential hypertension. *Clin Sci (Lond)*. 1984;66(3):299-305.
508. Kondowe GB, Kelly JG, Copeland S, and Johnston GD. The effect of chronic captopril therapy on platelet angiotensin II receptor density and vascular responsiveness to angiotensin II infusion. *Eur J Clin Pharmacol*. 1987;31(5):525-30.
509. Kono T, Oseko F, Ikeda F, Nanno M, and Endo J. Biological activity of des-Asp1-Ileu8-angiotensin II (Ileu8-angiotensin III) in man. *J Clin Endocrinol Metab*. 1976;43(4):940-3.
510. Kono T, Oseko F, Ikeda F, Nanno M, and Endo J. Biological activity of high dose of des-asp 1-ileu 8-angiotensin II in man. *Acta Endocrinol (Copenh)*. 1977;86(1):156-61.
511. Kono T, Taniguchi A, Imura H, Oseko F, and Khosla MC. Agonistic activities of isoleucine8-angiotensin II in man. *Endocrinol Jpn*. 1985a;32(5):701-8.
512. Kono T, Taniguchi A, Imura H, Oseko F, and Khosla MC. Relative biological activities of Asn1-,Val5-angiotensin II Ile5-angiotensin II and Sar1-angiotensin II in man. *Life Sci*. 1985b;37(4):365-9.
513. Kornerup HJ, Pedersen EB, and Petersen VP. Bartter's syndrome without hyperplasia of the juxtaglomerular apparatus treated with indomethacin. *Acta Med Scand*. 1978;204(3):235-9.
514. Kosachunhanun N, Hunt SC, Hopkins PN, Williams RR, Jeunemaitre X, Corvol P, Ferri C, Mortensen RM, Hollenberg NK, and Williams GH. Genetic determinants of nonmodulating hypertension. *Hypertension*. 2003;42(5):901-8.
515. Kotchen TA, Kotchen JM, Guthrie GP Jr, Berk MR, Knapp CF, and McFadden M. Baroreceptor sensitivity in prehypertensive young adults. *Hypertension*. 1989;13(6 Pt 2):878-83.
516. Kraiem Z, Rosenthal T, Rotzak R, and Lunenfeld BAngiotensin II and K challenge following prolonged ACTH administration to normal subjects. *Acta Endocrinol (Copenh)*. 1979;91(4):657-65.
517. Kraiem Z, Rosenthal T, Rotzak R, and Lunenfeld B. Adrenal desensitization following prolonged ACTH administration to normal subjects. *J Steroid Biochem*. 1980;12:469-72.
518. Krejcy K, Eichler HG, Jilma B, Kapiotis S, Wolzt M, Zanaschka G, Gasic S, Schutz W, and Wagner O. Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. *Can J Physiol Pharmacol*. 1996;74(1):9-14.
519. Krejcy K, Wolzt M, Kreuzer C, Breiteneder H, Schutz W, Eichler HG, and Schmetterer L. Characterization of angiotensin-II effects on cerebral and ocular circulation by noninvasive methods. *Br J Clin Pharmacol*. 1997;43(5):501-8.
520. Krekels MM, Spiering W, Schaper NC, Houben AJ, and de Leeuw PW. Dissociation between the renal effects of angiotensin I and II in sodium-restricted normal subjects. *Cardiovasc Res*. 1998;38(1):215-20.
521. Krikken JA, Dallinga-Thie GM, Navis G, and Dullaart RP. Renin-angiotensin-aldosterone responsiveness to low sodium and blood pressure reactivity to angiotensin-II are unrelated to cholesteryl ester transfer protein mass in healthy subjects. *Expert Opin Ther Targets*. 2008;12(11):1321-8.
522. Krovetz LJ, McLoughlin TG, and Schiebler GL. Left ventricular function in children studied by increasing peripheral resistance with angiotensin. *Circulation*. 1968;37(5):729-37.
523. Krum H, Louis WJ, Brown DJ, and Howes LG. Pressor dose responses and baroreflex sensitivity in quadriplegic spinal cord injury patients. *J Hypertens*. 1992;10(3):245-50.
524. Kuchel O, Horky K, Kapitola J, and Motlik K. Blood-pressure hyperreactivity to angiotensin in man. *Lancet*. 1964a;2(7373):1341-2.
525. Kuchel O, Horky K, Pazourek M, and Gregorova I. Pressor hyporeactivity to angiotensin in Addison's disease. *Lancet*. 1964b;2(7373):1316-7.
526. Kurozumi H, Yokota Y, and Fukuzaki H. Role of afterload in progression of dilated cardiomyopathy--evaluation with force-velocity relation. *Jpn Circ J*. 1989;53(1):20-6.
527. Kyle PM, de Swiet M, Buckley D, Serra Serra V, and Redman CW. Noninvasive assessment of the maternal cerebral circulation by transcranial Doppler ultrasound during angiotensin II infusion. *Br J Obstet Gynaecol*. 1993;100(1):85-91.
528. Kyle PM, Buckley D, Kissane J, de Swiet M, and Redman CW. The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. *Am J Obstet Gynecol*. 1995;173(3 Pt 1):865-72.
529. Lacroix A, Tremblay J, Touyz RM, Deng LY, Lariviere R, Cusson JR, Schiffrin EL, and Hamet P. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia Cushing's syndrome and orthostatic hypotension. *J Clin Endocrinol Metab*. 1997;82(8):2414-22.
530. Lang CC, Rahman AR, Choy AM, and Struthers AD. Renal interactions between the renin-angiotensin system and the sympathetic nervous system in man. *J Hypertens Suppl*. 1991;9(6):S206-7.
531. Lang CC, Rahman AR, Balfour DJ, and Struthers AD. Prazosin blunts the antinatriuretic effect of circulating angiotensin II in man. *J Hypertens*. 1992;10(11):1387-95.
532. Laragh JH, Angers M, Kelly WG, and Lieberman S. Hypotensive agents and pressor substances. The effect of epinephrine norepinephrine angiotensin II and others on the secretory rate of aldosterone in man. *JAMA*. 1960;174:234-40.
533. Laragh JH, Cannon PJ, Bentzel CJ, Sicinski AM, and Meltzer JI. Angiotensin II norepinephrine and renal transport of electrolytes and water in normal man and in cirrhosis with ascites. *J Clin Invest*. 1963;42(7):1179-92.
534. Larsson PT, Schwieler JH, Wallen NH, and Hjemdahl P. Acute effects of angiotensin II on fibrinolysis in healthy volunteers. *Blood Coagul Fibrinolysis*. 1999;10(1):19-24.
535. Larsson PT, Schwieler JH, and Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. *Blood Coagul Fibrinolysis*. 2000;11(1):61-9.
536. Laurent S, Lacolley P, Billaud E, Arcaro G, and Safar M. Large and small forearm arteries of essential hypertensives are less reactive to angiotensin II than to noradrenaline. *J Hypertens Suppl*. 1989;7(6):S76-7.
537. Lebel M, and Grose JH. Selective hypoaldosteronism: a study of steroid biosynthetic pathways under adrenocorticotrophin and angiotensin II infusion. *Clin Sci Mol Med Suppl*. 1976;3:335s-7s.
538. Lebel M, and Grose JH. Angiotensin II effect on plasma steroids in selective hypoaldosteronism. *Horm Metab Res*. 1982;14(8):432-6.
539. Lebel M, Grose J H, and Falardeau P. Modulation of renal hemodynamics by renal eicosanoids during vasopressor infusions in man. *Prostaglandins Leukot Essent Fatty Acids*. 1989;35(1):41-9.
540. Leenen FH, Smith DL, Farkas RM, Boer WH, Reeves RA, and Marquez-Julio A. Cardiovascular effects of indapamide in hypertensive patients with or without renal failure. A dose-response curve. *Am J Med*. 1988;84(1B):76-85.
541. Lely AT, Krikken JA, Bakker SJ, Boomsma F, Dullaart RP, Wolffenbuttel BH, and Navis G. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. *J Clin Endocrinol Metab*. 2007;92(5):1821-6.
542. Lely AT, Heerspink HJ, Zuurman M, Visser FW, Kocks MJ, Boomsma F, and Navis G. Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene-environment interaction in healthy volunteers. *J Hypertens*. 2010;28(12):2414-21.
543. Lenz K, Hortnagl H, Magometschnigg D, Kleinberger G, Druml W, and Laggner A. Function of the autonomic nervous system in patients with hepatic encephalopathy. *Hepatology*. 1985;5(5):831-6.
544. Leonetti G, Terzoli L, and Zanchetti A. Calcium antagonists and responsiveness of the adrenal glands to aldosterone-releasing stimuli in hypertensive patients. *J Hypertens Suppl*. 1987;5(4):S119-22.
545. Levenson JA, Safar ME, Simon AC, Kheder AI, Daou JN, and Levy BI. Systemic arterial compliance and diastolic runoff in essential hypertension. *Angiology*. 1981;32(6):402-13.
546. Lewis PJ, George CF, and Dollery CT. Clinical evaluation of indoramin a new antihypertensive agent. *Eur J Clin Pharmacol*. 1973;6(4):211-6.
547. Lianos EA, Alavi N, Tobin M, Venuto R, and Bentzel CJ. Angiotensin-induced sodium excretion patterns in cirrhosis: role of renal prostaglandins. *Kidney Int*. 1982;21(1):70-7.
548. Liberman B, Wajchenberg BL, and Bezas AG. Effect of non-pressor doses of synthetic B-angiotensin II. in adrenocortical insufficiency. *Arq Bras Endocrinol Metabol*. 1967;16(1):3-14.
549. Lifton RP, Hopkins PN, Williams RR, Hollenberg NK, Williams GH, and Dluhy RG. Evidence for heritability of non-modulating essential hypertension. *Hypertension*. 1989;13(6 Pt 2):884-9.
550. Lim HS, Cho JY, Oh DS, Chung JY, Hong KS, Bae KS, Yu KS, Lee KH, Jang IJ, and Shin SG. Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II. *Eur J Clin Pharmacol*. 2007;63(1):17-26.
551. Lima MC, Ajzen HA, Ribeiro AB, Andrade U, and Ramos OL. Effect of angiotensin II on urinary magnesium calcium and sodium excretion in normal subjects. *Am J Med Sci*. 1972;263(3):173-9.
552. Limas CJ, Guiha NH, Lekagul O, and Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. *Circulation*. 1974;49(4):754-60.
553. Linde R, Winn S, Latta D, and Hollifield J. Graded dose effects of angiotensin II on aldosterone production in man during various levels of potassium intake. *Metabolism*. 1981;30(6):549-53.
554. Lipworth BJ, and Dagg KD. Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. *Chest*. 1994a;105(5):1360-4.
555. Lipworth BJ, and Dagg KD. Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow. *Br J Clin Pharmacol*. 1994b;37(3):273-8.
556. Ljungman S, Aurell M, Hartford M, Wikstrand J, and Berglund G. Effects of subpressor doses of angiotensin II on renal hemodynamics in relation to blood pressure. *Hypertension*. 1983a;5(3):368-74.
557. Ljungman S, Aurell M, Hartford M, Wikstrand J, and Berglund G. Effects of subpressor doses of angiotensin II on renal haemodynamics at different blood-pressure levels. *Acta Med Scand Suppl*. 1983b;677:93-6.
558. Ljutic D, and Rumboldt Z. The influence of the atrial natriuretic factor on venous tone in man. *Int J Clin Pharmacol Res*. 1989;9(4):255-60.
559. London GM, Safar ME, Weiss YA, Corvol PL, Lehner JP, Menard JM, Simon AC, and Milliez PL. Volume-dependent parameters in essential hypertension. *Kidney Int*. 1977;11(3):204-8.
560. Loon N, Shemesh O, Morelli E, and Myers BD. Effect of angiotensin II infusion on the human glomerular filtration barrier. *Am J Physiol*. 1989;257(4 Pt 2):F608-14.
561. Lopes de Faria SR, Zanella MT, Andriolo A, Ribeiro AB, and Chacra AR. Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. *Clin Pharmacol Ther*. 1988;44(6):670-4.
562. Lopez JM, Rodriguez JA, and Marusic ET. Plasma aldosterone response to angiotensin II and potassium chloride infusions in hypopituitary patients. *Clin Endocrinol (Oxf)*. 1980;13(4):331-7.
563. Loquet P, Broughton Pipkin F, Symonds EM, and Rubin PC. Influence of raising maternal blood pressure with angiotensin II on utero-placental and feto-placental blood velocity indices in the human. *Clin Sci (Lond)*. 1990;78(1):95-100.
564. Loquet P, Broughton Pipkin F, Symonds EM, and Rubin PC. The influence of angiotensin II-induced vasoconstriction on common carotid artery blood flow and velocity-time profiles in normal women. *Ultrasound Obstet Gynecol*. 1991;1(3):171-4.
565. Lorenz R, Spengler U, Fischer S, Duhm J, and Weber PC. Platelet function thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. *Circulation*. 1983;67(3):504-11.
566. Lottermoser K. Unger T, Gohlke P. Vetter H. and Dusing R. Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans. *Am J Hypertens*. 2003;16(6):445-52.
567. Lottermoser K, Hertfelder HJ, Gohlke P, Vetter H, and Dusing R. Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects. *Clin Exp Hypertens*. 2004;26(1):13-26.
568. Louis WJ, and Doyle AE. The effects of varying doses of angiotensin on renal function and blood pressure in man and dogs. *Clin Sci*. 1965;29(3):489-504.
569. Louis WJ, and Doyle AE. The effects of aldosterone and angiotensin on renal function. *Clin Sci*. 1966;30(2):179-89.
570. Loup R, Favre L, and Vallotton MB. Effect of noradrenaline vasopressin and angiotensin II on renal prostaglandins in man. *Clin Sci (Lond)*. 1986;70(4):371-7.
571. Love DR, Brown JJ, Chinn RH, Johnson RH, Lever AF, Park DM, and Robertson JI. Plasma renin in idiopathic orthostatic hypotension: differential response in subjects with probable afferent and efferent autonomic failure. *Clin Sci*. 1971;41(4):289-99.
572. Lubash GD, Muiesan GE, Alicandri CL, Garfinkel DJ, Siekierski EC, and McConnaughey CK. Plasma angiotensin serum 'angiotensinase activity' and blood pressure response during angiotensin II amide infusions in normal volunteers. *Experientia*. 1971;27(1):68-9.
573. Lucchini E, Kressebuch H, and Beretta-Piccoli C. Yohimbine and aldosterone responsiveness to angiotensin II or corticotrophin in normal subjects. *Clin Exp Hypertens A*. 1989;11(4):649-63.
574. Lufkin EG, Katz FH, and Herman RH. Primary aldosteronism due to hyperplasia of zona glomerulosa: failure of suppression by DOCA or stimulation by angiotensin. *Am J Med Sci*. 1972;264(5):367-74.
575. Luik PT, Hoogenberg K, Kerstens MN, Beusekamp BJ, De Jong PE, Dullaart RP, and Navis GJ. The influence of the ACE ( I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive normoalbuminuric Type 1 diabetes mellitus. *Diabetologia*. 2003;46(8):1131-9.
576. Lunzer MR, Newman SP, Bernard AG, Manghani KK, Sherlock SP, and Ginsburg J. Impaired cardiovascular responsiveness in liver disease. *Lancet*. 1975;2(7931):382-5.
577. Luparini RL, Ferri C, Santucci A, and Balsano F. Atrial natriuretic peptide in non-modulating essential hypertension. *Hypertension*. 1993;21(6 Pt 1):803-9.
578. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, and Brown NJ. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. *Hypertension*. 2006;48(6):1050-7.
579. Luukkainen T, Eisalo A, Jaervinen PA, and Viranko M. Effect of angiotensin on urinary electrolytes before and after lipid infusion in early human pregnancy. *Acta Obstet Gynecol Scand*. 1964;43:28-34.
580. Mabe K, Ito M, and Okamura H. Effects of norethisterone on pressor response to angiotensin II in men. *Obstet Gynecol*. 1992;80(2):291-5.
581. Mace PJ, and Watson RD, Skan W, and Littler WA. Inhibition of the baroreceptor heart rate reflex by angiotensin II in normal man. *Cardiovasc Res*. 1985;19(9):525-7.
582. MacGilchrist AJ, Sumner D, and Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. *Hepatology*. 1991;13(4):689-94.
583. Magness RR, Cox K, Rosenfeld CR, and Gant NF. Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. *Am J Obstet Gynecol.* 1994;171(3):668-79.
584. Magrini F, Reggiani P, Ciulla M, Meazza R, and Fratianni G. Coronary haemodynamic effects of angiotensin II in mild essential hypertension in man. *Clin Sci (Lond)*. 1992;82(2):133-7.
585. Magrini F, Reggiani P, Paliotti R, Bonagura F, Ciulla M, and Vandoni P. Coronary hemodynamics and the renin angiotensin system. *Clin Exp Hypertens*. 1993;15 Suppl 1:139-55.
586. Mahler F, Brunner HH, Bollinger A Casty M, and Anliker M. Changes in phasic femoral artery flow induced by various stimuli: a study with percutaneous pulsed Doppler ultrasound. *Cardiovasc Res*. 1977;11(5):254-60.
587. Maillard MP, Rossat J, Nussberger J, Ramis J, Pontes C, Burnier M, and Brunner HR. Pharmacologic profile of UR-7247 an orally active angiotensin II AT1 receptor antagonist in healthy volunteers. p6. *J Cardiovasc Pharmacol*. 2000a;35(3):383-9.
588. Maillard MP, Rossat J, Brunner HR, and Burnier M. Tasosartan enoltasosartan and angiotensin II receptor blockade: the confounding role of protein binding. *J Pharmacol Exp Ther*. 2000b;295(2):649-54.
589. Major P, Kuchel O, Boucher R, Nowaczynski W, and Genest J. Selective hypopituitarism with severe hyponatremia and secondary hyporeninism. *J Clin Endocrinol Metab*. 1978;46(1):15-9.
590. Malchoff CD, Hughes JM, and Carey RM. Effect of upright posture on the aldosterone responses to dopamine metoclopramide angiotensin II and adrenocorticotropin. *J Clin Endocrinol Metab*. 1987;65(1):203-7.
591. Mangioni C, and Morandini G. Effect of angiotensin on urine flow and electrolyte excretion in normal and toxemic pregnancy. *Mal Cardiovasc*. 1967;8(4):515-28.
592. Mann JF, Leidig M, and Ritz E. Human angiotensin II receptors are regulated by angiotensin II. *Clin Exp Hypertens A*. 1988;10(1):151-68.
593. Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, and Scaroni C. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure plasma renin activity and aldosterone in primary aldosteronism. *Clin Sci (Lond)*. 1981;61 Suppl 7:289s-93s.
594. Markiewicz M. Results of treatment of myocardial infarction accompanied by shock in relation to drugs applied. *Pol Med J*. 1969;8(2):279-83.
595. Marks AD, Marks DB, Kim YN, Moctezuma J, Adlin EV, and Channick BJ. The pressor response to angiotensin II in patients with low renin essential hypertension. *Circ Res*. 1978;42(6):864-9.
596. Marks AD, Marks DB, Kanefsky TM, Adlin VE, and Channick BJ. Enhanced adrenal responsiveness to angiotensin II in patients with low renin essential hypertension. *J Clin Endocrinol Metab*. 1979;48(2):266-70.
597. Marone C, Luisoli S, Bomio F, Beretta-Piccoli C, Bianchetti MG, and Weidmann P. Pressor factors and cardiovascular pressor responsiveness after short-term antihypertensive therapy with the calcium antagonist nifedipine alone or combined with a diuretic. *J Hypertens Suppl*. 1984;2(3):S449-52.
598. Marone C, Luisoli S, Bomio F, Beretta-Piccoli C, Bianchetti MG, and Weidmann P. Body sodium-blood volume state aldosterone and cardiovascular responsiveness after calcium entry blockade with nifedipine. *Kidney Int*. 1985;28(4):658-65.
599. Mason PA, Fraser R, Morton JJ, Semple PF, and Wilson A. The effect of angiotensin II infusion on plasma corticosteroid concentrations in normal man. *J Steroid Biochem*. 1976;7(10):859-61.
600. Mason PA, Fraser R, Morton JJ, Semple PF, and Wilson A. The effect of sodium deprivation and of angiotensin II infusion on the peripheral plasma concentrations of 18-hydroxycorticosterone aldosterone and other corticosteroids in man. *J Steroid Biochem*. 1977;8(8):799-804.
601. Mason PA, Fraser R, Semple PF, and Morton JJ. The interaction of ACTH and angiotensin II in the control of corticosteroid plasma concentration in man. *J Steroid Biochem*. 1979;10(2):235-9.
602. Mathias CJ, Matthews WB, and Spalding JM. Postural changes in plasma renin activity and responses to vasoactive drugs in a case of Shy-Drager syndrome. *J Neurol Neurosurg Psychiatry*. 1977;40(2):138-43.
603. Mathias CJ, Kooner JS, and Peart S. Neurogenic components of hypertension in human renal artery stenosis. *Clin Exp Hypertens A*. 1987;9 Suppl 1:293-306.
604. Matsuda Y, Toma Y, Matsuzaki M, Moritani K, Satoh A, Shiomi K, Ohtani N, Kohno M, Fujii T, Katayama K, Matsuda M, and Kusukawa R. Change of left atrial systolic pressure waveform in relation to left ventricular end-diastolic pressure. *Circulation*. 1990;82(5):1659-67.
605. Matsukawa T, Gotoh E, Miyajima E, Yamada Y, Shionoiri H, Tochikubo O, and Ishii M. Angiotensin II inhibits baroreflex control of muscle sympathetic nerve activity and the heart rate in patients with essential hypertension. *J Hypertens Suppl*. 1988;6(4):S501-4.
606. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H, and Ishii M. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. *Am J Physiol*. 1991;261(3 Pt 2):R690-6.
607. Matsukawa T, and Mano T. Atrial natriuretic hormone inhibits angiotensin II-stimulated sympathetic nerve activity in humans. *Am J Physiol*. 1996;271(2 Pt 2):R464-71.
608. Matsukawa T, and Miyamoto T. Does infusion of ANG II increase muscle sympathetic nerve activity in patients with primary aldosteronism? *Am J Physiol Regul Integr Comp Physiol*. 2008;294(6):R1873-9.
609. Matsukawa T, and Miyamoto T. Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. *Am J Physiol Regul Integr Comp Physiol*. 2011;300(3):R624-9.
610. Matulla B, Streit G, Pieh S, Findl O, Entlicher J, Graselli U, Eichler HG, Wolzt M, and Schmetterer L. Effects of losartan on cerebral and ocular circulation in healthy subjects. *Br J Clin Pharmacol*. 1997;44(4):369-75.
611. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, and Burnier M. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. *Hypertension*. 1999;33(3):850-5.
612. McCaa RE, Read VH, Cowley AW Jr, Bower JD, Smith GV, and McCaa CS. Influence of acute stimuli on plasma aldosterone concentration in anephric man and kidney allograft recipients. *Circ Res*. 1973;33(3):313-22.
613. McCaa RE, Langford HG, Montalvo JM, Andy OJ, Read VH, and McCaa CS. Regulation of aldosterone biosynthesis during sodium deficiency. Evidence for an essential role of the pituitary gland. *Hypertension*. 1981;3(3 Pt 2):I74-80.
614. McCloy RM, Baldus WP, Summerskill WH, and Maher FT. Angiotensin-induced natriuresis in cirrhosis in the absence of endogenous aldosterone secretion. *Ann Intern Med*. 1966;64(6):1271-6.
615. McGibney D, Singleton W, Silke B, and Taylor SH. Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists. *Br J Clin Pharmacol*. 1983;15(1):15-9.
616. McGiff JC, Muzzarelli RE, Duffy PA, Gonzalez Y, Pierce CE, and Frawley TF. Interrelationships of renin and aldosterone in a patient with hypoaldosteronism. *Am J Med*. 1970;48(2):247-53.
617. McKinnon RP, and Sinclair CJ. Angiotensinamide in the treatment of probable anaphylaxis to succinylated gelatin (Gelofusine). *Anaesthesia*. 1994;49(4):309-11.
618. McManus F, Fraser R, Davies E, Connell JM, and Freel EM. Plasma steroid profiling and response to trophins to illustrate intra-adrenal dynamics. *J Endocrinol*. 2015;224(2):149-57.
619. McMurray JJ, and Struthers AD. Renal effects of angiotensin II atrial natriuretic peptide and their interaction in man. *J Hypertens Suppl*. 1987;5(5):S59-62.
620. McMurray J, and Struthers AD. Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in man. *Clin Sci (Lond)*. 1988;74(4):419-25.
621. McVeigh GE, McMaster M, Linton T, Whitehead E, Johnston GD. A comparison of the haemodynamic and hormonal effects of low and conventional dose cyclopenthiazide in normal volunteers. *Eur J Clin Pharmacol*. 1990;38(4):351-7.
622. Mediskou P, Yavropoulou MP, Kotsa K, Tsekmekidou X, Psarakou-Gotzamani A, Papazisi A, Chlorou A, and Yovos JG. The renin-angiotensin-aldosterone axis in patients with nontumoral hyperprolactinemia. *Clin Endocrinol (Oxf)*. 2011;74(3):306-11.
623. Mehrotra MP, Hasan M, and Tandan S. Angiotensin infusion test in the diagnosis of renal hypertension. *J Assoc Physicians India*. 1974;22(4):289-92.
624. Meier A, Gubelin U, Weidmann P, Grimm M, Keusch G, Gluck Z, Minder I, and Beretta-Piccoli C. Age-rated profile of cardiovascular reactivity to norepinephrine and angiotensin II in normal and hypertensive man. *Klin Wochenschr*. 1980;58(21):1183-8.
625. Meier A, Weidmann P, Grimm M, Keusch G, Gluck Z, Minder I, and Ziegler WH. Pressor factors and cardiovascular pressor responsiveness in borderline hypertension. *Hypertension*. 1981;3(3):367-72.
626. Menard J, Guyene TT, Chatellier G, Kleinbloesem CH, and Bernadet P. Renin release regulation during acute renin inhibition in normal volunteers. *Hypertension*. 1991;18(3):257-65.
627. Mendelsohn FA, Johnston CI, Doyle AE, Scoggins BA, Denton DA, and Coghlan JP. Renin, angiotensin II, and adrenal corticosteroid relationships during sodium deprivation and angiotensin infusion in normotensive and hypertensive man. *Circ Res*. 1972;31(5):728-39.
628. Mendelsohn FA, Doyle AE, and Gray GW. Lack of response of sympathetic nervous system to angiotensin infusion. *Lancet*. 1980;1(8166):492-3.
629. Mendlowitz M, Naftchi N, Wolf RL, and Gitlow SE. Reactivity of the digital blood vessels to angiotensin II in normotensive and hypertensive subjects. *Am Heart J*. 1961;62:221-4.
630. Merillon JP, Neukirch F, Motte G, Aumont MC, Curien ND, Prasquier R, and Gourgon R. The left ventricular end-systolic pressure-volume ratio. Studies during changes in load and inotropism in the human. *Eur Heart J*. 1981;2(1):41-8.
631. Merillon JP, Fontenier GJ, Lerallut JF, Jaffrin MY, Motte GA, Genain CP, and Gourgon RR. Aortic input impedance in normal man and arterial hypertension: its modification during changes in aortic pressure. *Cardiovasc Res*. 1982;16(11):646-56.
632. Merillon JP, Lebras Y, Chastre J, Lerallut JF, Motte G, Fontenier G, Huet Y, Jaffrin MY, and Gourgon R. Forward and backward waves in the arterial system their relationship to pressure waves form. *Eur Heart J*. 1983;4 Suppl G:13-20.
633. Mersey JH, Williams GH, Hollenberg NK, and Dluhy RG. Relationship between aldosterone and bradykinin. *Circ Res*. 1977;40(5 Suppl 1):I84-8.
634. Mersey JH, Ceballos L, and Swartz S. Inhibition of captopril-induced renin release by angiotensin II. *J Cardiovasc Pharmacol*. 1987;10(5):575-9.
635. Messerli FH, Nowaczynski W, Honda M, Genest J, Boucher R, Kuchel O, and Rojo-Ortega JM. Effects of angiotensin II on steroid metabolism and hepatic blood flow in man. *Circ Res*. 1977;40(2):204-7.
636. Messerli FH, Weidmann P, DeChatel R, and Maxwell MH. Responsiveness of plasma aldosterone: dependency upon basal secretory activity. *Klin Wochenschr*. 1978;56(14):719-26.
637. Meyer JS, Shimazu K, Fukuuchi Y, Ouchi T, Okamoto S, Koto A, and Ericsson AD. Cerebral dysautoregulation in central neurogenic orthostatic hypotension (Shy-Drager syndrome). *Neurology*. 1973;23(3):262-73.
638. Miki T, Yokota Y, and Fukuzaki H. Afterload mismatch in patients with hypertrophic nonobstructive cardiomyopathy. *Jpn Circ J*. 1990;54(6):603-15.
639. Millar EA, Angus RM, Hulks G, Morton JJ, Connell JM, and Thomson NC. Activity of the renin-angiotensin system in acute severe asthma and the effect of angiotensin II on lung function. *Thorax*. 1994;49(5):492-5.
640. Millar EA, Nally JE, and Thomson NC. Angiotensin II potentiates methacholine-induced bronchoconstriction in human airway both in vitro and in vivo. *Eur Respir J*. 1995;8(11):1838-41.
641. Millar JA, McLean K, and Reid JL. Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man. *Clin Sci (Lond)*. 1981;61 Suppl 7:65s-8s.
642. Millar JA. Plasma active and inactive renin in man during infusion of angiotensin II with and without prior administration of nifedipine. *Clin Exp Hypertens A*. 1982a;4(11-12):2415-24.
643. Millar JA, Struthers AD, Beastall GH, and Reid JL. Effect of nifedipine on blood pressure and adrenocortical responses to trophic stimuli in humans. *J Cardiovasc Pharmacol*. 1982b;4 Suppl 3:S330-4.
644. Millar JA, McLean KA, Sumner DJ, and Reid JL. The effect of the calcium antagonist nifedipine on pressor and aldosterone responses to angiotensin II in normal man. *Eur J Clin Pharmacol*. 1983;24(3):315-21.
645. Millasseau SC, Kelly RP, Ritter JM, and Chowienczyk PJ. The vascular impact of aging and vasoactive drugs: comparison of two digital volume pulse measurements. *Am J Hypertens*. 2003;16(6):467-72.
646. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. *J Am Soc Nephrol*. 1999;10(8):1778-85.
647. Miller JA, Anacta LA, and Cattran DC. Impact of gender on the renal response to angiotensin II. *Kidney Int*. 1999a;55(1):278-85.
648. Miller JA, Thai K, and Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. *Kidney Int*. 1999b;56(6):2173-80.
649. Miller JA, Curtis JR, and Sochett EB. Relationship between diurnal blood pressure renal hemodynamic function and the renin-angiotensin system in type 1 diabetes. *Diabetes*. 2003;52(7):1806-11.
650. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR, Zimpelmann J, Gao W, Cattran DC, and Scholey JW. Gender differences in the renal response to renin-angiotensin system blockade. *J Am Soc Nephrol*. 2006;17(9):2554-60.
651. Mintz DH, Finster J, and Stept M. Effect of angiotensin II on immunoreactive insulin. *J Clin Endocrinol Metab*. 1967;27(5):671-8.
652. Miyajima E, Shigemasa T, Yamada Y, Tochikubo O, and Ishii M. Angiotensin II blunts while an angiotensin-converting enzyme inhibitor augments reflex sympathetic inhibition in humans. *Clin Exp Pharmacol Physiol*. 1999;26(10):797-802.
653. Miyoshi A, Makino H, Hiramatsu M, Takahashi K, Yamane Y, Takahara J, Suzuki S, Ota Z, Ofuji T, and Takehisa Y. Bartter's syndrome--case report. *Acta Med Okayama*. 1979;33(4):305-14.
654. Mizuno K, Yamazaki M, and Fukuchi S. A comparative study on (des-aspartyl1)-angiotensin II and angiotensin II in patients with essential hypertension. *Jpn Heart J*. 1980;21(3):357-65.
655. Mizuno O, Tamai H, Fujita M, Kobayashi N, Komaki G, Matsubayashi S, and Nakagawa T. Vascular responses to angiotensin II in anorexia nervosa. *Biol Psychiatry*. 1993;34(6):401-6.
656. Mohring J, Glanzer K, Maciel JA Jr, Dusing R, Kramer HJ, Arbogast R, and Koch-Weser J. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. *J Cardiovasc Pharmacol*. 1980;2(4):367-76.
657. Montanari A, Biggi A, Carra N, Ziliotti M, Fasoli E, Musiari L, Perinotto P, and Novarini A. Endothelin-A receptors mediate renal hemodynamic effects of exogenous angiotensin II in humans. *Hypertension*. 2003;42(4):825-30.
658. Moore TJ, Williams GH, Dluhy RG, Bavli SZ, Himathongkam T, and Greenfield M. Altered renin-angiotensin-aldosterone relationships in normal renin essential hypertension. *Circ Res*. 1977;41(2):167-71.
659. Moore TJ, Thein-Wai W, Dluhy RG, Dawson-Hughes BF, Hollenberg NK, and Williams GH. Abnormal adrenal and vascular responses to angiotensin II and an angiotensin antagonist in acromegaly. *J Clin Endocrinol Metab*. 1980;51(2):215-22.
660. Moore TJ, Taylor T, and Williams GH. Human platelet angiotensin II receptors: regulation by the circulating angiotensin level. *J Clin Endocrinol Metab*. 1984;58(5):778-82.
661. Moore TJ, Lazarus JM, and Hakim RM. Reduced angiotensin receptors and pressor responses in hypotensive hemodialysis patients. *Kidney Int*. 1989;36(4):696-701.
662. Morgan DR, Dixon LJ, Hanratty CG, Hughes SM, Leahey WJ, Rooney KP, Johnston GD, and McVeigh GE. Impaired endothelium-dependent and -independent vasodilation in elderly patients with chronic heart failure. *Eur J Heart Fail*. 2004;6(7):901-8.
663. Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M, and Lloyd P. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. *Clin Pharmacol Ther*. 1997;61(1):35-44.
664. Morgan T. The response of the blood pressure to an infusion of angiotensin in patients with essential malignant and renovascular hypertension. *Australas Ann Med*. 1967;16(2):168-72.
665. Morimoto S, Uchida K, Miyamoto M, Kigoshi T, Morise T, Takimoto H, and Takeda R. Plasma aldosterone response to angiotensin II in sodium-restricted elderly subjects with essential hypertension. *J Am Geriatr Soc*. 1981;29(7):302-7.
666. Morimoto S, Uchida K, Kigoshi T, Hosojima H, Yamamoto I, and Azukizawa S. Responsiveness of plasma aldosterone to angiotensin II in patients with diabetes mellitus. *Endocrinol Jpn*. 1983;30(5):671-8.
667. Moriwaki Y, Yamamoto T, Tsutsumi Z, Takahashi S, and Hada T. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. *Metabolism*. 2002;51(7):893-5.
668. Morris AD, Petrie JR, Anderson J, Connell JM, and Donnelly R. Effects of angiotensin II on insulin sensitivity: a placebo-controlled study. *Clin Sci (Lond)*. 1993;85(4):431-6.
669. Morris AD, Petrie JR, Ueda S, Connell JM, Elliott HL, Small M, and Donnelly R. Pressor and subpressor doses of angiotensin II increase insulin sensitivity in NIDDM. Dissociation of metabolic and blood pressure effects. *Diabetes*. 1994;43(12):1445-9.
670. Morris JA, O'Grady JP, Hamilton CJ, and Davidson EC. Vascular reactivity to angiotensin II infusion during gestation. *Am J Obstet Gynecol*. 1978;130(4):379-84.
671. Motwani JG, and Struthers AD. Captopril augments both basal and frusemide-induced natriuresis in normal man by suppression of circulating angiotensin II. *Br J Clin Pharmacol*. 1992a;34(1):25-31.
672. Motwani JG, and Struthers AD. Dose-response study of the redistribution of intravascular volume by angiotensin II in man. *Clin Sci (Lond)*. 1992b;82(4):397-405.
673. Motwani JG, and Struthers AD. Interactive effects of indomethacin angiotensin II and frusemide on renal haemodynamics and natriuresis in man. *Br J Clin Pharmacol*. 1994;37(4):355-61.
674. Mueller HS, Gregory JJ, Giannelli S Jr, and Ayres SM. Systemic hemodynamic and myocardial metabolic effects of isoproterenol and angiotensin after open-heart surgery. *Circulation*. 1970;42(3):491-500.
675. Muller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, and Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy normotensive subjects. *Eur J Clin Pharmacol*. 1994;47(3):231-45.
676. Mulrow PJ. The role of the renin-angiotensin system in the hypertension associated with renal vascular disease. *Can Med Assoc J*. 1964;90:277-80.
677. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, and Brunner HR. Drug concentration response relationships in normal volunteers after oral administration of losartan an angiotensin II receptor antagonist. *Clin Pharmacol Ther*. 1992;51(5):513-21.
678. Mune T, Morita H, Yasuda K, Yamakita N, and Miura K. Reduced response to metoclopramide and anomalous rising response to upright posture of plasma aldosterone concentration in Japanese patients with aldosterone-producing adenoma. *J Clin Endocrinol Metab*. 1993;77(4):1020-7.
679. Murphey LJ, Morrow JD, Sawathiparnich P, Williams GH, Vaughan DE, and Brown NJ. Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives. *Free Radic Biol Med*. 2003;35(7):711-8.
680. Murphy MB, Brown MJ, Scriven AJ, Heavey DJ, and Dollery CT. Nifedipine and alpha adrenoceptor antagonism. *Clin Pharmacol Ther*. 1984;36(6):745-9.
681. Murphy MB, Weber RR, Nelson K, and Goldberg LI. The role of alpha-adrenoceptor blockade in the antihypertensive effects of fenoldopam in humans. *Clin Pharmacol Ther*. 1988;44(1):49-55.
682. Mustafa HI, Raj SR, Diedrich A, Black BK, Paranjape SY, Dupont WD, Williams GH, Biaggioni I, and Robertson D. Altered systemic hemodynamic and baroreflex response to angiotensin II in postural tachycardia syndrome. *Circ Arrhythm Electrophysiol*. 2012;5(1):173-80.
683. Muto S, Fujisawa G, Natsume T, Asano Y, Yaginuma T, Hosoda S, and Saito T. Hyponatremia and hyperreninemic hypoaldosteronism in a critically ill patient: combination of insensitivity to angiotensin II and tubular unresponsiveness to mineralocorticoid. *Clin Nephrol*. 1990;34(5):208-13.
684. Nadler J, Zipser RD, Coleman R, and Horton R. Stimulation of renal prostaglandins by pressor hormones in man: comparison of prostaglandin E2 and prostacyclin (6 keto prostaglandin F1 alpha). *J Clin Endocrinol Metab*. 1983;56(6):1260-5.
685. Nagai H, Matsunaga M, Ogawa K, Pak CH, Kanatsu K, Hara A, Kono T, and Kawai C. Dynamic changes in plasma inactive renin levels in Bartter's syndrome after administration of captopril and angiotensin II. *Clin Exp Pharmacol Physiol*. 1986;13(1):69-75.
686. Nagamitsu A, Greish K, and Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. *Jpn J Clin Oncol*. 2009;39(11):756-66.
687. Nakada T, Kubota Y, Sasagawa I, Yagisawa T, Watanabe M, and Ishigooka M. Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma. *J Urol*. 1995;153(6):1775-80.
688. Nakagawa Y, Toya K, Natsume H, Nasuda K, Takeuchi H, Kubota A, Ogawa H, and Igarashi Y. Long-term follow-up of a girl with the neonatal form of Bartter's syndrome. *Endocr J*. 1997;44(2):275-81.
689. Nakamura T, Ito M, Matsui K, Yoshimura T, Kawasaki N, and Maeyama M. Significance of angiotensin sensitivity test for prediction of pregnancy-induced hypertension. *Obstet Gynecol*. 1986;67(3):388-94.
690. Nanivadekar SA, Gulati OP, Pinto IJ, Panday SR, Kelkar MD, and Parulkar GB. Hypertension in the young: a prospective study of 50 patients of 30 years and below with special reference to angiotensin II studies. *Indian Heart J*. 1979;31(1):13-20.
691. Naruse M, Naruse K, Jibiki K, Nomura K, Demura R, Demura H, and Shizume K. Endocrine characterization of the adrenal adenomas in a case of primary aldosteronism. *Tokai J Exp Clin Med*. 1984;9(3):175-82.
692. Nassif AC, Nolan TR, and Corcoran AC. Angiotensin II in treatment of hypotensive states. *JAMA*. 1963;183:751-4.
693. Navis G, de Jong PE, Donker AJ, van der Hem GK, and de Zeeuw D. Effects of enalaprilic acid on sodium excretion and renal hemodynamics in essential hypertension. *J Clin Hypertens*. 1985;1(3):228-38.
694. Negus P, Tannen RL, and Dunn MJ. Indomethacin potentiates the vasoconstrictor actions of angiotensin II in normal man. *Prostaglandins*. 1976;12(2):175-80.
695. Nesbit WS, and Levagood FB. Preliminary observations on a clinical evaluation of angiotensin II a new pressor agent. *Grace Hosp Bul*. 1961;39:9-12.
696. Newby DE, Lee MR, Gray AJ, and Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. *Br J Clin Pharmacol*. 1995;40(1):103-4.
697. Nicholl DD, Hemmelgarn BR, Turin TC, MacRae JM, Muruve DA, Sola DY, and Ahmed SB. Increased urinary protein excretion in the "normal" range is associated with increased renin-angiotensin system activity. *Am J Physiol Renal Physiol*. 2012;302(5):F526-32.
698. Nicholl DD, Hanly PJ, Poulin MJ, Handley GB, Hemmelgarn BR, Sola DY, and Ahmed SB. Evaluation of continuous positive airway pressure therapy on renin-angiotensin system activity in obstructive sleep apnea. *Am J Respir Crit Care Med*. 2014;190(5):572-80.
699. Nicholls MG, Espiner EA, and Donald RA. Aldosterone and renin-angiotensin responses to stimuli in patients with treated congestive heart failure. *J Lab Clin Med*. 1976;87(6):1005-15.
700. Nicholls MG, Grekin RJ, and Padfield PL. Angiotensin II-induced aldosterone stimulation in man is not dependent upon adrenocorticotropin. *J Clin Endocrinol Metab*. 1980;51(5):1171-4.
701. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, and Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. *Circulation*. 1999;100(21):2131-4.
702. Nicotero JA, Moutsos SE, Perez-Stable E, Turrian HE, and Shapiro AP. Diagnostic and physiologic implications of the angiotensin infusion test. *N Engl J Med*. 1966;274(26):1464-8.
703. Nieminen MM, Linkola J, Fyhrquist F, Tikkanen I, and Forslund T. Renin-aldosterone axis in ethanol intoxication: effect of A II infusion. *Int J Clin Pharmacol Ther Toxicol*. 1985;23(3):137-40.
704. Nolan JP, Cobb LA, and Thompson JI. Circulatory responses to angiotensin in man. *Clin Pharmacol Ther*. 1967;8(2):235-42.
705. Nomura K, Toraya S, Horiba N, Ujihara M, Aiba M, and Demura H. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. *J Clin Endocrinol Metab*. 1992;75(1):323-7.
706. Noveck RJ, McMahon FG, Quiros A, and Giles T. Extrarenal contributions to indapamide's antihypertensive mechanism of action. *Am Heart J*. 1983;106(1 Pt 2):221-9.
707. Nowaczynski W, Koiw E, Biron P, Chretien M, and Genest J. Effects of angiotensin infusions on urinary excretion of compound III and substances other than aldosterone. *Can J Biochem Physiol*. 1962;40:727-38.
708. O'Brien PM, and Broughton Pipkin F. The effect of essential fatty acid and specific vitamin supplements on vascular sensitivity in the mid-trimester of human pregnancy. *Clin Exp Hypertens B*. 1983;2(2):247-54.
709. O'Brien PM, Morrison R, and Broughton Pipkin F. The effect of dietary supplementation with linoleic and gammalinolenic acids on the pressor response to angiotensin II--a possible role in pregnancy-induced hypertension? *Br J Clin Pharmacol*. 1985;19(3):335-42.
710. O'Callaghan CJ, Komersova K, and Louis WJ. Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. *Hypertension*. 1998;31(1):104-9.
711. O'Connell JE, Jardine AG, Davies DL, McQueen J, and Connell JM. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. *Clin Sci (Lond)*. 1993;85(1):19-26.
712. Oda T, Hamamoto K, and Morinaga H. Stress echocardiography for children--Comparison between handgrip ergometer and angiotensin tests. *Jpn Circ J*. 1983;47(11):1334.
713. Oelkers W, Dusterdieck G, and Morton JJ. Arterial angiotensin II and venous immunoreactive material before and during angiotensin infusion in man. *Clin Sci*. 1972;43(2):209-18.
714. Oelkers W, Brown JJ, Fraser R, Lever AF, Morton JJ, and Robertson JI. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. *Circ Res*. 1974;34(1):69-77.
715. Oelkers W, Schoneshofer M, Schultze G, Brown JJ, Fraser R, Morton JJ, Lever AF, and Robertson JI. Effect of prolonged low-dose angiotensin II infusion on the sensitivity of adrenal cortex in man. *Circ Res*. 1975;36(6 Suppl 1):49-56.
716. Oelkers W, Schoneshofer M, Schultze G, and Bauer B. Effect of prolonged low-dose infusions of ile5-angiotensin II on blood pressure aldosterone and electrolyte excretion in sodium replete man. *Klin Wochenschr*. 1978a;56(1):37-41.
717. Oelkers W, Schoneshofer M, Schultze G, Wenzler M, Bauer B, L'Age M, and Fehm HL. Prolonged infusions of Ile5-angiotensin-II in sodium replete and deplete man: effects on aldosterone ACTH cortisol blood pressure and electrolyte balance. *J Clin Endocrinol Metab*. 1978b;46(3):402-13.
718. Oelkers W, Kleiner S, and Bahr V. Effects of incremental infusions of atrial natriuretic factor on aldosterone renin and blood pressure in humans. *Hypertension*. 1988;12(4):462-7.
719. Ogawa T, Fujise Y, Shibata S, Abiru M, Takigami Y, Miura T, Kikuchi K, Fukazawa Y, and Iimura O. Bartter's syndrome with gouty arthritis. *Intern Med*. 1992;31(9):1120-4.
720. Ogihara T, Maruyama A, Nugent CA, Hata T, Mikami H, and Kumahara Y. Familial Bartter's syndrome. *Arch Intern Med*. 1982;142(5):906-8.
721. Ogihara T, Nagano M, Higaki J, Kohara K, and Mikami H. Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects. *J Cardiovasc Pharmacol*. 1995;26(3):490-4.
722. Olgaard K, Madsen S, and Hammer M. The adrenocortical response to angiotensin II infusion in anephric and non-nephrectomized patients on regular hemodialysis. *Acta Med Scand*. 1977;202(3):213-9.
723. Olsen KS, Svendsen LB, and Larsen FS. Validation of transcranial near-infrared spectroscopy for evaluation of cerebral blood flow autoregulation. *J Neurosurg Anesthesiol*. 1996;8(4):280-5.
724. Oney T, and Kaulhausen H. Effect of angiotensin infusion during pregnancy on fetal heart rate and on fetal activity. *Eur J Obstet Gynecol Reprod Biol*. 1982a;13(3):133-7.
725. Oney T, and Kaulhausen H. Effect of sodium chloride and sorbitol infusions on vascular angiotensin reactivity during third trimester pregnancy. *Arch Gynecol*. 1982b;231(2):99-105.
726. Oney T, and Kaulhausen H. The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy. *Am J Obstet Gynecol*. 1982c;142(1):17-20.
727. Oney T, Bellmann O, and Kaulhausen H. Relationship between serum prolactin concentration vascular angiotensin sensitivity and arterial blood pressure during third trimester pregnancy. *Arch Gynecol Obstet*. 1988;243(2):83-90.
728. Orr FR, and Filipich RL. Studies with angiotensin in nephrogenic diabetes insipidus. *Can Med Assoc J*. 1967;97(14):841-5.
729. Otabe S, Muto S, Asano Y, Ohbu E, Koyama K, Okita N, Yamada K, and Nonaka K. Selective hypoaldosteronism in a patient with Sjogren's syndrome: insensitivity to angiotensin II. *Nephron*. 1991;59(3):466-70.
730. Ozono R, Matsuura H, Oshima T, Ishibashi K, Ishida M, Ishida T, Watanabe M, Kajiyama G, and Kambe M. Modulation of target tissue response to angiotensin II and sodium sensitivity in Japanese patients with essential hypertension. *Hypertens Res*. 1996;19(3):141-5.
731. Padfield P,. and Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. *J Endocrinol*. 1977;74(2):251-9.
732. Padfield PL, Grekin RJ, and Nicholls MG. Clinical syndromes associated with disorders of renal tubular chloride transport: excess and deficiency of a circulating factor? *Med Hypotheses*. 1984;14(4):387-400.
733. Page A, Reich H, Zhou J, Lai V, Cattran DC, Scholey JW, and Miller JA. Endothelial nitric oxide synthase gene/ gender interactions and the renal hemodynamic response to angiotensin II. *J Am Soc Nephrol*. 2005;16(10):3053-60.
734. Palmgren E, Widgren B, Aurell M, and Herlitz H. Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased response to prostaglandins. *J Hypertens*. 2003;21(5):969-76.
735. Parmley WW, Tomoda H, Diamond G, Forrester JS, and Crexells C. Dissociation between indices of pump performance and contractility in patients with coronary artery disease and acute myocardial infarction. *Chest*. 1975;67(2):141-6.
736. Pasanisi F, Elliott HL, Meredith PA, Sumner DJ, and Reid JL. Effect of calcium channel blockers on adrenergic and nonadrenergic vascular responses in man. *J Cardiovasc Pharmacol*. 1985a;7(6):1166-70.
737. Pasanisi F, Elliott HL, and Reid JL. Vascular and aldosterone responses to angiotensin II in normal humans: effects of nicardipine. *J Cardiovasc Pharmacol*. 1985b;7(6):1171-5.
738. Payne RA, Symeonides CN, Webb DJ, and Maxwell SR. Pulse transit time measured from the ECG: an unreliable marker of beat-to-beat blood pressure. *J Appl Physiol (1985)*. 2006;100(1):136-41.
739. Payne RA, Isnardi D, Andrews PJ, Maxwell SR, and Webb DJ. Similarity between the suprasystolic wideband external pulse wave and the first derivative of the intra-arterial pulse wave. *Br J Anaesth*. 2007;99(5):653-61.
740. Payne RM, Horwitz LD, and Mullins CB. Comparison of isometric exercise and angiotensin infusion as stress test for evaluation of left ventricular function. *Am J Cardiol*. 1973;31(4):428-33.
741. Peart WS, and Brown JJ. Effect of angiotensin (hypertensin or angiotonin) on urine flow and electrolyte excretion in hypertensive patients. *Lancet*. 1961;1(7167):28-9.
742. Peltola P. The effect of angiotensin on the excretion of free and conjugated 5-hydroxyindoleacetic acid in man. *Annales medicinae experimentalis et biologiae Fenniae*. 1970;48(1):24-7.
743. Perloff JK, Binnion PF, Caulfield WH, and DeLeon AC Jr. The use of angiotensin in the assessment of left ventricular function in fixed orifice aortic stenosis. *Circulation*. 1967;35(2):347-57.
744. Petrie MC, Hillier C, Morton JJ, and McMurray JJ. Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans. *J Hypertens*. 2000;18(1):61-4.
745. Petrie MC, McDonald J, E, Hillier C, Morton JJ, and McMurray JJ. Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. *Br J Clin Pharmacol*. 2001;52(2):165-8.
746. Philipp T, Distler A, and Cordes U. Sympathetic nervous system and blood-pressure control in essential hypertension. *Lancet*. 1978a;2(8097):959-63.
747. Philipp T, Distler A, Cordes U, and Wolff HP. Plasma noradrenaline and the pressor action of exogenous noradrenaline in normotensive subjects and patients with essential hypertension. *Clin Sci Mol Med Suppl*. 1978b;4:61s-3s.
748. Phillips PA, Rolls BJ, Ledingham JG, Morton JJ, and Forsling ML. Angiotensin II-induced thirst and vasopressin release in man. *Clin Sci (Lond)*. 1985;68(6):669-74.
749. Pidgeon GB, Richards AM, Nicholls MG, Bailey RR, Lynn KL, Lewis LK, and Yandle TG. Effect of ouabain on pressor responsiveness in normal man. *Am J Physiol*. 1994;267(5 Pt 1):E642-7.
750. Plavsic C, and Lambic L. Clinical investigations with angiotensin II. effects of angiotensin II infusion on electrocardiogram and skin temperature. *Cardiologia*. 1964;44:17-27.
751. Plovsing RR, Wamberg C, Sandgaard NC, Simonsen JA, Holstein-Rathlou NH, Hoilund-Carlsen PF, and Bie P. Effects of truncated angiotensins in humans after double blockade of the renin system. *Am J Physiol Regul Integr Comp Physiol*. 2003;285(5):R981-91.
752. Polinsky RJ, Kopin IJ, Ebert MH, and Weise V. Pharmacologic distinction of different orthostatic hypotension syndromes. *Neurology*. 1981;31(1):1-7.
753. Portaluppi F, Vergnani L, Margutti A, Ambrosio MR, Bondanelli M, Trasforini G, Rossi R, and Degli Uberti EC. Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man. *J Clin Endocrinol Metab*. 1993;77(3):816-20.
754. Price DA, De'Oliveira JM, Fisher ND, and Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist eprosartan in healthy men. *Hypertension*. 1997;30(2 Pt 1):240-6.
755. Price DA, De'Oliveira JM, Fisher ND, Williams GH, and Hollenberg NK. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. *Am J Hypertens*. 1999;12(4 Pt 1):348-55.
756. Price DA, Fisher ND, Osei SY, Lansang MC, and Hollenberg NK. Renal perfusion and function in healthy African Americans. *Kidney Int*. 2001;59(3):1037-43.
757. Price DA, Fisher ND, Lansang MC, Stevanovic R, Williams GH, and Hollenberg NK. Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt. *Hypertension*. 2002;40(2):186-9.
758. Punzengruber C, and Silberbauer K. Effect of angiotensin II infusion on a prostaglandin I2-metabolite and on left ventricular function. *Basic Res Cardiol*. 1986;81(3):283-8.
759. Pusterla C, Beretta-Piccoli C, Stadler P, Weidmann P, Favre L, and Vallotton M. Blood pressure regulation on low and high sodium diets in normotensive members of normotensive or hypertensive families. *J Hypertens Suppl*. 1986;4(6):S310-3.
760. Pusterla C, Beretta-Piccoli C, Stadler P, Weidmann P, and Shaw S. Sodium and responses to infused noradrenaline and angiotensin II in subjects predisposed to hypertension. *J Hum Hypertens*. 1988;1(4):267-76.
761. Quest DW, Gopalakrishnan V, McNeill JR, and Wilson TW. Effect of losartan on angiotensin II-mediated endothelin and prostanoid excretion in humans. *Am J Hypertens*. 2000;13(12):1288-94.
762. Quinones MA, Gaasch WH, Cole J, S, and Alexander JK. Echocardiographic determination of left ventricular stress-velocity relations. *Circulation*. 1975;51(4):689-700.
763. Quinones MA, Gaasch WH, and Alexander JK. Influence of acute changes in preload afterload contractile state and heart rate on ejection and isovolumic indices of myocardial contractility in man. *Circulation*. 1976;53(2):293-302.
764. Rabinowe SL, Redgrave JE, Shoback DM, Podolsky S, Hollenberg NK, and Williams GH. Renin suppression by saline is blunted in nonmodulating essential hypertension. *Hypertension*. 1987;10(4):404-8.
765. Radfar N, Gill JR Jr, Bartter FC, Bravo E, Taylor AA, and Bowden RE. Hypokalemia in Bartter's syndrome and other disorders produces resistance to vasopressors via prostaglandin overproduction. *Proc Soc Exp Biol Med*. 1978;158(3):502-7.
766. Radice M, Folli G, Giani P, Tavecchia A, and Mariotti G. Latent myocardial contractile impairment in patients with angina pectoris. *Acta Cardiologica*. 1975;30(5):333-41.
767. Rado JP, Borbely L, Tako J, and Banos C. Effects of furosemide uring antidiuresis and antinatriuresis induced by angiotensin. *Med Pharmacol Exp Int J Exp Med*. 1967;17(4):373-7.
768. Rado JP, Borbely L, Szende L, and Tako J. Changes in distal sodium reabsorption during angiotensin infusion in response to furosemide. *Pharmacology*. 1968;1(6):369-74.
769. Rado JP, Borbely L, Szende L, and Tako J. Extreme antidiuresis in response to chlorpropamide administered intravenously during angiotensin infusion in diabetes insipidus. *Med Exp Int J Exp Med*. 1969;19(5):245-53.
770. Rado JP, Szende L, and Borbely L. Effects of ethacrynic acid on specific renal functions without and during angiotensin infusion in man. *Arch Int Pharmacodyn Ther*. 1970a;186(1):142-54.
771. Rado JP, Szende L, Tako J, and Borbely L. Studies on the sites of action of ethacrynic acid and furosemide during angiotensin infusion. *J Clin Pharmacol J New Drugs*. 1970b;10(a6):375-81.
772. Rado JP, and Borbely L. Evidences for proximal tubular site of action of intravenous ethacrynic acid (Lyovac-Edecrin) obtained during antiotensin infusion in diabetes insipidus. *Endokrinologie*. 1970c;56(3):309-18.
773. Rahman AR, Motwani JG, Lang CC, and Struthers AD. Circulating angiotensin II and renal sodium handling in man: a dose-response study. *Clin Sci (Lond)*. 1993;85(2):147-56.
774. Raine JM, and Bishop JM. Alterations in ventilation-perfusion relationships in the lung after breathing inert dust or bronchoconstrictor aerosols and after short periods of voluntary hyperventilation. *J Clin Invest*. 1964;43:557-70.
775. Rakugi H, Ogihara T, Nakamaru M, Saito H, Shima J, Sakaguchi K, and Kumahara Y. Renal interaction of atrial natriuretic peptide with angiotensin II: glomerular and tubular effects. *Clin Exp Pharmacol Physiol*. 1989a;16(2):97-107.
776. Rakugi H, Ogihara T, Nakamaru M, Saito H, Shima J, Sakaguchi K, and Kumahara Y. Role of angiotensin II in the renal response to atrial natriuretic peptide in normal subjects. *J Cardiovasc Pharmacol*. 1989b;13 Suppl 6:S55-8.
777. Ram CV, Anderson RJ, Hart GR, and Crumpler CP. Alpha adrenergic blockade by prazosin in therapy of essential hypertension. *Clin Pharmacol Ther*. 1981;29(6):719-22.
778. Ramesh S, Wilton SB, Holroyd-Leduc JM, Turin TC, Sola DY, and Ahmed SB. Testosterone is associated with the cardiovascular autonomic response to a stressor in healthy men. *Clin Exp Hypertens*. 2015;37(3):184-91.
779. Ramin SM, Ramin KD, Cox K, Magness RR, Shearer VE, and Gant NF. Comparison of prophylactic angiotensin II versus ephedrine infusion for prevention of maternal hypotension during spinal anesthesia. *Am J Obstet Gynecol*. 1994;171(3):734-9.
780. Ramsay SG, Clayton RA, Dagg KD, Thomson LJ, Nally JE, and Thomson NC. Effect of angiotensin II on histamine-induced bronchoconstriction in the human airway both in vitro and in vivo. *Respir Med.* 1997;91(10):609-15.
781. Rayyis SS, and Horton R. Effect of angiotensin II on adrenal and pituitary function in man. *J Clin Endocrinol Metab*. 1971;32(4):539-46.
782. Reams GP, and Bauer JH. Angiotensin II potentiates the vasoconstrictive effect of norepinephrine in normotensive and hypertensive man. *J Clin Hypertens*. 1987;3(4):610-6.
783. Regan TJ, Levinson GE, Oldewurtel HA, Frank MJ, Weisse AB, and Moschos CB. Ventricular function in noncardiacs with alcoholic fatty liver: role of ethanol in the production of cardiomyopathy. *J Clin Invest*. 1969;48(2):397-407.
784. Rehman A, Rahman AR, Rasool AH, and Naing NN. The effects of angiotensin II on pulse wave velocity in healthy humans. *Int J Clin Pharmacol Ther*. 2001;39(10):423-30.
785. Rehman A, Rahman AR, and Rasool AH. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors. *J Hum Hypertens*. 2002;16(4):261-6.
786. Reich H, Duncan JA, Weinstein J, Cattran DC, Scholey JW, and Miller JA. Interactions between gender and the angiotensin type 1 receptor gene polymorphism. *Kidney Int*. 2003;63(4):1443-9.
787. Reid JL, Pasanisi F, Meredith PA, and Elliott HL. Clinical pharmacological studies on the interaction between alpha-adrenoceptors and calcium antagonists. *J Cardiovasc Pharmacol*. 1985;7 Suppl 6:S206-9.
788. Rhie FH, Christlieb AR, Sandor T, Gleason RE, Rand LI, Shah ST, and Soeldner JS. Retinal vascular reactivity to norepinephrine and angiotensin II in normals and diabetics. *Diabetes*. 1982;31(12):1056-60.
789. Ribstein J, Picard A, Armagnac C, Sissmann J, and Mimran A. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men. *J Cardiovasc Pharmacol*. 2001;37(4):449-60.
790. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, and Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. *Circ Res*. 1992;71(6):1501-7.
791. Richards AM, Crozier IG, Espiner EA, Yandle TG, and Nicholls MG. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. *Hypertension*. 1993a;22(2):231-6.
792. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, and Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. *J Hypertens*. 1993b;11(4):407-16.
793. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, and Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. *Circulation*. 1993;87(6):1969-73.
794. Rieu P, Faucher C, Baumelou A, Deray G, Bletry O, Godeau P, and Jacobs C. Medical nephrectomy with CsA and angiotensin II in a case of life-threatening membranous glomerulonephritis. *Nephrol Dial Transplant*. 1994;9(1):83-4.
795. Rodriguez-Portales JA, Lopez-Moreno JM, and Mahana D. Inhibition of the kallikrein-kinin system and vascular reactivity in Bartter's syndrome. *Hypertension*. 1985;7(6 Pt 1):1017-22.
796. Rodriguez Portales JA, Arteaga E, Lopez Moreno JM, and Biglieri EG. Zona glomerulosa function after life-long suppression in two siblings with the hypertensive virilizing form of congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 1988;66(2):349-54.
797. Rodriguez-Portales JA, and Fardella C. Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure. *J Endocrinol Invest*. 1994;17(5):307-11.
798. Rodriguez-Soriano J, Vallo A, and Oliveros R. Bartter's syndrome presenting with features resembling renal tubular acidosis. Improvement of renal tubular defects by indomethacin. *Helv Paediatr Acta*. 1978;33(2):141-51.
799. Rogacz S, Hollenberg NK, and Williams GH. Role of angiotensin II in the hormonal renal and electrolyte response to sodium restriction. *Hypertension*. 1987;9(3):289-94.
800. Rogacz S, Williams GH, and Hollenberg NK. Time course of enhanced adrenal responsiveness to angiotensin on a low salt diet. *Hypertension*. 1990;15(4):376-80.
801. Roguska J, Simon NM, and del Greco F. Pressor response to angiotensin II in hypertension. Correlation with plasma renin activity and response to norepinephrine and metaraminol. *Am J Cardiol*. 1968;21(5):705-13.
802. Ronan JA Jr, Steelman RB, Schrank JP, and Cochran PT. The angiotensin infusion test as a method of evaluating left ventricular function. *Am Heart J*. 1975;89(5):554-60.
803. Rosenblum M, Simpson DP, and Evenson M. Factitious Bartter's syndrome. *Arch Intern Med*. 1977;137(9):1244-5.
804. Rosendorff C, Patton J, Radford HM, and Kalliatakis B. Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. *J Cardiovasc Pharmacol*. 1992;19 Suppl 6:S105-9.
805. Rosenfeld BA, Nguyen ND, Sung I, and Faraday N. Neuroendocrine stress hormones do not recreate the postoperative hypercoagulable state. *Anesth Analg*. 1998;86(3):640-5.
806. Rosler A, Theodor R, Boichis H, Gerty R, Ulick S, Alagem M, Tabachinik E, Cohen B, and Rabinowitz D. Metabolic responses to the administration of angiotensin II K and ACTH in two salt-wasting syndromes. *J Clin Endocrinol Metab*. 1977;44(2):292-301.
807. Rosler A. The natural history of salt-wasting disorders of adrenal and renal origin. *J Clin Endocrinol Metab*. 1984;59(4):689-700.
808. Rosman PM, Agrawal R, Goodman AD, and Steiner AL. Effect of angiotensin II on cyclic guanosine monophosphate and cyclic adenosine monophosphate in human plasma. *J Clin Endocrinol Metab*. 1976;42(3):531-6.
809. Ross J Jr, and Braunwald E. The study of left ventricular function in man by increasing resistance to ventricular ejection with angiotensin. *Circulation*. 1964;29:739-49.
810. Rousso P, Buclin T, Nussberger J, Brunner-Ferber F, Brunner HR, and Biollaz J. Effects of MDL 100,240 a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers. *J Cardiovasc Pharmacol*. 1998;31(3):408-17.
811. Ruilope L, Paya C, Alcazar JM, Sancho-Rof J, Garcia-Robles R, Rodicio J, Hammond TG, Knox FG, and Romero JC. Failure of angiotensin II to reduce plasma renin activity in hypertensive pregnant women. *J Hypertens Suppl*. 1984;2(3):S251-4.
812. Ruilope LM, Miranda B, Robles RG, Hammond TG, Sancho J, Romero JC, and Rodicio JL. Effect of exogenous angiotensin II infusion after one year of captopril therapy in essential hypertension. *Postgrad Med J*. 1986;62 Suppl 1:90-3.
813. Ryding J, Heslet L, Hartvin T, and Jonsson V. Reversal of 'refractory septic shock' by infusion of amrinone and angiotensin II in an anthracycline-treated patient. *Chest*. 1995;107(1):201-3.
814. Safar ME, London G, Weiss Y, Simon A, and Milliez P. Vascular reactivity to angiotensin in borderline hypertension. *Biomedicine*. 1974a;21(12):491-4.
815. Safar ME, London GM, Weiss YA, and Milliez PL. Borderline hypertension: correlation between the cardiac output and the vascular reactivity to norepinephrine. *Acta Clin Belg*. 1974b;29(5):299-303.
816. Saito I, Saruta T, Nakamura R, Misumi J, Kondo K, and Matsuki S. The mechanism of low-renin hypertension: aldosterone response to sodium restriction and upright posture angiotensin II ACTH and potassium in patients with hypertension. *Jpn Circ J*. 1976;40(8):911-9.
817. Saito T, Hirota Y, Kita Y, Shimizu G, Kaku K, and Kawamura K. Evaluation of left ventricular contractility in hypertrophic cardiomyopathy from end-systolic pressure-volume relation. *Jpn Circ J*. 1987;51(5):511-9.
818. Sanchez-Ramos L, O'Sullivan MJ, and Garrido-Calderon J. Effect of low-dose aspirin on angiotensin II pressor response in human pregnancy. *Am J Obstet Gynecol*. 1987;156(1):193-4.
819. Sanchez-Ramos L, Briones DK, Kaunitz AM, Delvalle GO, Gaudier FL, and Walker CD. Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients. *Obstet Gynecol*. 1994;84(3):349-53.
820. Sander-Jensen K, Secher NH, Astrup A, Christensen NJ, Damkjaer-Nielsen M, Giese J, Warberg J, and Bie P. Angiotensin II attenuates reflex decrease in heart rate and sympathetic activity in man. *Clin Physiol*. 1988;8(1):31-40.
821. Sann L, David M, Richard P, Floret D, Sassard J, Bizollon CA, and Francois R. Effect of sodium restriction and angiotensin II infusion in Bartter's syndrome. *Pediatr Res*. 1976;10(12):971-7.
822. Sannerstedt R, Bojs G, and Varnauskas E. Hemodynamic effect of angiotensin II in minute amounts. Observations on normal subjects at rest and during exercise. *Scand J Clin Lab Invest*. 1963;15:159-66.
823. Sannerstedt R, and Varnauskas E. Influence of angiotensin on the hemodynamic response to exercise in normotensive subjects. *Circulation*. 1968;38(6):1097-103.
824. Sannerstedt R. Comparison of hemodynamic responses to exercise in hypertensive patients and in healthy subjects given angiotensin. *Cardiology*. 1973;58(4):203-8.
825. Saruta T, Okuno T, Eguchi T, Nakamura R, Saito I, Kondo K, Oka M, and Matsuki S. Responses of aldosterone-producing adenomas to ACTH and angiotensins. *Acta Endocrinol (Copenh)*. 1979;92(4):702-9.
826. Saruta T, Kitajima W, Hayashi M, Kato E, and Matsuki S. Renin and aldosterone in hypothyroidism: relation to excretion of sodium and potassium. *Clin Endocrinol (Oxf)*. 1980;12(5):483-9.
827. Saruta T, Nagahama S, Eguchi T, Oka M, and Kanbegawa A. Renin aldosterone and other mineralocorticoids in hyperkalemic patients with chronic renal failure showing mild azotemia. *Nephron*. 1981;29(3-4):128-32.
828. Saruta T, Fujimaki M, Senba S, Saito I, and Konishi K. Aldosterone and other mineralocorticoids in Bartter's syndrome. *J Lab Clin Med*. 1984;103(6):848-53.
829. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, and Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. *J Clin Endocrinol Metab*. 1986;62(2):275-9.
830. Saruta T, Tominaga T, Yamakawa H, Ohno Y, and Suzuki H. Blood pressure sensitivity to salt calcium metabolism and insulin sensitivity in essential hypertension. *Clin Exp Pharmacol Physiol*. 1995;22(12):S406-11.
831. Sasaki H, Kawasaki T, Okumura M, Asano T, Abe K, and Arakawa K. Bartter's syndrome: effect of indomethacin on prostaglandins urinary kallikrein renin-angiotensin-aldosterone system and the response to angiotensin II antagonist. *Endocrinol Jpn*. 1980;27(4):417-29.
832. Sasaki K, Murabayashi S, Baba T, Aoyagi K, Matsunaga M, Takebe K, and Nigawara K. The mechanism of aldosterone response to furosemide test in patients with Shy-Drager syndrome. *Horm Metab Res*. 1983;15(12):610-5.
833. Sato H, Sato K, Sato Y, Asamura M, Kanamaru R, Sugiyama Z, Kitahara T, Mimata Y, Wakui A, Suzuki M, Hori K, Abe I, Saito S, and Sato H. Induced hypertension chemotherapy of cancer patients by selective enhancement of drug delivery to tumor tissue with angiotensin II. *Sci Rep Res Inst Tohoku Univ Med*. 1981;28(1-4):32-44.
834. Sato H, Sugiyama K, Hoshi M, Urushiyama M, Ishizuka K. Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging. *World J Surg*. 1995;19(6):836-42.
835. Sato T, Maebashi M, Goto K, and Yoshinaga K. Interrelationship between angiotensin and catecholamines. *Jpn Heart J*. 1968;9(1):13-9.
836. Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, and Seely EW. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. *Hypertension*. 2010;55(5):1239-45.
837. Saxenhofer H, Morger D, Weidmann P, Ferrier C, and Shaw SG. Modulation of noradrenergic but not angiotensinergic blood pressure control by beta-blockade with carteolol. *J Hypertens*. 1991;9(11):1049-56.
838. Sayk F, Wobbe I, Twesten C, Meusel M, Wellhoner P, Derad I, and Dodt C. Prolonged blood pressure elevation following continuous infusion of angiotensin II-a baroreflex study in healthy humans. *Am J Physiol Regul Integr Comp Physiol*. 2015;309(11):R1406-14.
839. Scaroni C, Opocher G, and Mantero F. Renin-angiotensin-aldosterone system: a long-term follow-up study in 17 alpha-hydroxylase deficiency syndrome (17OHDS). *Clin Exp Hypertens A*. 1986;8(4-5):773-80.
840. Scaroni C, Biason A, Carpene G, Opocher G, and Mantero F. 17-alpha-hydroxylase deficiency in three siblings: short- and long-term studies. *J Endocrinol Invest*. 1991;14(2):99-108.
841. Schachinger H, Dieterle T, Martina B, Haberthur C, Huber PR, Bock A, Drewe J, and Gyr K. Increased renovascular response to angiotensin II in persons genetically predisposed to arterial hypertension disappears after chronic angiotensin-converting enzyme inhibition. *J Hypertens*. 2004;22(1):175-80.
842. Schachinger H, Klarhofer M, Linder L, Drewe J, and Scheffler K. Angiotensin II decreases the renal MRI blood oxygenation level-dependent signal. *Hypertension*. 2006;47(6):1062-6.
843. Schaison G, Couzinet B, Gourmelen M, Elkik F, and Bougneres P. Angiotensin and adrenal steroidgenesis: study of 21-hydroxylase-deficient congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 1980;51(6):1390-4.
844. Schiffl H, Weidmann P, Beretta-Piccoli C, Cottier C, Seiler AJ, and Ziegler WH. Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness. *Eur J Clin Pharmacol*. 1982;23(3):215-20.
845. Schiffrin EL, Gutkowska J, Julesz J, Thibault G, and Genest J. Effect of low normal and high normal sodium intake on hormonal and metabolic responses to ACTH angiotensin II and an acute salt load in normal subjects. *Clin Invest Med*. 1984;7(3):149-55.
846. Schindler C, Brosnihan KB, Ferrario CM, Bramlage P, Maywald U, Koch R, Oertel R, and Kirch W. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. *J Clin Pharmacol*. 2007;47(1):112-20.
847. Schlaich MP, Klingbeil AU, Jacobi J, Delles C, Schneider MP, Schmidt BM, and Schmieder RE. Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. *J Hypertens*. 2002;20(1):117-24.
848. Schmitt F, Martinez F, Brillet G, Nguyen-Khoa T, Brouard R, Sissmann J, Lacour B, and Grunfeld JP. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects. *J Cardiovasc Pharmacol*. 1998;31(2):314-21.
849. Schneider AG, Hofmann L, Wuerzner G, Glatz N, Maillard M, Meuwly JY, Eggimann P, Burnier M, and Vogt B. Renal perfusion evaluation with contrast-enhanced ultrasonography. *Nephrol Dial Transplant*. 2012;27(2):674-81.
850. Schneider PB. Orthostatic hypotension. Observations on the effect of levarterenol and hypertensin II. *Arch Intern Med*. 1962;110:240-8.
851. Schneider-Helmert D. Experimental elevations of blood pressure induced as an internal stimulus during sleep in man: effects on cortical vigilance and response thresholds in different sleep stages. *Sleep*. 1983;6(4):339-46.
852. Schohn D, Weidmann P, Jahn H, and Beretta-Piccoli C. Norepinephrine-related mechanism in hypertension accompanying renal failure. *Kidney Int*. 1985;28(5):814-22.
853. Schohn DC, and Jahn HA. Effects of a potassium-sparing/thiazide diuretic combination on cardiovascular reactivity to vasopressor agents. *Am J Cardiol*. 1990;65(23):14K-7K.
854. Schohn DC, Jahn HA, and Pelletier BC. Dose-related cardiovascular effects of spironolactone. *Am J Cardiol*. 1993;71(3):40A-5A.
855. Scholer D, Birkhauser M, Peytremann A, Riondel AM, Vallotton MB, and Muller AF. Response of plasma aldosterone to angiotensin II ACTH and potassium in man. *Acta Endocrinol (Copenh)*. 1973;72(2):293-307.
856. Schoneshofer M, and Oelkers W. Effect of prolonged infusions of angiotensin II on eight serum corticosteroids in man on different sodium diets. *Horm Metab Res*. 1980;12(11):614-20.
857. Schou M, Gabrielsen A, Bruun NE, Skott P, Pump B, Dige-Petersen H, Frandsen E, Bie P, Warberg J, Christensen N, J, and Norsk P. Angiotensin II attenuates the natriuresis of water immersion in humans. *Am J Physiol Regul Integr Comp Physiol*. 2002;283(1):R187-96.
858. Schroeder ET, Shear L, Sancetta SM, and Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. 3. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. *Am J Med*. 1967;43(6):887-96.
859. Schutz W, Hortnagl H, and Magometschnigg D. Function of the autonomic nervous system in young untreated hypertensive patients. *Int J Cardiol*. 1986;10(2):133-40.
860. Schwarz R, and Retzke U. Cardiovascular response to infusions of angiotensin II in pregnant women. *Obstet Gynecol*. 1971;38(5):714-8.
861. Scroop GC, Walsh JA, and Whelan RF. A comparison of the effects of intra-arterial and intravenous infusions of angiotensin and noradrenaline on the circulation in man. *Clin Sci*. 1965;29(2):315-26.
862. Scroop GC, and Whelan RF. A central vasomotor action of angiotensin in man. *Clinical science*. 1966;30(1):79-90.
863. Scroop GC, and Whelan RF. The effects of alpha-adrenergic receptor blockade and sympathetic denervation of the pressor action of angiotensin in man. *Aust J Exp Biol Med Sci*. 1968;46(5):563-72.
864. Seely EW, Moore TJ, Rogacz S, Gordon MS, Gleason RE, Hollenberg NK, and Williams GH. Angiotensin-mediated renin suppression is altered in non-modulating hypertension. *Hypertension*. 1989;13(1):31-7.
865. Seely EW, Brosnihan KB, Jeunemaitre X, Okamura K, Williams GH, Hollenberg NK, and Herrington DM. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system blood pressure and renal blood flow in postmenopausal women. *Clin Endocrinol (Oxf)*. 2004;60(3):315-21.
866. Segel N, Harris P, and Bishop JM. The effects of synthetic hypertensin of the systemic and pulmonary circulations in man. *Clin Sci*. 1961;20:49-61.
867. Segel N, Bayley TJ, Paton A, Dykes PW, and Bishop JM. The effects of synthetic vasopressin and angiotensin on the circulation in cirrhosis of the liver. *Clin Sci*. 1963;25:43-55.
868. Seidelin PH, Coutie WJ, Pai MS, Morton JJ, and Struthers AD. The interaction between noradrenaline and angiotensin II in man: evidence for a postsynaptic and against a presynaptic interaction. *J Hypertens Suppl*. 1987a;5(5):S121-4.
869. Seidelin PH, Coutie W J, and Struthers AD. The effect of angiotensin II on endogenous noradrenaline release in man. *Br J Clin Pharmacol*. 1987b;24(6):699-704.
870. Seidelin PH, McMurray JJ, Brown RA, and Struthers AD. The effect of angiotensin II and noradrenaline alone and in combination on renal sodium excretion in man. *Br J Clin Pharmacol*. 1989a;27(6):803-9.
871. Seidelin PH, McMurray J J, and Struthers AD. Mechanisms of the antinatriuretic action of physiological doses of angiotensin II in man. *Clin Sci (Lond)*. 1989b;76(6):653-8.
872. Seifert C, and Oelkers W. Aldosterone response to sodium deprivation and angiotensin II in patients with hypopituitarism. *Acta Endocrinol (Copenh)*. 1981;96(3):361-9.
873. Sekine K, Kojima I, Fujita T, Uchino K, Isozaki S, and Ogata E. Factitious Bartter's syndrome induced by surreptitious intake of furosemide. *Endocrinol Jpn*. 1982;29(5):653-7.
874. Semple PF, Buckingham JC, Mason PA, and Fraser R. Suppression of plasma ACTH concentration by angiotensin II infusion in normal humans and in a subject with a steroid 17-alpha-hydroxylase defect. *Clin Endocrinol*. 1979;10:137-44.
875. Senba S, Konishi K, Saruta T, Ozawa Y, Kato E, Amagasaki Y, and Nakata I. Hypokalemia and prostaglandin overproduction in Bartter's syndrome. *Nephron*. 1984;37(4):257-63.
876. Shapiro AP, Moutsos SE, and Krifcher E. Patterns of pressor response to noxious stimuli in normal hypertensive and diabetic subjects. *J Clin Invest*. 1963;42:1890-8.
877. Sharma AM, Schattenfroh S, Thiede HM, Oelkers W, and Distler A. Effects of sodium salts on pressor reactivity in salt-sensitive men. *Hypertension*. 1992;19(6 Pt 1):541-8.
878. Shen WF, Roubin GS, Choong CY, Hutton BF, Harris PJ, Fletcher PJ, and Kelly DT. Evaluation of relationship between myocardial contractile state and left ventricular function in patients with aortic regurgitation. *Circulation*. 1985;71(1):31-8.
879. Shenker Y, Bates ER, Egan BH, Hammoud J, and Grekin RJ. Effect of vasopressors on atrial natriuretic factor and hemodynamic function in humans. *Hypertension*. 1988;12(1):20-5.
880. Shenker Y. Atrial natriuretic hormone and aldosterone regulation in salt-depleted state. *Am J Physiol*. 1989;257(4 Pt 1):E583-7.
881. Shigetomi S, Ojima M, Ueno S, Tosaki H, Kohno H, and Fukuchi S. Two adult familial cases of selective hypoaldosteronism due to insufficiency of conversion of corticosterone to aldosterone. *Endocrinol Jpn*. 1986;33(6):787-94.
882. Shimamoto K, Nakagawa M, Fukuyama S, Ura N, Murakami H, Yonekura S, Iwakura M, Yamaguchi Y, Ise T, Saitoh S, Sakakibara T, Satoh S, Matsuda K, and Iimura O. Effects of norepinephrine and angiotensin II on plasma atrial natriuretic peptide concentration in humans. *J Cardiovasc Pharmacol*. 1989;13 Suppl 6:S59-62.
883. Shiroto H, Ando H, Ebitani I, Hara M, Numazawa K, Kawamura S, and Sasaki H. Normotensive primary aldosteronism. *Am J Med*. 1980;69(4):603-6.
884. Shoback DM, Williams GH, Hollenberg NK, Davies RO, Moore TJ, and Dluhy RG. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man. *J Clin Endocrinol Metab*. 1983a;57(4):764-70.
885. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, and Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. *J Clin Invest*. 1983b;72(6):2115-24.
886. Shoji M, Kimura T, Ota K, Inoue M, Sato K, Ohta M, Yamamoto T, Furuyama T, Abe K, and Yoshinaga K. Impaired water diuresis in a patient with pseudo-Bartter syndrome. *Endocrinol Jpn*. 1992;39(1):65-71.
887. Sieber C, Gnadinger M, Del Pozo E, Shaw S, and Weidmann P. Effect of a new somatostatin analogue SMS 201-995 (sandostatin) on the renin-aldosterone axis. *Clin Endocrinol (Oxf)*. 1988;28(1):25-32.
888. Siemensen HC, Rothenberger W, Voelkel N, Kohl PV, and Sill V. Pressure response of pulmonary vasculature to vasoconstricting agents. *Z Kardiol*. 1973;62(8):760-6.
889. Silah JG, Jones RE, Bashour FA, and Kaplan NM. The effect of acute administration of chlorothiazide upon the pressor responsiveness to angiotensin and norepinephrine. *Am Heart J*. 1965;69:301-5.
890. Silah JG, Strong CG, Nowaczynski W, and Genest J. The angiotensin infusion test and peripheral venous renin activity. *Can Med Assoc J*. 1967;96(21):1397-400.
891. Sim JS, Dick JB, and Struthers AD. Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients. *J Renin Angiotensin Aldosterone Syst*. 2004;5(3):109-13.
892. Simmons JL, Payne RB, Ajzen H, and Woods JW. The angiotensin infusion test. *J Urol*. 1966;96(2):115-8.
893. Simon G. and Snyder D. K. Altered pressor responses in long-term nitrendipine treatment. *Clin Pharmacol Ther*. 1984;36(3):315-9.
894. Singer DR, Markandu ND, Morton JJ, Miller MA, Sagnella GA, and MacGregor GA. Angiotensin II suppression is a major factor permitting excretion of an acute sodium load in humans. *Am J Physiol*. 1994;266(1 Pt 2):F89-93.
895. Singh S, and Malhotra RP. Comparative study of angiotensin and nor-adrenaline in hypotensive states (shock). *J Assoc Physicians India*. 1966;14(11):639-45.
896. Singh S, and Malhotra RP. Electrocardiographic moniteering of patients of shock on angiotensin and noradrenaline therapy. *J Assoc Physicians India*. 1967;15(4):163-71.
897. Slaton PE Jr, and Biglieri EG. Reduced aldosterone excretion in patients with autonomic insufficiency. *J Clin Endocrinol Metab*. 1967;27(1):37-45.
898. Slaton PE Jr, Schambelan M, and Biglieri EG. Stimulation and suppression of aldosterone secretion in patients with an aldosterone-producing adenoma. *J Clin Endocrinol Metab*. 1969;29(2):239-50.
899. Sluiter HE, Wetzels JF, Huysmans FT, and Koene RA. The natriuretic effect of the dihydropyridine calcium antagonist felodipine: a placebo-controlled study involving intravenous angiotensin II in normotensive volunteers. *J Cardiovasc Pharmacol*. 1987;10 Suppl 10:S154-61.
900. Smith AL, Neigh JL, Hoffman JC, and Wollman H. Effects of general anesthesia on autoregulation of cerebral blood flow in man. *J Appl Physiol*. 1970;29(5):665-9.
901. Smith DH, Neutel JM, and Weber MA. Effects of angiotensin II on pressor responses to norepinephrine in humans. *Life Sci*. 1991;48(25):2413-21.
902. Smith RW. Cardiovascular alterations in toxemia. *Am J Obstet Gynecol*. 1970;107(7):979-83.
903. Smulyan H, Cuddy RP, and Eich RH. Hemodynamic effects of pressor agents in septic and myocardial infarction shock. *JAMA*. 1964;190:188-94.
904. Smyth HS, Sleight P, and Pickering GW. Reflex regulation of arterial pressure during sleep in man. A quantitative method of assessing baroreflex sensitivity. *Circ Res*. 1969;24(1):109-21.
905. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, and Miller JA. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. *J Am Soc Nephrol*. 2006;17(6):1703-9.
906. Solaiman AZ, Feehan RP, Chabitnoy AM, Leuenberger UA, and Monahan KD. Ventilatory responses to chemoreflex stimulation are not enhanced by angiotensin II in healthy humans. *Auton Neurosci*. 2014;183:72-9.
907. Soma M, Honda M, and Hatano M. Effects of angiotensin II and angiotensin III on prostacyclin release in man. *Nihon Jinzo Gakkai Shi*. 1983;25(9):1093-101.
908. Sommerville KJ, and McKellar JB. Angiotensin II in the management of excision of phaeochromocytoma. *Anaesthesia*. 1989;44(2):128-9.
909. Sorensen SS, Danielsen H, Jespersen B, and Pedersen EB. Hypotension in end-stage renal disease: effect of postural change exercise and angiotensin II infusion on blood pressure and plasma concentrations of angiotensin II aldosterone and arginine vasopressin in hypotensive patients with chronic renal failure treated by dialysis. *Clin Nephrol*. 1986;26(6):288-96.
910. Sowers JR, Golub MS, Berger ME, and Whitfield LA. Dopaminergic modulation of pressor and hormonal responses in essential hypertension. *Hypertension*. 1982;4(3):424-30.
911. Sowers JR, and Beck FW. Dopaminergic modulation of corticosteroid responses to angiotensin II in man. *Clin Exp Hypertens A*. 1983a;5(5):651-64.
912. Sowers JR, Martin VI, and Beck FW. Effects of dietary sodium on circadian rhythm and physiological responses of 18-hydroxycorticosterone. *Clin Sci (Lond)*. 1983b;64(3):295-301.
913. Sowers JR, and Beck FW. Role of dopamine in the regulation of aldosterone and 18-hydroxycorticosterone secretion in man. *J Endocrinol Invest*. 1984;7(5):473-9.
914. Spaanderman ME, Ekhart TH, de Leeuw PW, and Peeters LL. Angiotensin II sensitivity in nonpregnant formerly preeclamptic women and healthy parous controls. *J Soc Gynecol Investig*. 2004;11(6):416-22.
915. Spark RF, Gordon SJ, Dale SL, and Melby JC. Aldosterone production after suppression of corticotropic secretory activity. *Arch Intern Med*. 1968;122(5):394-8.
916. Spark RF, Dale SL, Kahn PC, and Melby JC. Activation of aldosterone secretion in primary aldosteronism. *J Clin Invest*. 1969;48(1):96-104.
917. Speckart P, Golub M, Zia P, Zipser R, and Horton R. The effect of angiotensin II and indomethacin on immunoreactive prostaglandin "A" levels in man. *Prostaglandins*. 1976;11(3):481-8.
918. Speckart P, Zia P, Zipser R, and Horton R. The effect of sodium restriction and prostaglandin inhibition on the renin-angiotensin system in man. *J Clin Endocrinol Metab*. 1977;44(5):832-7.
919. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, and de Leeuw PW. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. *Hypertension*. 2000;36(3):411-6.
920. Spitz B, Magness RR, Cox SM, Brown CE, Rosenfeld CR, and Gant NF. Low-dose aspirin. I. Effect on angiotensin II pressor responses and blood prostaglandin concentrations in pregnant women sensitive to angiotensin II. *Am J Obstet Gynecol*. 1988;159(5):1035-43.
921. Spooren PF, Gans RO, Ader HJ, Vermes I, and Donker AJ. Urinary albumin excretion rate during angiotensin II infusion in microalbuminuric patients with insulin and non-insulin-dependent diabetes mellitus. *Nephrol Dial Transplant*. 1997;12(2):281-5.
922. Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T, Lo J, Adler GK, and Grinspoon SK. RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. *J Clin Endocrinol Metab*. 2015;100(8):2873-82.
923. Staessen J, Fagard R, Hespel P, Lijnen P, Moerman E, and Amery A. Acute calcium entry blockade inhibits the blood pressure but not the hormonal responses to angiotensin II. *Eur J Clin Pharmacol*. 1989;36(6):567-73.
924. Stanciu C, Frasin M, Cijevschi C, Balan G, Pancu D, and Haulica I. Effects of angiotensin on the human lower esophageal sphincter pressure. *Med Interne*. 1981;19(4):359-61.
925. Stangier J, Su CA, van Heiningen PN, Meinicke T, van Lier JJ, de Bruin H, Tamminga WJ, and Jonkman JH. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. *J Cardiovasc Pharmacol*. 2001;38(5):672-85.
926. Stepniakowski KT, Goodfriend TL, and Egan BM. Fatty acids enhance vascular alpha-adrenergic sensitivity. *Hypertension*. 1995;25(4 Pt 2):774-8.
927. Stone SR, Whalley PJ, and Pritchard JA. Inferior vena cava and ovarian vein ligation during late pregnancy. *Obstet Gynecol*. 1968;32(2):267-73.
928. Stott DJ, Robertson JI, and Ball SG. Specificity of the serotonergic antagonist ketanserin. *J Hypertens Suppl*. 1985;3(3):S191-3.
929. Stowasser M, Bachmann AW, Jonsson JR, Tunny TJ, Klemm SA, and Gordon RD. Clinical biochemical and genetic approaches to the detection of familial hyperaldosteronism type I. *J Hypertens*. 1995;13(12 Pt 2):1610-3.
930. Stowasser M, Huggard PR, Rossetti TR, Bachmann AW, and Gordon RD. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. *J Clin Endocrinol Metab*. 1999;84(11):4031-6.
931. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, and Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. *J Clin Endocrinol Metab*. 2000;85(6):2160-6.
932. Straznicky NE, Louis WJ, McGrade P, and Howes LG. The effects of dietary lipid modification on blood pressure cardiovascular reactivity and sympathetic activity in man. *J Hypertens*. 1993;11(4):427-37.
933. Straznicky NE, Howes LG, Lam W, and Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. *Am J Cardiol*. 1995;75(8):582-6.
934. Streeten DH, Schletter FE, Clift GV, Stevenson CT, and Dalakos TG. Studies of the renin-angiotensin-aldosterone system in patients with hypertension and in normal subjects. *Am J Med*. 1969;46(6):844-61.
935. Streeten DH, and Anderson GH Jr. Simplified screening procedures for primary aldosteronism. Studies on the mechanism of the hyper-responsiveness to furosemide and standing. *Clin Exp Hypertens A*. 1982;4(9-10):1663-76.
936. Struthers AD, Pai S, Seidelin PH, Coutie WJ, and Morton JJ. Evidence in humans for a postsynaptic interaction between noradrenaline and angiotensin II with regard to systolic but not diastolic blood pressure. *J Hypertens*. 1987;5(6):671-6.
937. Sturrock ND, Lang CC, Coutie WJ, and Struthers AD. Cyclosporin-induced renal vasoconstriction is augmented by frusemide and by angiotensin II in humans. *J Hypertens*. 1995;13(9):987-91.
938. Sugawara A, Nakao K, Itoh H, Yamada T, Saito Y, Mukoyama M, Arai H, Hosoda K, Shirakami G, Morii N, Shiono S, and Imura H. Cosecretion of peptides derived from gamma-human atrial natriuretic polypeptide in normal volunteers and patients with essential hypertension and adrenal disorders. *J Hypertens Suppl*. 1988a;6(4):S327-9.
939. Sugawara A, Nakao K, Kono T, Morii N, Yamada T, Itoh H, Shiono S, Saito Y, Mukoyama M, Arai H, and Imura H. Atrial natriuretic factor in essential hypertension and adrenal disorders. *Hypertension*. 1988b;11(2 Pt 2):I212-6.
940. Sugiyama H, Uchimura I, Odakura T, and Maezawa H. Plasma renin and aldosterone in adult-onset diabetics with persistent proteinuria. *Jpn J Med*. 1981;20(3):194-201.
941. Sun B, Williams J S, Pojoga L, Chamarthi B, Lasky-Su J, Raby B A, Hopkins PN, Jeunemaitre X, Brown N J, Ferri C, and Williams GH. Renin gene polymorphism: its relationship to hypertension renin levels and vascular responses. *J Renin Angiotensin Aldosterone Syst*. 2011;12(4):564-71.
942. Sunderlin FS Jr, Anderson GH, Jr, Streeten DH, and Blumenthal SA. The renin-angiotensin-aldosterone system in diabetic patients with hyperkalemia. *Diabetes*. 1981;30(4):335-40.
943. Swinton NW Jr. The angiotensin infusion test: preliminary experience. *Lahey Clin Found Bull*. 1966;15(1):16-24.
944. Szmuilowicz ED, Adler GK, Williams JS, Green DE, Yao TM, Hopkins PN, and Seely EW. Relationship between aldosterone and progesterone in the human menstrual cycle. *J Clin Endocrinol Metab*. 2006;91(10):3981-7.
945. Szmuilowicz ED, Adler GK, Ricchiuti V, Hopkins PN, and Seely EW. Relationships between endogenous sex hormone concentrations and vascular function in postmenopausal women. *J Clin Endocrinol Metab*. 2007;92(12):4738-41.
946. Tajiri M, Aizawa Y, Sakai S, Imai K, and Hirasawa Y. Vascular responsiveness and body fluid status in patients on chronic hemodialysis. *J Dial*. 1980;4(4):167-77.
947. Takamitsu Y, Fujiwara Y, Sasaki E, Miki S, Orita Y, and Abe H. Role of mesangial proliferation in angiotensin II and antidiuretic hormone induced changes in glomerular filtration rate. *Jpn Circ J*. 1985;49(11):1135-43.
948. Takeda K, Kono K, Tamano K, Takahashi M, Nakamura Y, Masuda T, Hosoya K, Yoshihara T, and Yagi S. New interpretation of systolic time intervals from active cross-bridge model. *Jpn Circ J*. 1993;57(4):299-311.
949. Takeda R, Morimoto S, Uchida K, Miyamori I, and Hashiba T. Effect of age on plasma aldosterone response to exogenous angiotensin II in normotensive subjects. *Acta Endocrinol (Copenh)*. 1980;94(4):552-8.
950. Takeda R, Morimoto S, Uchida K, Hashiba T, Kigoshi THonjo A, and Fujimura A. Aldosterone responsiveness to angiotensin II after sodium restriction in subjects with low renin essential hypertension. *Clin Exp Hypertens A*. 1982;4(6):937-49.
951. Takematsu H, Tomita Y, and Kato T. Angiotensin-induced hypertension and chemotherapy for multiple lesions of malignant melanoma. *Br J Dermatol*. 1985;113(4):463-5.
952. Takeshita A, Imaizumi T, Yamamoto K, and Nakamura M. Limited maximal vasodilator capacity of forearm resistance vessels in hypertrophic cardiomyopathy. *J Cardiol Suppl*. 1987;16:89-90.
953. Takeuchi K, Imai Y, Omata K, Sato H, Saito T, Ota K, Kimura T, Yoshinaga K, and Abe K. A case of secondary aldosteronism similar to Bartter's syndrome with no abnormality in renal chloride reabsorption. *Tohoku J Exp Med*. 1993;169(2):141-57.
954. Takeuchi M, Igarashi Y, Tomimoto S, Odake M, Hayashi T, Tsukamoto T, Hata K, Takaoka H, and Fukuzaki H. Single-beat estimation of the slope of the end-systolic pressure-volume relation in the human left ventricle. *Circulation*. 1991;83(1):202-12.
955. Talledo OE. Renin-angiotensin system in normal and toxemic pregnancies. I. Angiotensin infusion test. *Am J Obstet Gynecol*. 1966;96(1):141-3.
956. Taniguchi H, Koyama H, Masuyama M, Takada A, Mugitani T, Tanaka H, Hoshima M, and Takahashi T. Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PETJ *Nucl Med*. 1996;37(9):1522-3.
957. Taylor T, Moore TJ, Hollenberg NK, and Williams GH. Converting-enzyme inhibition corrects the altered adrenal response to angiotensin II in essential hypertension. *Hypertension*. 1984;6(1):92-9.
958. Tham TC, McKaigue JP, Guy S, Shanks RG, and Riddell JG. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man. *Br J Clin Pharmacol*. 1993;36(3):251-6.
959. Thomas VL, and Nielsen MS. Administration of angiotensin II in refractory septic shock. *Crit Care Med*. 1991;19(8):1084-6.
960. Tobe SW, Blendis LM, Morali GA, Warner LC, Logan AG, and Skorecki KL. Angiotensin II modulates atrial natriuretic factor-induced natriuresis in cirrhosis with ascites. *Am J Kidney Dis*. 1993;21(5):472-9.
961. Toering TJ, van der Graaf AM, Visser FW, Buikema H, Navis G, Faas MM, and Lely AT. Gender differences in response to acute and chronic angiotensin II infusion: a translational approach. *Physiol Rep*. 2015a;3(7).
962. Toering TJ, van der Graaf AM, Visser FW, Groen H, Faas MM, Navis G, and Lely AT. Higher filtration fraction in formerly early-onset preeclamptic women without comorbidity. *Am J Physiol Renal Physiol*. 2015b;308(8):F824-31.
963. Tomita K, Matsuda O, Ideura T, Shiigai T, and Takeuchi J. Renin-angiotensin-aldosterone system in mild diabetic nephropathy. *Nephron*. 1982;31(4):361-7.
964. Tomlinson B, Bompart F, Graham BR, Liu JB, and Prichard BN. Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol propranolol and hydralazine. *Drugs*. 1988;36 Suppl 6:37-47.
965. Tomura N, Saito Y, Hirata K, Matsudaira N, Tamakawa Y, and Kato T. Tumor vascularity under angiotensin II-induced hypertension--angiographic observations. *Radiat Med*. 1986;4(2):60-6.
966. Tomura N, Kato T, Kanno I, Shishido F, Inugami A, Uemura K, Higano S, Fujita H, Mineura K, and Kowada M. Increased blood flow in human brain tumor after administration of angiotensin II: demonstration by PET. *Comput Med Imaging Graph*. 1993;17(6):443-9.
967. Torres C, Lozano R, Whittembury J, and Monge C. Effect of angiotensin on the kidney of the high altitude native. *Nephron*. 1970;7(6):489-98.
968. Townsend RR, DiPette DJ, Lieux TR, and Wolfe RR. The role of the renin-angiotensin system in insulin sensitivity in normotensive subjects. *Am J Med Sci*. 1993a;305(2):67-71.
969. Townsend RR, and DiPette DJ. Pressor doses of angiotensin II increase insulin-mediated glucose uptake in normotensive men. *Am J Physiol*. 1993b;265(3 Pt 1):E362-6.
970. Townsend RR. The effects of angiotensin-II on lipolysis in humans. *Metabolism*. 2001;50(4):468-72.
971. Tran D, Lowy A, Howes JB, and Howes LG. Effects of cerivastatin on forearm vascular responses blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. *Diabetes Obes Metab*. 2005;7(3):273-81.
972. Tranquilli AL, Mariani ML, Mazzanti L, Valensise H, Garzetti GG, and Romanini C. Magnesium pyrrolidone carboxylate infusion reduces angiotensin II pressor response in pregnant women at risk for hypertension. *Am J Obstet Gynecol*. 1992;167(4 Pt 1):885-8.
973. Tranquilli AL, Conti C, Rezai B, Garzetti GG, and Romanini C. Nifedipine reduces pressor responsiveness to angiotensin II in pregnant women. *Clin Exp Obstet Gynecol*. 1994;21(1):45-8.
974. Trevisan R, Bruttomesso D, Vedovato M, Brocco S, Pianta A, Mazzon C, Girardi C, Jori E, Semplicini A, Tiengo A, and Del Prato S. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. *Diabetes*. 1998;47(8):1347-53.
975. Trilli LE, and Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. *Ann Pharmacother.* 1994;28(10):1165-8.
976. Tristani FE, and Cohn JN. Studies in clinical shock and hypotension. VII. Renal hemodynamics before and during treatment. *Circulation*. 1970;42(5):839-51.
977. Troughton RW, Frampton CM, Lewis LK, Yandle TG, Richards AM, and Nicholls MG. Differing thresholds for modulatory effects of adrenomedullin infusion on haemodynamic and hormone responses to angiotensin II and adrenocorticotrophic hormone in healthy volunteers. *Clin Sci (Lond)*. 2001;101(1):103-9.
978. Trujillo A, Eggena P, Barrett J, and Tuck M. Renin regulation in type II diabetes mellitus: influence of dietary sodium. *Hypertension*. 1989;13(3):200-5.
979. Tsuchiya M, Honda M, and Hatano M. A study on dehydroepiandrosterone sulfate in patients with essential hypertension. *Jpn Circ J*. 1982;46(6):568-76.
980. Tsunoda S, Tsushima T, Nishioka T, Ohno N, Fukunaga T, Takano K, Yumura W, Shizume K, and Branch RA. Familial Bartter's syndrome and the effect of indomethacin in one family member. *J Urol*. 1982;127(5):1000-5.
981. Tuchelt H, Eschenhagen G, Bahr V, Schwietzer G, Thiede HM, and Oelkers W. Role of atrial natriuretic factor in changes in the responsiveness of aldosterone to angiotensin II secondary to sodium loading and depletion in man. *Clin Sci (Lond)*. 1990;79(1):57-65.
982. Tuck ML, Chandler DW, and Mayes DM. The influences of ACTH dietary sodium upright posture and angiotensin II on plasma 18-hydroxy-11-deoxycorticosterone levels in normal subjects. *J Clin Endocrinol Metab*. 1977;45(5):893-902.
983. Tuck ML, and Mayes DM. Mineralocorticoid biosynthesis in patients with hyporeninemic hypoaldosteronism. *J Clin Endocrinol Metab*. 1980;50(2):341-7.
984. Tunny TJ, Gordon RD, Klemm SA, and Cohn D. Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin. *Clin Endocrinol (Oxf)*. 1991;34(5):363-9.
985. Tunny TJ, Klemm SA, Stowasser M, and Gordon RD. Angiotensin-responsive aldosterone-producing adenomas: postoperative disappearance of aldosterone response to angiotensin. *Clin Exp Pharmacol Physiol*. 1993;20(5):306-9.
986. Tunny TJ, Jonsson JR, Klemm SA, Ballantine DM, Stowasser M, and Gordon RD. Association of restriction fragment length polymorphism at the atrial natriuretic peptide gene locus with aldosterone responsiveness to angiotensin in aldosterone-producing adenoma. *Biochem Biophys Res Commun*. 1994;204(3):1312-7.
987. Uchida K, Azukizawa S, Nakano S, Kaneko M, Kigoshi T, Morimoto S, and Matsui A. Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure. *South Med J*. 1994;87(11):1153-5.
988. Udhoji VN, and Weil MH. Circulatory effects of angiotensin levarterenol and metaraminol in the treatment of shock. *N Engl J Med*. 1964;270:501-5.
989. Ueda H, Shiba M, and Yasuda H. Some hemodynamic and clinico-pathological consideration of congestive heart failure with special reference to therapeutic effect. *Jpn Circ J*. 1964;28:187-97.
990. Ueda S, Meredith PA, Howie CA, and Elliott HL. A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects. *Br J Clin Pharmacol*. 1993;36(6):561-6.
991. Ueda S, Elliott HL, Morton JJ, and Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. *Hypertension*. 1995;25(6):1266-9.
992. Ueda S, Donnelly R, Panfilov V, Morris AD, and Elliott HL. Lacidipine: effects on vascular pressor responses throughout the dosage interval in normotensive subjects. *Br J Clin Pharmacol*. 1998;46(2):127-32.
993. Ueda Y, Honda M, and Hatano M. Response of adrenal steroids to angiotensin II in essential hypertension. *J Steroid Biochem*. 1979;11(5-6):1527-34.
994. Uehlinger DE, Weidmann P, Gnadinger MP, and Shaw S. Effects of human atrial natriuretic peptide on the pressor action of noradrenaline and angiotensin II in normal subjects. *J Hypertens Suppl*. 1985;3(3):S319-21.
995. Uehlinger DE, Weidmann P, Gnaedinger MP, Shaw S, and Lang RE. Depressor effects and release of atrial natriuretic peptide during norepinephrine or angiotensin II infusion in man. *J Clin Endocrinol Metab*. 1986;63(3):669-74.
996. Underwood PC, Sun B, Williams JS, Pojoga LH, Chamarthi B, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, and Williams GH. The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study. *J Clin Endocrinol Metab*. 2010;95(9):E75-9.
997. Underwood PC, Chamarthi B, Williams JS, Vaidya A, Garg R, Adler GK, Grotzke MP, Staskus G, Wadwekar D, Hopkins PN, Ferri C, McCall A, McClain D, and Williams GH. Nonmodulation as the mechanism for salt sensitivity of blood pressure in individuals with hypertension and type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2012;97(10):3775-82.
998. Usberti M, Federico S, Di Minno G, Ungaro B, Ardillo G, Pecoraro C, Cianciaruso B, Cerbone AM, Cirillo F, Pannain M, Gargiulo A, and Andreucci VE. Effects of angiotensin II on plasma ADH prostaglandin synthesis and water excretion in normal humans. *Am J Physiol*. 1985;248(2 Pt 2):F254-9.
999. Usberti M, Rondina M, Campisi S, Brognoli M, Poiesi C, Bove S, Montresor G, and Ghielmi S. Effect of angiotensin II on proximal tubular reabsorption in normal humans. *Am J Nephrol*. 1991;11(4):271-5.
1000. Uza G, Mihu S, and Missits P. Effect of angiotensin II on plasma free fatty acids in hypertensive subjects with and without overweight. *Revue roumaine de medecine interne*. 1973;10(1):37-41.
1001. Uza G, and Crisnic I. Effect of angiotensin II upon platelet adhesiveness and the thrombelastogram in patients with essential arterial hypertension. *Pathol Eur*. 1975;10(4):327-32.
1002. Vagnucci AI, Lauler DP, Hickler RB, and Thorn GW. Acute infusion of synthetic angiotensin II in patients with essential hypertension. Its effect on renal hemodynamics and on electrolyte and water excretion. *Circulation*. 1964;29:SUPPL:523-32.
1003. Vaidya A, Sun B, Larson C, Forman JP, and Williams JS. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. *J Clin Endocrinol Metab*. 2012;97(7):2456-65.
1004. Vaidya A, Underwood PC, Annes JP, Sun B, Williams GH, Forman JP, and Williams JS. The influence of sodium- and calcium-regulatory hormone interventions on adipocytokines in obesity and diabetes. *Metabolism*. 2013;62(4):539-47.
1005. Vaile JC, Fletcher J, Littler WA, Coote JH, and Townend JN. Angiotensin II modulates cardiovascular autonomic control in the absence of baroreflex loading. *Heart (British Cardiac Society)*. 1998;80(2):127-33.
1006. Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, and Mauri Nicolas JM. Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. *Kidney Int Suppl*. 1996;55:S104-6.
1007. Vallotton MB, Merkelbach U, and Gaillard RC. Studies of the factors modulating antidiuretic hormone excretion in man in response to the osmolar stimulus: effects of oestrogen and angiotensin II. *Acta Endocrinol (Copenh)*. 1983;104(3):295-302.
1008. van der Bel R, Coolen BF, Nederveen AJ, Potters WV, Verberne HJ, Vogt L, Stroes ES, and Krediet CT. Magnetic resonance imaging-derived renal oxygenation and perfusion during continuous steady-state angiotensin-II infusion in healthy humans. *J Am Heart Assoc*. 2016;5(3):e003185.
1009. van der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, and Navis G. Enhanced responses of blood pressure renal function and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. *J Am Soc Nephrol*. 2002;13(4):1025-33.
1010. van der Linde NA, Boomsma F, and van den Meiracker AH. Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. *J Hypertens*. 2005;23(5):1009-15.
1011. van der Linde NA, Sijbrands EJ, Boomsma F, and van den Meiracker AH. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. *Hypertension*. 2006;47(6):1125-30.
1012. van der Starre PJ, and Reneman RS. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade. *J Cardiovasc Pharmacol*. 1988;11 Suppl 1:S54-61.
1013. van Hamersvelt HW, Sluiter HE, Wetzels JF, Koene RA, and Huysmans FT. Is natriuresis on felodipine due to reversal of the renal effects of angiotensin II? *Kidney Int Suppl*. 1992;36:S73-7.
1014. van Schaik BA, Hene RJ, and Geyskes GG. Influence of nicardipine on blood pressure renal function and plasma aldosterone in normotensive volunteers. *Br J Clin Pharmacol*. 1985;20 Suppl 1:88S-94S.
1015. van Twist DJ, Houben AJ, de Haan MW, Mostard GJ, Kroon AA, and de Leeuw PW. Angiotensin-(1-7)-induced renal vasodilation in hypertensive humans is attenuated by low sodium intake and angiotensin II co-infusion. *Hypertension*. 2013;62(4):789-93.
1016. van Twist DJ, Houben AJ, de Leeuw PW, and Kroon AA. Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion. *J Hypertens*. 2016;34(8):1607-14.
1017. Van Waes L, Schurgers M, and Demeulenaere L. The Rhodiascit system--individual response to reinfusion possibly related to angiotensin sensitivity: preliminary results. *Postgrad Med J*. 1975;51(598):567-70.
1018. Venkat Raman G, Albano JD, Millar JG, and Lee HA. Bartter's syndrome and diabetes mellitus. *J Intern Med*. 1990;228(5):525-31.
1019. Vierhapper H, Waldhausl W, and Nowotny P. Effect of indomethacin upon angiotensin-induced changes in blood pressure and plasma aldosterone in normal man. *Eur J Clin Invest*. 1981;11(2 Suppl 1):85-9.
1020. Vierhapper H, and Waldhausl W. Reduced pressor effect of angiotensin II and of noradrenaline in normal man following the oral administration of the calcium-antagonist nifedipine. *Eur J Clin Invest*. 1982a;12(3):263-7.
1021. Vierhapper H, Waldhausl W, Jorg J, and Nowotny P. Unchanged angiotensin II-induced release of aldosterone during infusion of prostaglandin E2 in indomethacin-treated healthy subjects. *Horm Metab Res*. 1982b;14(12):682-3.
1022. Vierhapper H, Waldhausl W, and Nowotny P. The effect of insulin on the rise in blood pressure and plasma aldosterone after angiotensin II in normal man. *Clin Sci (Lond)*. 1983;64(4):383-6.
1023. Vierhapper H, Nowotny P, and Waldhausl W. Impaired angiotensin II-induced release of aldosterone in hyperthyroid patients. *Horm Metab Res*. 1984;16(11):617.
1024. Vierhapper H. Effect of human atrial natriuretic peptide on angiotensin II-induced secretion of aldosterone in man. *Klin Wochenschr*. 1986a;64 Suppl 6:50-2.
1025. Vierhapper H, Nowotny P, and Waldhausl W. Prolonged administration of human atrial natriuretic peptide in healthy men. Reduced aldosteronotropic effect of angiotensin II. *Hypertension*. 1986b;8(11):1040-3.
1026. Villarreal H, Arcila H, Diaz J, and Sierra P. Effect of angiotensin on renal transport of sodium in renovascular hypertension. *Am J Cardiol*. 1967a;19(6):793-6.
1027. Villarreal H, Arcila H, Diaz J, and Sierra P. Effect of angiotensin on the renal transport of sodium in essential hypertension. *Circulation*. 1967b;35(5):889-94.
1028. Vincent J, Elliott HL, Meredith PA, and Reid JL. Trimazosin: relationships between hypotensive effect vascular responsiveness and drug and metabolite concentrations. *J Cardiovasc Pharmacol*. 1985;7(5):913-8.
1029. Vincent J, Blaschke TF, and Hoffman BB. Vascular reactivity to phenylephrine and angiotensin II: comparison of direct venous and systemic vascular responses. *Clin Pharmacol Ther*. 1992a;51(1):68-75.
1030. Vincent J, Dachman W, Blaschke TF, and Hoffman BB. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. *J Clin Invest*. 1992b;90(5):1763-8.
1031. Vincent RD Jr, Werhan CF, Norman PF, Shih GH, Chestnut DH, Ray T, Ross EL, Bofill JA, and Shaw DB. Prophylactic angiotensin II infusion during spinal anesthesia for elective cesarean delivery. *Anesthesiology*. 1998;88(6):1475-9.
1032. Vincent WA, Kashemsant U, Cuddy RP, Fried AH, Smulyan H, and Eich RH. Vanillymandelic acid excretion in labile hypertensive subjects: its variation and response to norepinephrine and angiotensin infusion. *Am J Med Sci*. 1965;249:79-85.
1033. Vingerhoedt NM, Gilles R, Howes JB, Griffin M, and Howes LG. Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers. *J Renin Angiotensin Aldosterone Syst*. 2003;4(4):244-8.
1034. Visser FW, Boonstra AH, Titia Lely A, Boomsma F, and Navis G. Renal response to angiotensin II is blunted in sodium-sensitive normotensive men. *Am J Hypertens*. 2008;21(3):323-8.
1035. Vittorio TJ, Lang CC, Katz SD, Packer M, Mancini DM, and Jorde UP. Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. *Circulation*. 2003;107(2):290-3.
1036. Volpi R, Chiodera P, Caffarri G, Vescovi PP, Capretti L, Gatti C, and Coiro V. Influence of nitric oxide on hypoglycemia - or angiotensin II-stimulated ACTH and GH secretion in normal men. *Neuropeptides*. 1996a;30(6):528-32.
1037. Volpi R, Chiodera P, Capretti L, Caiazza A, Caffarri G, Magotti M G, Boni S, and Coiro V. Inhibition by somatostatin of the growth hormone but not corticotropin response to angiotensin II in normal men. *Horm Res*. 1996b;45(6):269-72.
1038. von Scheidt W, Bohm M, Schneider B, Autenrieth G, and Erdmann E. Cholinergic baroreflex vasodilatation: defect in heart transplant recipients due to denervation of the ventricular baroreceptor. *Am J Cardiol*. 1992;69(3):247-52.
1039. Vos PF, Koomans HA, Boer P, and Dorhout Mees EJ. Effects of angiotensin II on renal sodium handling and diluting capacity in man pretreated with high-salt diet and enalapril. *Nephrol Dial Transplant*. 1992;7(10):991-6.
1040. Vos PF, Boer P, Braam B, and Koomans HA. The origin of urinary angiotensins in humans. *J Am Soc Nephrol*. 1994;5(2):215-23.
1041. Vos PF, Boer P, Braam B, and Koomans HA. Efficacy of intrarenal ACE-inhibition estimated from the renal response to angiotensin I and II in humans. *Kidney Int*. 1995;47(1):274-81.
1042. Vuagnat A, Giacche M, Hopkins PN, Azizi M, Hunt SC, Vedie B, Corvol P, Williams GH, and Jeunemaitre X. Blood pressure response to angiotensin II low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs. *J Mol Med (Berl)*. 2001;79(4):175-83.
1043. Wallace JM, Lopez G, Malo-Camacho R, DeLeon JA, Walker JP, Kirksey TD, and Derrick JR. Hemodynamic effects of angiotensin during surgical anesthesia. *Am Heart J*. 1967;73(3):326-33.
1044. Wallenburg HC, Dekker GA, Makovitz JW, and Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. *Lancet*. 1986;1(8471):1-3.
1045. Wallenburg HC, Dekker GA, Makovitz JW, and Rotmans N. Effect of low-dose aspirin on vascular refractoriness in angiotensin-sensitive primigravid women. *Am J Obstet Gynecol*. 1991;164(5 Pt 1):1169-73.
1046. Wambach G, Helber A, Bonner G, Konrads A, Hummerich W, Meurer KA, and Kaufmann W. Characterization of a group of essential hypertensives with impaired regulation of aldosterone. *Clin Exp Hypertens A*. 1982;4(9-10):1835-49.
1047. Wambach G, Meiners U, Bonner G, Konrads A, and Helber A. Cardiovascular and adrenal sensitivity to angiotensin II in essential hypertension. *Klin Wochenschr*. 1984;62(23):1097-101.
1048. Waser M, Ziegler W H, and Beretta-Piccoli C. Mechanism of action of ketanserin: studies on cardiovascular reactivity in essential and diabetes-associated hypertension. *J Hypertens*. 1988;6(6):471-9.
1049. Watanabe K, Aizawa Y, Shibata A, Obata N, Kobayashi N, and Ohta T. Depression of heart function after angiotensin II infusion in patients on chronic hemodialysis. *Clin Exp Dial Apheresis*. 1981;5(4):349-59.
1050. Watson WE. The effect of adrenaline noradrenaline and hypertensin on the vascular distensibility of the hand. *Br J Anaesth*. 1962;34:350-6.
1051. Wax SH, Al-Hussaini M, and McDonald DF. Effect of angiotensin on the iodine 131 sodium o-iodohippurate renogram in hypertensive patients. *Surg Forum*. 1964;15:498-9.
1052. Webb DJ, Benjamin N, Cockcroft JR, and Collier JG. Augmentation of sympathetic venoconstriction by angiotensin II in human dorsal hand veins. *Am J Hypertens*. 1989;2(9):721-3.
1053. Wedeen R, and Zucker G. Angiotensin II in the treatment of shock. *Am J Cardiol*. 1963;11:82-6.
1054. Weeke B, and Krogsgaard AR. Angiotensin infusion test in arterial hypertension. *Acta Med Scand*. 1966;180(3):349-53.
1055. Weidmann P, Endres P, and Siegenthaler W. Plasma renin activity and angiotensin pressor dose in hypertension correlation and diagnostic implications. *Br Med J*. 1968;3(5611):154-6.
1056. Weidmann P, Horton R, Maxwell MH, Franklin SS, and Fichman M. Dynamic studies of aldosterone in anephric man. *Kidney Int*. 1973a;4(4):289-98.
1057. Weidmann P, Reinhart R, Maxwell MH, Rowe P, Coburn JW, and Massry SG. Syndrome of hyporeninemic hypoaldosteronism and hyperkalemia in renal disease. *J Clin Endocrinol Metab*. 1973b;36(5):965-77.
1058. Weidmann P, Beretta-Piccoli C, Keusch G, Gluck Z, Mujagic M, Grimm M, Meier A, and Ziegler WH. Sodium-volume factor cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. *Am J Med*. 1979;67(5):779-84.
1059. Weidmann P, Beretta-Piccoli C, Link L, Bianchetti MG, Boehringer K, and Morton JJ. Cardiovascular counterregulation during sympathetic inhibition in normal subjects and patients with mild hypertension. *Hypertension*. 1983a;5(6):873-80.
1060. Weidmann P, Beretta-Piccoli C, Meier A, Keusch G, Gluck Z, and Ziegler WH. Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of sympathetic axis and sodium. *Kidney Int*. 1983b;23(2):320-6.
1061. Weidmann P, Matter DR, Matter EE, Gnadinger MP, Uehlinger DE, Shaw S, and Hess C. Glucocorticoid and mineralocorticoid stimulation of atrial natriuretic peptide release in man. *J Clin Endocrinol Metab*. 1988;66(6):1233-9.
1062. Weidmann P, Schohn D, Gnadinger MP, Burgisser E, Ferrier C, and Jahn H. Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure. *Am J Nephrol*. 1989;9(4):269-78.
1063. Wenzel RR, Siffert W, Bruck H, Philipp T, and Schafers RF. Enhanced vasoconstriction to endothelin-1 angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. *Pharmacogenetics*. 2002;12(6):489-95.
1064. Werner M, Bock KD, Brandenburger J, and Sack H. Effects of angiotensin and norepinephrine infusions on total plasma volume and extracellular fluid space in man. *Clin Pharmacol Ther*. 1968;9(2):162-7.
1065. Westling H, Jansson L, Jonson B, and Nilsen R. Vasoactive drugs and elastic properties of human arteries in vivo with special reference to the action of nitroglycerine. *Eur Heart J*. 1984;5(8):609-16.
1066. Whalley PJ, Everett RB, Gant NF, Cox K, and MacDonald PC. Pressor responsiveness to angiotensin II in hospitalized primigravid women with pregnancy-induced hypertension. *Am J Obstet Gynecol*. 1983;145(4):481-3.
1067. Whiteley SM, and Dade JP. Treatment of hypotension in septic shock. *Lancet*. 1996;347(9001):622.
1068. Whitfield L, Sowers JR, Tuck ML, and Golub MS. Dopaminergic control of plasma catecholamine and aldosterone responses to acute stimuli in normal man. *J Clin Endocrinol Metab*. 1980;51(4):724-9.
1069. Whitworth JA, Connell JM, Lever AF, and Fraser R. Pressor responsiveness in steroid-induced hypertension in man. *Clin Exp Pharmacol Physiol*. 1986;13(4):353-8.
1070. Whitworth JA, Connell JM, Gordon D, and Scoggins BA. Effects of indomethacin on steroid-induced changes in pressor responsiveness in man. *Clin Exp Pharmacol Physiol*. 1988;15(4):305-10.
1071. Widgren BR, Herlitz H, Aurell M, Berglund G, Wikstrand J, and Andersson OK. Increased systemic and renal vascular sensitivity to angiotensin II in normotensive men with positive family histories of hypertension. *Am J Hypertens*. 1992;5(3):167-74.
1072. Widgren BR, Urbanavicius V, Wikstrand J, Attvall S, and Persson B. Low-dose angiotensin II increases glucose disposal rate during euglycemic hyperinsulinemia. *Am J Hypertens*. 1993;6(10):892-5.
1073. Wigle ED, Adelman AG, Auger P, and Marquis Y. Mitral regurgitation in muscular subaortic stenosis. *Am J Cardiol*. 1969;24(5):698-706.
1074. Wilkinson IB, MacCallum H, Hupperetz PC, van Thoor CJ, Cockcroft JR, and Webb DJ. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. *J Physiol*. 2001;530(Pt 3):541-50.
1075. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, and Webb DJ. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. *Cardiovasc Res*. 2002;53(2):341-7.
1076. Willemsen JM, Rabelink TJ, Boer P, and Gaillard CA. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. *J Hum Hypertens*. 2004;18(12):857-63.
1077. Williams GH, Bailey GL, Hampers CL, Lauler DP, Merrill JP, Underwood RH, Blair-West JR, Coghlan JP, Denton DA, Scoggins BA, and Wright RD. Studies on the metabolism of aldosterone in chronic renal failure and anephric man. *Kidney Int*. 1973;4(4):280-8.
1078. Williams GH, Braley LM, and Underwood RH. The regulation of plasma 18-hydroxy 11-deoxycorticosterone in man. *J Clin Invest*. 1976;58(1):221-9.
1079. Williams GH, Dluhy RG, and Moore TJ. Aldosterone regulation in essential hypertension: altered adrenal responsiveness to angiotensin II. *Mayo Clin Proc*. 1977;52(5):312-6.
1080. Williams GH, Hollenberg NK, Moore TJ, Dluhy RG, Bavli SZ, Solomon HS, and Mersey JH. Failure of renin suppression by angiotensin II in hypertension. *Circ Res*. 1978;42(1):46-52.
1081. Williams GH, Hollenberg NK, Moore TJ, Swartz SL, and Dluhy RG. The adrenal receptor for angiotensin II is altered in essential hypertension. *J Clin Invest*. 1979;63(3):419-27.
1082. Williams GH, Gordon MS, Stuenkel CA, Conlin PR, and Hollenberg NK. Dopamine and nonmodulating hypertension. *Am J Hypertens*. 1990;3(6 Pt 2):112S-5S.
1083. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, and Hollenberg NK. Non-modulation as an intermediate phenotype in essential hypertension. *Hypertension*. 1992;20(6):788-96.
1084. Williams JS, Solomon SD, Crivaro M, and Conlin PR. Dietary sodium intake modulates myocardial relaxation responsiveness to angiotensin II. *Transl Res*. 2006;148(2):49-54.
1085. Williams R, Zimmon DS, Thompson E, and Sherlock S. The Estimation of Segmental Hepatic Venous Flow in Man. *Gastroenterology*. 1964;46:525-30.
1086. Williams S, Abbott D, Morfis L, Manwaring P, Diamond T, and Howes LG. Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. *J Hypertens*. 1998;16(5):705-11.
1087. Williams TD, Laycock JF, Lightman SL, and Guy RL. Increased sensitivity to pressor hormones in central diabetes insipidus. *Eur J Clin Invest*. 1988;18(4):375-9.
1088. Wilson RJ, Mills IH, and De Bono E. Cardiovascular reflexes and the control of aldosterone production and sodium excretion. *Proc R Soc Med*. 1969;62(12):1257-8.
1089. Wisgerhof M, and Brown RD. Increased adrenal sensitivity to angiotensin II in low-renin essential hypertension. *J Clin Invest*. 1978a;61(6):1456-62.
1090. Wisgerhof M, Carpenter PC, and Brown RD. Increased adrenal sensitivity to angiotensin II in idiopathic hyperaldosteronism. *J Clin Endocrinol Metab*. 1978b;47(5):938-43.
1091. Wisgerhof M, and Brown RD. The metabolic clearance of aldosterone decreases similarly during infusion of angiotensin II in patients with essential hypertension and in normal subjects. *J Clin Endocrinol Metab*. 1979;49(1):107-9.
1092. Wisgerhof M, Brown RD, Hogan MJ, Carpenter PC, and Edis AJ. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. *J Clin Endocrinol Metab*. 1981;52(2):195-8.
1093. Wisgerhof M, Mellinger RC, and Zafar MS. Failure of angiotensin II to stimulate increases in concentrations of adrenal androgens 17-hydroxyprogesterone or adrenocorticotropin in congenital 21-hydroxylase deficiency. *J Clin Endocrinol Metab*. 1983;56(3):627-31.
1094. Wisgerhof M, and Mellinger RC. Effect of bromocriptine treatment on the aldosterone response to angiotensin II and adrenocorticotropin in idiopathic hyperaldosteronism. *J Clin Endocrinol Metab*. 1985;61(1):192-5.
1095. Witzgall H, Lorenz R, von Werder K, and Weber PC. Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism. *Clin Sci (Lond)*. 1985;68(3):291-9.
1096. Wolf RL, Mendlowitz M, Gitlow SE, and Naftchi N. Metabolism of angiotensin II-I-131 in normotensive and hypertensive human subjects. *Circulation*. 1961;23:754-8.
1097. Wolf RL, Mendlowitz M, Gitlow SE, and Naftchi N. The metabolism of angiotension II. *Circ Res*. 1962;11:195-208.
1098. Wolf RL, Mendlowitz M, Roboz J, Naftchi NE, and Gitlow SE. Recent studies on I-131-labelled angiotensin II and analogues. *Can Med Assoc J*. 1964;90:295-8.
1099. Wolzt M, Ugurluoglu A, Schmetterer L, Dorner G, Zanaschka G, Mensik C, and Eichler HG. Exogenous L-arginine does not affect angiotensin II-induced renal vasoconstriction in man. *Br J Clin Pharmacol*. 1998;45(1):71-5.
1100. Wood JE. Peripheral venous and arteriolar responses to infusions of angiotensin in normal and hypertensive subjects. *Circ Res*. 1961;9:768-74.
1101. Woodland E, Tunny TH, Hamlet SM, and Gordon RD. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism. *Clin Exp Pharmacol Physiol*. 1985;12(3):245-8.
1102. Woods TJ, McCaa RE, Bower JD, and McCaa CS. Aldosterone response to angiotensin II in patients with terminal renal failure and after bilateral nephrectomy. *Trans Am Soc Artif Intern Organs*. 1974;20A:154-60.
1103. Wray GM, and Coakley JH. Severe septic shock unresponsive to noradrenaline. *Lancet*. 1995;346(8990):1604.
1104. Yamada K, Watanabe M, Nishikawa T, Mikami K, Shirai K, Tamura Y, Yamamoto M, Kumagai A, Matsuda Y, and Moriya H. Quantitative and qualitative estimation of urinary kallikrein in a patient with Bartter's syndrome. *Endocrinol Jpn*. 1978;25(6):583-9.
1105. Yamakado M, Umezu M, Nagano M, and Tagawa H. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. *Clin Invest Med*. 1991;14(6):623-9.
1106. Yamakita N, Murase H, Yasuda K, Noritake N, Mercado-Asis LB, and Miura K. Possible hyperaldosteronism and discrepancy in enzyme activity deficiency in adrenal and gonadal glands in Japanese patients with 17 alpha-hydroxylase deficiency. *Endocrinol Jpn*. 1989;36(4):515-36.
1107. Yamamoto H, Arakawa K, Yamashita T, Murakami H, Sakai T, Torii S, and Nakamura M. A new pharmacologic phonocardiography by the use of angiotensin. *Am Heart J*. 1971;81(1):29-37.
1108. Yamamoto M, Takata S, Yagi S, Iwase N, Kiyokawa H, Noto Y, Ikeda T, and Hattori N. Effects of insulin on pressor responsiveness and baroreflex function in diabetes mellitus. *Jpn Circ J*. 1986;50(10):943-8.
1109. Yamamoto Y. Effect of pressor agents on blood pressure plasma renin activity and plasma aldosterone concentration in essential hypertension. *Japanese Heart Journal*. 1975;16(4):404-20.
1110. Yasuda G, Shionoiri H, Hayashi S, Umemura S, Ikeda Y, and Ishii M. Cushing's disease: evaluation of mineralocorticoid-induced hypertension. *Intern Med*. 1993;32(10):784-8.
1111. Yasuda G, Nagasawa T, Umemura S, Shionoiri H, and Ishii M. The impaired control of plasma renin activity in hypertensive patients with end-stage renal disease due to chronic glomerulonephritis. *Clin Nephrol*. 1994a;42(5):300-8.
1112. Yasuda G, Shionoiri H, Umemura S, Takasaki I, and Ishii M. Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma. *Eur J Endocrinol*. 1994b;131(6):582-8.
1113. Yoshimura T, Matsui K, Ito M, Yunohara T, Kawasaki N, Nakamura T, and Okamura H. Effects of highly purified eicosapentaenoic acid on plasma beta thromboglobulin level and vascular reactivity to angiotensin II. *Artery*. 1987;14(5):295-303.
1114. Yu PN, Luria MN, Finlayson JK, Stanfield CA, Constantine H, and Flatley FJ. The effects of angiotensin on pulmonary circulation and ventricular function. *Circulation*. 1961;24:1326-37.
1115. Yunge M, and Petros A. Angiotensin for septic shock unresponsive to noradrenaline. *Arch Dis Child*. 2000;82(5):388-9.
1116. Zalucky AA, Nicholl DD, Mann MC, Hemmelgarn BR, Turin TC, Macrae JM, Sola DY, and Ahmed SB. Sex influences the effect of body mass index on the vascular response to angiotensin II in humans. *Obesity (Silver Spring)*. 2014;22(3):739-46.
1117. Zalucky AA, Nicholl DD, Hanly PJ, Poulin MJ, Turin TC, Walji S, Handley GB, Raneri JK, Sola DY, and Ahmed SB. Nocturnal hypoxemia severity and renin-angiotensin system activity in obstructive sleep apnea. *Am J Respir Crit Care Med*. 2015;192(7):873-80.
1118. Zipser RD, Hoefs JC, Speckart PF, Zia PK, and Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. *J Clin Endocrinol Metab*. 1979;48(6):895-900.
1119. Zipser RD, Davenport MW, Martin KL, Tuck ML, Warner NE, Swinney RR, Davis CL, and Horton R. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. *J Clin Endocrinol Metab*. 1981a;53(4):867-73.
1120. Zipser RD, Little TE, Wilson W, and Duke R. Dual effects of antidiuretic hormone on urinary prostaglandin E2 excretion in man. *J Clin Endocrinol Metab*. 1981b;53(3):522-6.
1121. Zipser RD, and Smorlesi C. Regulation of urinary thromboxane B2 in man: influence of urinary flow rate and tubular transport. *Prostaglandins*. 1984;27(2):257-71.
1122. Zoccali C, Usherwood T, Brown JJ, Lever AF, Robertson JI, and Fraser R. A comparison of the effects of angiotensin II infusion and variations in salt intake on plasma aldosterone levels in normal subjects, patients with essential hypertension and patients with hyperaldosteronism. *J Steroid Biochem*. 1983;19(1A):327-31.
1123. Zolk O, Jacobi J, Pahl A, Fromm M F, and Schmieder RE. MDR1 genotype-dependent regulation of the aldosterone system in humans. *Pharmacogenet Genomics*. 2007;17(2):137-44.
1124. Zuspan FP, Talledo OE, and Chesley LC. Angiotensin and norepinephrine infusions during pregnancy: alterations in plasma epinephrine (E) and norepinephrine (NE). *J Clin Endocrinol Metab*. 1971;33(6):929-33.

**ACKNOWLEDGMENT**

Assistance with database searching and manuscript revision was provided by Richard Boehme, PhD, and Christopher Barnes, PhD, of Articulate Science LLC and funded by La Jolla Pharmaceutical Company.